
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

2119
10.1186/s12943-024-02119-3
Review
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
http://orcid.org/0000-0003-3442-7216
Tufail Muhammad 1
Jiang Can-Hua 1234
Li Ning liningoms@csu.edu.cn

1234
1 grid.216417.7 0000 0001 0379 7164 Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China
2 https://ror.org/00f1zfq44 grid.216417.7 0000 0001 0379 7164 Institute of Oral Precancerous Lesions, Central South University, Changsha, China
3 grid.216417.7 0000 0001 0379 7164 Research Center of Oral and Maxillofacial Tumor, Xiangya Hospital, Central South University, Changsha, China
4 grid.216417.7 0000 0001 0379 7164 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
18 9 2024
18 9 2024
2024
23 20314 8 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cancer cells undergo significant metabolic reprogramming to support their rapid growth and survival. This study examines important metabolic pathways like glycolysis, oxidative phosphorylation, glutaminolysis, and lipid metabolism, focusing on how they are regulated and their contributions to the development of tumors. The interplay between oncogenes, tumor suppressors, epigenetic modifications, and the tumor microenvironment in modulating these pathways is examined. Furthermore, we discuss the therapeutic potential of targeting cancer metabolism, presenting inhibitors of glycolysis, glutaminolysis, the TCA cycle, fatty acid oxidation, LDH, and glucose transport, alongside emerging strategies targeting oxidative phosphorylation and lipid synthesis. Despite the promise, challenges such as metabolic plasticity and the need for combination therapies and robust biomarkers persist, underscoring the necessity for continued research in this dynamic field.

Graphical Abstract

Keywords

Cancer metabolism
Glycolysis
Oxidative phosphorylation
Glutaminolysis
Lipid metabolism
National Natural Sciences Foundation of China82170974 Central South University Research Program of Advanced Interdisciplinary Studies2023QYJC038 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Cancer remains one of the leading causes of morbidity and mortality worldwide. Despite significant advancements in our understanding and treatment of cancer, the complexity and adaptability of malignant cells continue to pose ongoing challenges [1, 2]. One of the hallmark features of cancer cells is their altered metabolism, which supports rapid growth and survival in hostile environments [3, 4]. The study of cancer metabolism dates back to the early 20th century, when Otto Warburg first observed that cancer cells preferentially utilize glycolysis for energy production, even in sufficient oxygen – a phenomenon now known as the Warburg effect [5]. Warburg’s discovery was revolutionary, challenging the prevailing belief that oxidative phosphorylation in mitochondria was the primary energy source for all cells, including cancerous ones. Over the decades, subsequent research has expanded our understanding of the metabolic reprogramming in cancer cells, revealing a complex network of altered pathways that contribute to tumorigenesis and cancer progression.

The metabolic reprogramming in cancer cells is not limited to enhanced glycolysis. It encompasses a range of alterations in various metabolic pathways, including increased glucose uptake and lactate production even under aerobic conditions (aerobic glycolysis) [6], dependency on glutamine for anaplerosis and biosynthesis (glutaminolysis) [3], enhanced lipogenesis and altered fatty acid oxidation (lipid metabolism) [3], and changes in the metabolism of amino acids like serine and glycine [3]. Despite the emphasis on glycolysis, many cancer cells still rely on mitochondrial respiration for survival and proliferation. These alterations are driven by oncogenes and tumor suppressor genes, which rewire cellular metabolism to meet the demands of rapid cell division, resist cell death, and adapt to hypoxic conditions within the tumor microenvironment (TME) [7].

At the molecular level, several key regulators orchestrate the metabolic reprogramming in cancer cells. Oncogenes such as MYC and RAS promote anabolic processes and increase the uptake and utilization of nutrients [8]. When lost, tumor suppressor genes like TP53 and LKB1 can enhance glycolysis and biosynthetic pathways [9, 10]. Hypoxia-inducible factors (HIFs) induce the expression of glycolytic enzymes and glucose transporters in response to low oxygen levels [11, 12]. The AMP-activated protein kinase (AMPK) acts as a cellular energy sensor and regulator, balancing energy supply and demand [13, 14], while the mTOR signaling pathway promotes protein synthesis and cell growth, integrating signals from nutrients and growth factors [15].

Recognizing altered metabolism as a cancer hallmark has opened new avenues for therapeutic intervention [16, 17]. Targeting metabolic pathways offers the potential to disrupt the energy supply and biosynthetic processes essential for tumor growth [18, 19]. Some promising therapeutic strategies include inhibitors of glycolysis that target key glycolytic enzymes such as hexokinase and lactate dehydrogenase, glutamine antagonists that inhibit glutamine uptake or metabolism, lipid metabolism inhibitors that target fatty acid synthesis and oxidation pathways, and mitochondrial metabolism modulators that disrupt mitochondrial function and oxidative phosphorylation. Clinical trials are exploring these and other metabolic targets to develop effective treatments with minimal toxicity to normal cells.

This review aims to provide a detailed and integrated overview of the current understanding of altered metabolism in cancer. It explores key energy pathways, including glycolysis, oxidative phosphorylation, glutaminolysis, and lipid metabolism, highlighting their roles and regulatory mechanisms in cancer cells. The review also examines the regulation of these pathways by oncogenes and tumor suppressors, epigenetic modifications, and microenvironmental factors. Furthermore, it discusses therapeutic targets in cancer metabolism, including glycolysis inhibitors, oxidative phosphorylation, glutaminase, and lipid metabolism. Finally, it addresses challenges and future directions in overcoming metabolic plasticity, developing combination therapies, and identifying biomarkers for metabolic targeting, aiming to inform the development of novel therapeutic approaches.

Metabolic reprogramming in cancer

Cancer cells exhibit profound alterations in their metabolism, supporting their rapid growth, survival, and ability to adapt to diverse and often hostile environments. Herein, we shed light on two critical aspects of metabolic reprogramming in cancer: the Warburg effect and additional metabolic pathways that extend beyond this well-known phenomenon.

The Warburg effect is one of cancer cells’ most well-characterized metabolic alterations. Warburg observed that cancer cells favor glycolysis for energy production, even with adequate oxygen [20]. This preference for glycolysis over oxidative phosphorylation, despite its lower efficiency in ATP production, is a hallmark of many types of cancer [21].

In normal cells, glycolysis is typically followed by oxidative phosphorylation in the mitochondria under aerobic conditions, yielding up to 36 molecules of ATP per glucose molecule [22]. In contrast, glycolysis alone produces only 2 ATP molecules per glucose molecule. However, cancer cells compensate for this inefficiency by upregulating glucose transporters and glycolytic enzymes, leading to an increased glycolytic flux [22, 23]. This metabolic reprogramming supports rapid cell proliferation by providing both ATP and metabolic intermediates for biosynthetic processes, such as nucleotide and lipid synthesis.

Various oncogenic signals and mutations in tumor suppressor genes drive the Warburg effect. For instance, activating oncogenes like MYC and RAS enhances glycolytic enzyme expression [24], while mutations in tumor suppressors like TP53 and PTEN further promote glycolysis [25, 26]. Additionally, HIFs, which are stabilized in low oxygen conditions commonly found in tumors, increase the expression of glycolytic enzymes and glucose transporters, further reinforcing the Warburg effect [24].

While the Warburg effect is central to cancer metabolism, it is not the sole metabolic alteration observed in cancer cells. Several other metabolic pathways are reprogrammed to support the unique demands of tumor growth and survival. Glutaminolysis highlights cancer cells’ dependence on the amino acid glutamine, serving as a key nitrogen donor for nucleotide and amino acid biosynthesis and replenishing tricarboxylic acid (TCA) cycle intermediates. Enzymes such as glutaminase (GLS) are frequently upregulated, indicating potential therapeutic targets [27, 28]. Alterations in lipid metabolism, including enhanced de novo lipogenesis and changes in fatty acid oxidation, provide essential components for membrane biogenesis and additional energy sources. Despite the Warburg effect suggesting a reduced reliance on oxidative phosphorylation, many cancer cells still utilize mitochondrial respiration to meet energy demands and support biosynthetic pathways, playing crucial roles in apoptosis regulation and reactive oxygen species (ROS) production [29]. Beyond glutamine, other amino acids like serine and glycine are critical, with the serine-glycine-one-carbon (SGOC) metabolism pathway supporting nucleotide synthesis and redox balance. Enzymes such as serine hydroxymethyltransferase (SHMT) and glycine decarboxylase (GLDC) are often upregulated, underscoring their importance in cancer metabolism [29, 30].

While the Warburg effect has been widely studied, it is important to consider the interconnectedness of metabolic pathways such as glutaminolysis, lipid metabolism, and SGOC metabolism, which cancer cells utilize to meet their biosynthetic and energy demands. Targeting single pathways, like inhibiting GLS in glutaminolysis, has shown potential in certain cancers, but a combined therapeutic approach could yield better results. For example, combining glycolysis inhibitors with mitochondrial respiration inhibitors could cut off cancer cells’ access to multiple energy sources. Moreover, further research into how cancer cells switch between these pathways in response to treatments is crucial, as understanding this metabolic plasticity may reveal new vulnerabilities.

Metabolic synthetic lethalities in cancer

Metabolic synthetic lethality refers to the concept where the combination of a genetic mutation and a metabolic vulnerability leads to cancer cell death, while each factor alone does not. In cancer, this approach exploits the specific metabolic dependencies of tumor cells to induce selective cell death. Tumor cells often have altered metabolic pathways that can create unique vulnerabilities [31, 32].

Metabolic synthetic lethality offers a promising strategy for targeting tumors with specific genetic alterations, particularly those affecting the TCA cycle. This approach capitalizes on the unique metabolic dependencies created by mutations in key TCA cycle enzymes, leading to vulnerabilities that can be therapeutically exploited. Among the enzymes frequently mutated in various cancers are succinate dehydrogenase (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase (IDH). These mutations result in profound metabolic alterations that create therapeutic opportunities. Understanding how these mutations influence tumor metabolism is crucial for developing targeted treatments.

SDH mutations are genetic alterations that lead to the accumulation of succinate, disrupting the TCA cycle and causing metabolic imbalances in tumor cells. Mutations in SDH result in the accumulation of succinate, which profoundly alters tumor metabolism and creates several vulnerabilities. One significant adaptation in SDH-deficient tumors is an increased reliance on glycolysis for energy production. This heightened glycolytic activity represents a potential therapeutic target; inhibitors of glycolytic enzymes or glucose transporters may selectively affect these tumors [33, 34]. For example, in SDH-deficient tumors, which rely heavily on glycolysis due to TCA cycle impairment, WZB117, a GLUT1 inhibitor, can effectively reduce glucose uptake, decrease intracellular ATP, downregulate glycolytic enzymes, and inhibit tumor growth, making it a promising candidate for enhancing treatment outcomes and sensitizing tumors to other therapies [35]. Additionally, to compensate for the disrupted TCA cycle, SDH-mutant cells often become heavily dependent on glutamine metabolism. Targeting enzymes involved in glutamine utilization, such as glutaminase, could selectively impair these cancer cells. For instance, studies indicate that SDHB knockout cells exhibit heightened sensitivity to GLS-1 inhibitors, suggesting that targeting this enzyme could selectively impair the growth of SDH-mutant tumors [36, 37]. Moreover, the accumulation of succinate and subsequent disruptions in cellular redox balance can lead to increased oxidative stress. Therapeutic strategies that further elevate reactive oxygen species levels might overwhelm the oxidative stress tolerance of these cells, leading to selective cell death.

FH mutations cause fumarate accumulation, leading to distinct metabolic dependencies and vulnerabilities. One notable consequence is the upregulation of heme synthesis, as FH-mutant cells attempt to manage excess fumarate. Targeting heme oxygenase-1 (HO-1), which is involved in heme degradation, has shown potential in selectively targeting FH-deficient tumors [38, 39]. Another vulnerability arises from the dependency of some FH-deficient cells on argininosuccinate synthase to handle excess fumarate. Inhibiting this enzyme could provide a synthetic lethal approach. Additionally, like SDH-deficient tumors, FH-deficient cells often exhibit impaired oxidative phosphorylation and increased reliance on glycolysis [38, 39]. Combining glycolysis inhibitors with other agents could be a potent strategy against tumors. For example, recent studies demonstrated that combining arsenic trioxide (ATO) with HO-1 inhibitors enhances cytotoxicity, induces apoptosis, and modulates autophagy via an ROS-dependent mechanism in pancreatic ductal adenocarcinoma (PDAC) cells [40], while simultaneously targeting HO-1 and σR proteins with novel hybrid compounds shows enhanced antiproliferative activity in DU145 prostate and U87MG glioblastoma cells, highlighting promising strategies for developing more effective and less toxic anticancer therapies [41].

Moreover, mutations in IDH lead to the production of 2-hydroxyglutarate (2-HG), which induces distinctive metabolic changes in tumors. One major alteration is NAD + depletion, a consequence of altered metabolic pathways. IDH-mutant tumors are particularly sensitive to further NAD + depletion, suggesting that targeting NAD + salvage pathways could selectively impair these cells [42, 43]. Such as, treatment with NAMPT inhibitors resulted in significant reductions in intracellular NAD + levels and induced cell death specifically in IDH1/2-mutant cancer cell lines. The depletion of NAD + activated the energy sensor AMPK, triggered autophagy, and ultimately led to cytotoxicity in these cancer cells. This demonstrates a clear therapeutic strategy: by inhibiting NAMPT, which is already compromised in IDH1-mutant cells, it is possible to selectively target and kill these cancer cells while sparing normal cells that do not share this metabolic vulnerability [44, 45]. Furthermore, many IDH-mutant tumors become dependent on glutamine as a source of α-ketoglutarate to produce 2-HG [43, 46]. Targeting glutamine metabolism in these cancers could therefore be an effective therapeutic strategy. Additionally, IDH mutations can alter lipid metabolism, affecting lipid synthesis and fatty acid oxidation. Exploiting these metabolic changes through inhibition of key lipid metabolism enzymes might offer further therapeutic opportunities [43].

Overall, metabolic synthetic lethality offers a promising approach for cancer treatment by targeting the unique metabolic dependencies caused by TCA cycle mutations, enabling greater selectivity and reduced toxicity to normal cells. This strategy also has the potential to overcome resistance to conventional therapies and enhance efficacy when combined with targeted treatments or immunotherapies. Moreover, identifying specific TCA cycle mutations as biomarkers can help tailor therapies to patients most likely to benefit, making this approach a significant advancement in developing personalized and more effective cancer treatments.

Key energy pathways

Glycolysis

Glycolysis, the central metabolic pathway that converts glucose into pyruvate, plays a pivotal role in the altered metabolism of cancer cells [47, 48]. This process, fundamental to normal and malignant cells, has been extensively studied for its implications in cancer biology and therapeutic targeting. In cancer, glycolysis operates under significantly different dynamics than normal cells, often called the Warburg effect.

Cancer cells undergo significant metabolic alterations to support rapid growth and proliferation [49, 50]. One of the most notable changes is the upregulation of glucose transporters, particularly GLUT1, which enhances glucose influx into the cells [51, 52]. For example, a recent study has reported that GLUT1 is highly expressed in lung adenocarcinoma (LUAD), and its elevated levels are associated with poor patient survival. Functional studies have demonstrated that GLUT1 plays an oncogenic role in LUAD, as its knockdown results in decreased cell proliferation, colony formation, migration, and invasion while also inducing apoptosis in LUAD cells. Mechanistically, GLUT1 interacts directly with phosphorylated epidermal growth factor receptor (p-EGFR), preventing EGFR protein degradation via ubiquitin-mediated proteolysis [53]. These findings suggest that targeting GLUT1 could be a promising therapeutic strategy. Notably, combining GLUT1 inhibitors with EGFR-tyrosine kinase inhibitors (TKIs) like Gefitinib may enhance therapeutic efficacy in treating LUAD [53]. This increased glucose uptake is the foundation for 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging, a common technique used in cancer diagnosis. In addition to increased glucose uptake, cancer cells exhibit an enhanced glycolytic flux. This is characterized by higher glycolysis rates than normal cells, facilitated by upregulating key glycolytic enzymes such as hexokinase II [23]. Despite the presence of oxygen, cancer cells preferentially convert pyruvate to lactate via lactate dehydrogenase A (LDHA) [51], rather than oxidizing it in the mitochondria. This phenomenon, known as the Warburg effect, is a hallmark of cancer metabolism.

Various factors regulate the switch to glycolysis in cancer cells. Oncogenes such as HIF-1α, c-Myc, and Akt are known to promote glycolysis [51], whereas tumor suppressors like p53 act to suppress it. The loss of p53 in cancer cells often promotes a glycolytic phenotype [51]. For instance, HIF-1α is a key regulator of cellular response to hypoxia and promotes glycolysis through several mechanisms: it increases the expression of glucose transporters GLUT1 and GLUT3, enhancing glucose uptake; upregulates nearly all glycolytic enzymes, including hexokinases (HK1 and HK2), phosphofructokinases (PFKL and PFKP), and pyruvate kinase M (PKM); and enhances the expression of lactate dehydrogenase A (LDHA) and monocarboxylate transporter 4 (MCT4), facilitating lactate production and export. Additionally, HIF-1α reduces oxidative phosphorylation by promoting mitophagy and decreasing mitochondrial biogenesis [54]. While c-Myc directly activates the transcription of many glycolytic enzyme genes and cooperates with HIF-1α to enhance the transcription of key glycolytic enzymes such as hexokinase 2 (HK2) and pyruvate dehydrogenase kinase 1 (PDK1). This collaboration between c-Myc and HIF-1α leads to additive increases in glucose uptake and lactate production [55]. Furthermore, activation of signaling pathways like PI3K/Akt/mTOR enhances glycolysis, contributing to the metabolic reprogramming observed in cancer cells. For example, Akt activation increases glucose uptake by inhibiting thioredoxin-interacting protein (TXNIP), leading to higher expression of glucose transporters GLUT1 and GLUT4 on the cell surface [56]. It enhances glycolytic enzyme activity by phosphorylating and activating key enzymes such as hexokinase 2 (HK2) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB2), promoting glycolysis [56]. The PI3K/Akt pathway shifts metabolism towards aerobic glycolysis, making cancer cells dependent on glucose [56]. Akt also regulates metabolism through transcription factors by activating mTORC1 and inhibiting FOXO, and it may influence mitochondrial function to sustain TCA cycle flux [57]. Additionally, the pathway causes long-term metabolic reprogramming and interacts with other signaling pathways like HIF-1α to modulate glucose metabolism, contributing to the complex metabolic changes in cancer cells [58].

Targeting glycolysis offers a promising avenue for cancer therapy, aiming to exploit the metabolic vulnerabilities of cancer cells. Several strategies are being explored, including inhibition of glycolytic enzymes, targeting glucose transporters, and exploiting lactate production. Hexokinase inhibitors like 2-deoxyglucose (2-DG) disrupt glycolysis and induce cell death in cancer cells [52, 59]. Small molecules that promote the tetrameric, active form of PKM2 can shift metabolism away from glycolysis towards oxidative phosphorylation, inhibiting cancer cell proliferation [59, 60]. Inhibitors of GLUT1 can restrict glucose uptake, starving cancer cells of their primary energy source [52, 59]. Moreover, inhibiting LDHA blocks the conversion of pyruvate to lactate, accumulating toxic levels of pyruvate and disrupting redox balance [59, 61]. Agents that neutralize the acidic tumor microenvironment can impair cancer cell invasion and enhance immune cell activity [59, 62]. Combining glycolysis inhibitors with conventional therapies such as chemotherapy, radiation, or immunotherapy may enhance overall efficacy by concurrently targeting multiple cancer cell survival mechanisms. Figure 1 illustrates the glycolytic pathway in cancer cells, highlighting key steps, regulatory roles of oncogenes and tumor suppressors, the Warburg effect, reduced reliance on mitochondrial metabolism, potential therapeutic targets, and the clinical relevance of glycolytic metabolites as biomarkers and in 18 F-FDG PET imaging (Fig. 1).Fig. 1 This figure illustrates glycolysis as a key energy pathway in cancer cells, highlighting the pathway's steps from glucose to pyruvate, including all intermediate metabolites and enzymes (e.g., hexokinase, phosphofructokinase, pyruvate kinase). The roles of oncogenes and tumor suppressors in regulating glycolysis are indicated. The Warburg effect is highlighted by showing increased glycolytic flux and lactate production despite the presence of oxygen, with pyruvate diverted to lactate dehydrogenase instead of mitochondria. The contrast between glycolysis and oxidative phosphorylation in mitochondria is depicted, indicating the reduced reliance on mitochondrial metabolism in cancer cells. Potential therapeutic targets within the glycolytic pathway are showed, and suggestions for combining glycolytic inhibitors with other treatments are included. The clinical relevance is emphasized by showing how glycolytic metabolites or enzyme levels can serve as biomarkers for cancer diagnosis, with reference to 18F-fluorodeoxyglucose (FDG) PET imaging used for detecting high glycolytic activity in tumors

Oxidative phosphorylation

Oxidative phosphorylation (OXPHOS) is a fundamental metabolic pathway for ATP production through the mitochondria’s electron transport chain (ETC). Despite the prominence of the Warburg effect, which describes cancer cells’ preference for glycolysis even under aerobic conditions, OXPHOS remains crucial in many cancers and plays an important role in the progression of cancer and could be a potential therapeutic target (Fig. 2). While many cancer cells exhibit increased glycolysis, they often maintain functional OXPHOS. For example, leukemias and lymphomas can maintain functional OXPHOS despite their glycolytic activity, and similar observations are seen in pancreatic ductal adenocarcinoma, where OXPHOS remains active in this aggressive cancer type. Some melanomas, particularly the high OXPHOS subtype, exhibit increased OXPHOS alongside glycolysis, and endometrial carcinoma cells can also persist with active OXPHOS [63]. This dual capability allows cancer cells to adapt to varying environmental conditions, such as oxygen and nutrient availability fluctuations. OXPHOS serves as an additional ATP source when insufficient glycolysis occurs, ensuring a continuous energy supply essential for rapid cell division and growth [64, 65]. For example, acute myeloid leukemia (AML) cells demonstrate this dual metabolic capability [66, 67]. While many cancer cells primarily rely on glycolysis (the Warburg effect), AML cells, particularly leukemic stem cells (LSCs), strongly prefer OXPHOS [66, 68]. This metabolic flexibility allows AML cells to adapt to different microenvironments and resist chemotherapy. For instance, studies have shown that chemotherapy-resistant AML cells have enhanced mitochondrial respiration capacity. These cells, characterized by a low SoNar ratio, primarily reside in the vascular niche and are enriched with functional leukemia-initiating cells. The SoNar-low AML cells demonstrate higher levels of oxidative phosphorylation, contributing to their resistance to cytosine arabinoside (Ara-C), a common chemotherapy drug [66]. Furthermore, research has found that treatment-resistant AML LSCs can maintain OXPHOS even under challenging conditions [67]. This metabolic adaptation allows them to survive and potentially lead to disease relapse. The ability to switch between glycolysis and OXPHOS enables these cells to thrive in various oxygen and nutrient conditions within the bone marrow microenvironment [67, 69]. This dual metabolic capability in AML cells highlights the importance of targeting glycolysis and OXPHOS in developing more effective treatments. Cancer cells’ ability to switch between glycolysis and OXPHOS, known as metabolic flexibility, is vital for survival [70]. This adaptability supports cancer cells in hostile microenvironments, including hypoxia and nutrient scarcity [71]. For instance, cancer cells may rely more on OXPHOS during metastasis to meet their energy demands. This metabolic flexibility is a key factor in the resilience and aggressiveness of cancer cells [72].Fig. 2 This figure illustrates the role of Oxidative Phosphorylation (OXPHOS) in cancer metabolism, detailing key components, alterations, and therapeutic targets. The figure depicts the mitochondrial structure, including the electron transport chain (ETC) complexes I-IV and ATP synthase (Complex V), highlighting the flow of electrons from NADH and FADH2 to oxygen, producing water and ATP via chemiosmosis and the proton gradient. The figure also shows common cancer-associated alterations, such as the Warburg effect, mitochondrial dysfunction, and increased reactive oxygen species (ROS) production. Mutations in mtDNA genes can disrupt electron flow, leading to increased ROS production, which damages cellular components like DNA, proteins, and lipids, promoting further mutations and cancer progression. These mutations can also activate oncogenic signaling pathways such as NF-κB and HIF-1α. The bottom panel emphasizes therapeutic strategies, including ETC complex inhibitors, agents affecting mitochondrial biogenesis, and ROS modulation

Furthermore, mitochondrial dynamics and function are often altered in cancer cells. Proteins like Drp1 (dynamin-related protein 1) and Mfn1/2 (mitofusins) regulate mitochondrial fission and fusion processes, affecting OXPHOS efficiency [73, 74]. Additionally, cancer cells may enhance mitochondrial biogenesis through factors like PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) to boost their OXPHOS capacity. These adaptations ensure that mitochondria meet proliferating cancer cells’ increased energetic and biosynthetic demands [74, 75].

Moreover, key oncogenes and tumor suppressors modulate OXPHOS in cancer. For example, c-Myc enhances mitochondrial biogenesis and respiration, supporting rapid cell growth [74, 75]. Conversely, mutations in tumor suppressors like p53 can disrupt mitochondrial function and OXPHOS, contributing to tumor metabolic reprogramming. These genetic alterations highlight the complex regulation of OXPHOS in cancer and its contribution to tumorigenesis.

Hypoxia-inducible factors (HIFs) are transcription factors activated under low oxygen conditions, playing a critical role in reprogramming cellular metabolism [76, 77]. HIF-1α typically promotes glycolysis and suppresses OXPHOS by inducing pyruvate dehydrogenase kinase (PDK), which inhibits the entry of pyruvate into the tricarboxylic acid (TCA) cycle [78, 79]. However, HIF-2α has been shown to maintain OXPHOS in certain cancer contexts, illustrating the complexity of metabolic regulation under hypoxic conditions [12]. For example, one study demonstrated that HIF-1α primarily regulates VEGF expression in response to hypoxia and IGF-I in MCF-7 cells, while HIF-2α plays a dominant role in driving VEGF and other target gene expression in renal carcinoma cells with VHL loss. The findings also revealed a reciprocal relationship between HIF-1α and HIF-2α, where silencing HIF-2α enhances HIF-1α–mediated VEGF expression under hypoxic conditions. Additionally, the small-molecule inhibitor NSC-134,754 was shown to effectively reduce both HIF-1α and HIF-2α protein levels and VEGF expression, presenting a promising therapeutic strategy for targeting the HIF pathway in cancers [80]. In contrast, another study focusing on gastric cancer found that HIF-1α, but not HIF-2α, dimerizes with HIF-1β to regulate the expression of angiogenesis and glucose metabolism-related target genes, such as VEGF, in response to hypoxia. This emphasizes the critical role of HIF-1α in early-stage gastric cancer development and highlights important insights into the HIF pathway’s role in tumor progression, offering potential targets for therapeutic intervention [81].

OXPHOS is also implicated in cancer cell invasion and metastasis [63, 64]. Mitochondrial ATP production supports the energy-intensive processes of cell migration and invasion. Additionally, reactive oxygen species (ROS) generated by OXPHOS can activate signaling pathways that promote metastatic behaviors. OXPHOS in mitochondria is a major source of ROS in cells, as electron transport can lead to electron leakage and partial oxygen reduction, forming superoxide anions that convert to other ROS like hydrogen peroxide [82]. ROS are crucial signaling molecules at moderate levels, activating pathways in cancer progression and metastasis [83]. They can trigger several pro-metastatic signaling cascades, including the NF-κB pathway [84], which regulates genes related to cell survival, proliferation, and metastasis, and MAPK pathways that influence cell proliferation, survival, and migration [82]. Additionally, ROS can activate the PI3K-Akt pathway, promoting cell survival and metastasis [84]. ROS enhance cell motility and invasion by increasing the expression and activity of matrix metalloproteinases (MMPs), which degrade the extracellular matrix [82, 84]. They also induce epithelial-mesenchymal transition (EMT), endowing cancer cells with a more invasive phenotype, and stimulate the production of pro-angiogenic factors like VEGF, facilitating new blood vessel formation to support metastasis [83, 84]. Moreover, ROS contributes to anoikis resistance, allowing cancer cells to survive in circulation, establish metastases at distant sites, and aid in forming pre-metastatic niches in distant organs, creating environments conducive to secondary tumor establishment [85]. This highlights the role of OXPHOS in energy production and in facilitating cancer progression and metastasis [86, 87].

Similarly, cancer stem cells (CSCs) rely on OXPHOS for their metabolic flexibility and survival in diverse tumor microenvironments. CSCs are a subpopulation of cancer cells within a tumor that can self-renew, differentiate into various cell types, and drive tumor growth and recurrence. This metabolic flexibility allows CSCs to switch between glycolysis and OXPHOS, aiding survival in various tumor microenvironments and supporting therapy resistance. Furthermore, enhanced mitochondrial biogenesis and effective ROS management, regulated by key signaling pathways such as PI3K/AKT/mTOR and AMPK, further support the reliance of CSCs on OXPHOS for their mitochondrial function and energy metabolism [88, 89]. The reliance on OXPHOS makes CSCs resistant to conventional therapies targeting glycolysis-dependent cells, while their ability to enter quiescence and undergo EMT enhances their resilience and metastatic potential [90, 91]. Targeting OXPHOS in CSCs is an emerging strategy to eradicate these resilient cell populations and improve therapeutic outcomes.

Several agents targeting OXPHOS are under investigation, including metformin [92], phenformin [93], and IACS-010759 [94]. These inhibitors reduce ATP production, induce energetic stress, and selectively kill cancer cells with high OXPHOS dependence. Combining OXPHOS inhibitors with other treatments, such as glycolysis inhibitors or conventional chemotherapies, can enhance anti-tumor efficacy. This dual inhibition approach exploits the metabolic flexibility of cancer cells, pushing them beyond their energetic limits. Moreover, mitochondrial uncouplers, such as 2,4-dinitrophenol (DNP), dissipate the proton gradient across the mitochondrial membrane, reducing ATP synthesis and increasing metabolic stress [95, 96]. These agents show potential in preclinical models, though their use requires careful dosing due to potential toxicity [97, 98]. The development of safer and more effective mitochondrial uncouplers could provide another avenue for targeting OXPHOS in cancer.

Glutaminolysis

Glutaminolysis is a metabolic process that converts glutamine to glutamate and subsequently to α-ketoglutarate, which can enter the tricarboxylic acid (TCA) cycle to produce energy and support biosynthetic processes. This pathway is particularly important in cancer metabolism (Fig. 3), as many cancer cells exhibit an increased dependence on glutamine, making it a critical fuel source for their growth and survival [99].Fig. 3 This figure illustrates glutaminolysis as a Key Energy Pathway in Cancer. Glutamine is transported into cancer cells and converted to glutamate by glutaminase (GLS). Glutamate is further converted to α-ketoglutarate (α-KG), entering the TCA cycle to support energy production. Glutaminolysis also replenishes TCA cycle intermediates and produces biosynthetic precursors for macromolecule synthesis. Additionally, it generates NADPH to maintain redox balance. Key enzymes in this pathway are potential therapeutic targets for cancer treatment

Glutaminolysis begins with the uptake of glutamine, an abundant amino acid in the body, into the cell [100]. Once inside, glutamine is converted to glutamate by the enzyme glutaminase (GLS). Glutamate can then be further converted to α-ketoglutarate by either glutamate dehydrogenase (GDH) or transaminases. α-Ketoglutarate enters the TCA cycle, contributing to the production of ATP and providing intermediates for synthesizing nucleotides, amino acids, and lipids [101, 102]. This metabolic pathway is particularly active in rapidly proliferating cells, including cancer cells, which require a constant supply of these biosynthetic precursors.

Cancer cells often exhibit altered metabolism to support their rapid growth and proliferation. One of these alterations is an increased reliance on glutamine, making glutaminolysis a critical pathway in cancer metabolism. Glutamine provides a carbon source for the TCA cycle and nitrogen for synthesizing nucleotides and amino acids, essential for DNA replication and protein synthesis [100]. This contribution to the TCA cycle supports energy production and the synthesis of other metabolic intermediates [103]. Simultaneously, the nitrogen atoms in glutamine are utilized in the biosynthesis of nucleotides, the building blocks of DNA and RNA, and other amino acids [104]. For example, in rapidly dividing cells like cancer cells or immune cells responding to infection, glutamine is often consumed at high rates to support the increased demand for nucleotide synthesis during DNA replication and amino acid production for protein synthesis [105]. This makes glutamine a critical nutrient for cell growth, proliferation, and survival, particularly when rapid cell division or protein production is required.

Glutaminolysis supports cancer cell survival under various stress conditions, such as nutrient deprivation and hypoxia. By providing intermediates for the TCA cycle, glutaminolysis helps maintain cancer cells’ energy balance and redox status. For example, in renal cell carcinoma and glioblastoma cells, which exhibit a high dependency on glutamine. Under conditions of nutrient deprivation, these cancer cells increase the expression of glutamine transporters like SLC1A5, facilitating enhanced uptake of glutamine. Once inside the cell, glutamine is converted to glutamate by glutaminase, and subsequently, glutamate can be transformed into α-KG through the action of glutamate dehydrogenase (GLUD). This α-KG then enters the TCA cycle, replenishing its intermediates and sustaining energy production necessary for cell survival and growth during stress conditions [29, 106]. Additionally, cancer cells often rely on glutaminolysis to support their metabolic needs. The conversion of glutamine to α-KG not only fuels the TCA cycle but also contributes to the synthesis of nucleotides and amino acids, which are vital for cellular functions and proliferation. This metabolic adaptation allows cancer cells to thrive even when oxygen levels are low, demonstrating the importance of glutaminolysis in maintaining their viability under adverse conditions [100, 107].

Many cancer cells exhibit what is known as “glutamine addiction,” where they become highly dependent on glutamine for their growth and survival [108]. This phenomenon is driven by the activation of oncogenes such as MYC, which upregulate glutamine transporters and enzymes involved in glutaminolysis. For example, MYC increases the expression of glutaminase, enhancing the conversion of glutamine to glutamate and subsequently fueling the TCA cycle and biosynthetic processes [108]. This metabolic reprogramming towards increased glutaminolysis provides cancer cells with a growth advantage but also creates a vulnerability. Targeting glutamine metabolism can selectively impair the growth of glutamine-dependent cancer cells while sparing normal cells that are less reliant on this pathway.

The dependence of many cancers on glutaminolysis presents a potential target for therapeutic intervention. Inhibitors of glutaminase, such as CB-839, have shown promise in preclinical and clinical studies by reducing the proliferation of cancer cells and enhancing the efficacy of other anticancer therapies. These inhibitors block the conversion of glutamine to glutamate, disrupting the supply of α-ketoglutarate to the TCA cycle and reducing the production of ATP and biosynthetic precursors. Furthermore, combining glutaminase inhibitors with other metabolic inhibitors or conventional therapies could provide a more effective approach to cancer treatment. For instance, targeting glutaminolysis and glycolysis can simultaneously disrupt the two major metabolic pathways in cancer cells, leading to metabolic stress and cell death. Additionally, therapies that induce oxidative stress, such as radiation or certain chemotherapeutics, may be more effective when combined with glutaminase inhibitors, as cancer cells become more susceptible to oxidative damage when their antioxidant defenses are compromised. For example, in pre-clinical studies, CB-839 demonstrated significant antiproliferative effects in the triple-negative breast cancer (TNBC) cell line HCC-1806 by markedly reducing glutamine consumption, glutamate production, and levels of several tricarboxylic acid cycle intermediates, as well as decreasing oxygen consumption and glutathione levels. However, CB-839 showed limited activity in the estrogen receptor-positive cell line T47D. The sensitivity of TNBC cells to CB-839 was associated with their reliance on extracellular glutamine for growth, elevated intracellular levels of glutamate and glutamine, and higher expression of GAC. Additionally, CB-839 exhibited notable antitumor efficacy in xenograft models, including a patient-derived TNBC model and the basal-like HER2(+) cell line JIMT-1, both as a single agent and in combination with paclitaxel [109]. Moreover, another study evaluated the effects of CB-839 on radiation sensitivity using human HNSCC cell lines and xenograft models. The combination of IR and CB-839 significantly reduced cell survival, spheroid size, and tumor growth compared to either treatment alone. Additionally, CB-839 decreased the oxygen consumption rate/extracellular acidification rate ratio in CAL-27 and HN5 cells and increased oxidative stress and DNA damage in irradiated CAL-27 cells. These findings suggest that combining IR with CB-839 enhances the anti-tumor response in HNSCC, supporting further clinical investigation of this combination therapy [110].

Lipid metabolism

Lipid metabolism, a crucial cellular process, involves lipids’ synthesis, degradation, and utilization. In cancer, lipid metabolism is often reprogrammed to meet malignant cells’ high energy demands and rapid growth rates (Fig. 4). This metabolic reprogramming is a hallmark of cancer, enabling tumor cells to sustain their proliferative capabilities, evade apoptosis, and adapt to the tumor microenvironment [111, 112].Fig. 4 This figure illustrates the comprehensive pathways of lipid metabolism in cancer cells, highlighting key processes such as lipid uptake, storage, fatty acid synthesis, β-oxidation, and cholesterol metabolism. Lipid uptake involves lipoprotein lipase (LPL), fatty acid transporters (FAT/CD36, FABP), and the formation of lipid droplets. Fatty acid synthesis is detailed from the conversion of citrate to acetyl-CoA, catalyzed by enzymes including ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN), with regulation by stearoyl-CoA desaturase (SCD). The figure also depicts fatty acid oxidation (β-oxidation) within mitochondria and peroxisomes, mediated by carnitine palmitoyltransferase I (CPT1) and acyl-CoA dehydrogenases (ACAD). Cholesterol metabolism is shown, which can lead to the progression of cancer. Additionally, potential therapeutic targets and inhibitors, such as FASN and CPT1 inhibitors, are marked, underscoring their relevance in cancer treatment

Cancer cells exhibit significant alterations in lipid metabolism compared to normal cells. These changes include increased de novo lipogenesis [113], enhanced fatty acid uptake [112], and altered fatty acid oxidation [114]. De novo lipogenesis, the process by which cells synthesize fatty acids from non-lipid precursors, is upregulated in many cancers. Key enzymes involved in this pathway, such as ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN), are often overexpressed in tumor cells. This results in an abundant supply of fatty acids essential for membrane biogenesis, energy production, and the synthesis of signaling molecules. For example, in breast cancer, DNL is essential for sustaining the membrane composition and energy needs of rapidly proliferating tumor cells. Luminal subtypes rely heavily on DNL for fatty acid replenishment, while basal-like receptor-negative cancers tend to use exogenous fatty acids more. This metabolic shift is driven by various genomic and proteomic changes that influence lipogenic enzyme expression and activity [115, 116]. Inhibiting enzymes involved in DNL, such as FASN, has been shown to reduce tumor growth and enhance chemotherapy sensitivity, highlighting DNL as a promising target for therapeutic intervention [117, 118].

Furthermore, fatty acid uptake is also elevated in cancer cells, facilitated by overexpression of fatty acid transport proteins (FATPs) and CD36, a scavenger receptor involved in lipid uptake [119, 120]. This allows cancer cells to scavenge extracellular fatty acids, providing an additional energy source and building blocks for membrane synthesis. Furthermore, the process of fatty acid oxidation (FAO), which breaks down fatty acids to generate ATP, is often reprogrammed in cancer cells. While some cancers increase FAO to meet their energy demands, others decrease it to divert fatty acids toward lipid synthesis pathways [121].

Lipids serve not only as energy sources but also as critical signaling molecules in cancer. Lipid signaling pathways, mediated by molecules such as phosphoinositides, sphingolipids, and eicosanoids, play pivotal roles in cell proliferation, survival, migration, and invasion [111, 113]. For instance, the PI3K/Akt pathway, frequently activated in cancer, is heavily influenced by lipid signaling. Activation of PI3K catalyzes the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a lipid second messenger that recruits and activates Akt, promoting cell survival and growth [122].

Furthermore, sphingolipid metabolism is also intricately linked to cancer progression [123, 124]. Sphingolipid metabolism refers to the biochemical processes involved in synthesising, breaking down, and regulating sphingolipids, a lipid class that plays crucial roles in cell membrane structure and signaling. This pathway involves various enzymes and intermediates, such as ceramide and sphingosine, and is essential for cell growth, differentiation, apoptosis, and responses to stress. Ceramide, a central molecule in sphingolipid metabolism, can induce apoptosis, while its metabolites, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), promote cell proliferation and survival [125, 126]. The balance between these opposing lipid signals is often disrupted in cancer, favoring tumor growth and resistance to cell death [113].

The TME, composed of cancer cells, stromal cells, immune cells, and extracellular matrix, plays a crucial role in cancer progression and metastasis. Lipid metabolism within the TME is highly dynamic and contributes to the metabolic crosstalk between different cell types. Cancer-associated fibroblasts (CAFs) and adipocytes within the TME can supply fatty acids to cancer cells, supporting their metabolic needs. Additionally, hypoxic conditions within the TME can induce lipid droplet formation in cancer cells, serving as energy reservoirs that can be mobilized during periods of metabolic stress [114]. As, in a mouse model of gastric cancer, lipid aggregation in tumor-associated macrophages (TAMs) upregulated the expression of phosphoinositide 3-kinase (PI3K-γ) and promoted TAM polarization to the M2 phenotype. This lipid metabolism in TAMs is closely associated with immunosuppression and chemotherapy resistance [127]. Immune cells within the TME, such as TAMs, also exhibit altered lipid metabolism. TAMs can undergo metabolic reprogramming to support tumor growth and suppress anti-tumor immunity. For instance, TAMs often rely on FAO and exhibit increased lipid uptake, which can promote their pro-tumoral functions. Targeting the lipid metabolic pathways in these cells represents a potential therapeutic strategy to modulate the TME and enhance anti-tumor immunity [114].

Given the critical role of lipid metabolism in cancer, targeting lipid metabolic pathways offers promising therapeutic opportunities [128]. Inhibitors of key enzymes involved in de novo lipogenesis, such as FASN inhibitors, have shown potential in preclinical models [129]. Targeting fatty acid uptake and FAO are also being explored as therapeutic strategies. For instance, inhibitors of CD36 and FAO have demonstrated anti-tumor effects in various cancer models [130]. Furthermore, strategies to disrupt lipid signaling pathways, such as PI3K/Akt inhibitors and modulators of sphingolipid metabolism, are under investigation. Combining lipid metabolism-targeting therapies with conventional treatments, such as chemotherapy and immunotherapy, may enhance therapeutic efficacy and overcome resistance.

Regulation of metabolic pathways

Oncogenes and tumor suppressors

In cancer, metabolic pathways can be regulated through various mechanisms, including oncogenes, tumor suppressor genes, epigenetic modifications, and microenvironmental factors (Fig. 5). Cancer involves genetic alterations and significant metabolic changes [131, 132]. The deregulation of metabolic pathways is a hallmark of cancer, heavily influenced by the activities of oncogenes and tumor suppressors [133]. Understanding how these genes regulate metabolism is crucial for developing targeted cancer therapies.Fig. 5 The figure illustrates the regulatory landscape of metabolic pathways in cancer, highlighting key influences from oncogenes (e.g., MYC, RAS) and tumor suppressor genes (e.g., p53, PTEN). Epigenetic modifications (DNA methylation, histone marks) are shown in the figure with its regulatory role. Microenvironmental factors such as hypoxia, nutrient availability (glucose, glutamine), and immune interactions are illustrated to impact metabolic adaptations in cancer cells. Interactions and feedback loops between these regulatory elements are represented, emphasizing how oncogene activation may enhance glycolysis and alter mitochondrial function, and how epigenetic silencing affects metabolic enzyme expression

Oncogenes are mutated or overexpressed versions of normal genes, known as proto-oncogenes, that drive uncontrolled cell growth and proliferation [134, 135]. Several oncogenes are known to alter metabolic pathways to support the high energy and biosynthetic demands of rapidly proliferating cancer cells. For example, the MYC oncogene, a transcription factor, upregulates genes involved in glycolysis, glutaminolysis, and nucleotide biosynthesis. MYC enhances the expression of glucose transporters and glycolytic enzymes while stimulating glutamine metabolism, which feeds into the TCA cycle and supports biosynthesis [136, 137]. Similarly, the RAS family of proteins activates pathways like PI3K/AKT and MAPK, which enhance glucose uptake, glycolysis, lipid biosynthesis, and macromolecular synthesis, all crucial for cell growth and proliferation [138]. The PI3K/AKT pathway, a major regulator of cellular metabolism, promotes glucose uptake and glycolysis by upregulating glucose transporters and glycolytic enzymes [139]. Activated AKT enhances protein synthesis and inhibits apoptosis through mTOR signaling [140]. Another key player, HIF-1α, stabilizes under hypoxic conditions typical of tumors and increases the expression of glycolytic enzymes and glucose transporters, promoting anaerobic glycolysis. HIF-1α also upregulates vascular endothelial growth factor (VEGF), enhancing tumor angiogenesis and oxygen supply [141]. These oncogenes collectively shift cellular metabolism towards increased glycolysis, glutaminolysis, and lipid biosynthesis, supporting cancer cells’ rapid growth and energy demands.

In contrast, tumor suppressors are genes that inhibit cell growth and proliferation, acting as a defense against cancer [142, 143]. They often counteract the effects of oncogenes and maintain cellular homeostasis. The tumor suppressor p53, for example, is a transcription factor known as the “guardian of the genome.” It responds to cellular stress and DNA damage by inducing cell cycle arrest, apoptosis, and senescence [144]. p53 also regulates metabolism by inhibiting glycolysis and promoting OXPHOS [145]. It activates the expression of TIGAR, which lowers glycolysis and enhances the pentose phosphate pathway, providing antioxidant defense [146].

AMP-activated protein kinase (AMPK) is another critical tumor suppressor, acting as a cellular energy sensor activated by low ATP levels [147, 148]. AMPK inhibits anabolic processes and promotes catabolic processes to restore energy balance [149]. It inhibits mTOR signaling, reduces protein synthesis, and enhances fatty acid oxidation and glucose uptake [150]. LKB1, a tumor suppressor, activates AMPK and several other kinases involved in cellular metabolism, promoting oxidative metabolism and inhibiting mTOR, thereby reducing cell growth and proliferation [151].

The balance between oncogenes and tumor suppressors determines the metabolic phenotype of a cell [152]. In cancer cells, oncogenes are often upregulated or mutated, leading to enhanced glycolysis, glutaminolysis, and biosynthesis [21]. Conversely, tumor suppressors are often inactivated, removing their inhibitory effects on metabolism and allowing uncontrolled cell growth [153]. Targeting metabolic pathways influenced by oncogenes and tumor suppressors presents a promising approach to cancer therapy. For instance, glycolysis inhibitors, such as 2-deoxy-D-glucose, can starve cancer cells of energy, while glutaminase inhibitors can reduce the supply of TCA cycle intermediates [154]. AMPK activators can restore metabolic balance and inhibit cancer cell growth [155]. Therefore, understanding the metabolic regulation by oncogenes and tumor suppressors can lead to the development of personalized cancer therapies aimed at specific metabolic vulnerabilities of cancer cells. This approach holds promise for more effective and targeted treatments, potentially improving outcomes for cancer patients.

Epigenetic modifications

Epigenetic modifications are fundamental in regulating metabolic pathways in cancer, significantly influencing cancer progression, adaptation, and survival [156, 157]. These modifications, including DNA methylation, histone modifications, and non-coding RNAs, modulate gene expression without altering the underlying DNA sequence [157, 158]. The complex relationship between epigenetic changes and metabolic reprogramming is pivotal for the aggressive nature of cancer cells [159].

DNA methylation, the addition of a methyl group to the 5-carbon of cytosine residues within CpG dinucleotides, typically leads to gene silencing. This modification can silence key metabolic genes, affecting pathways such as glycolysis, the tricarboxylic acid (TCA) cycle, and lipid metabolism. For instance, the hypermethylation of genes regulating HIF-1α can enhance its stability and activity, promoting the glycolytic phenotype known as the Warburg effect, which is common in cancer cells [160]. Additionally, DNA methylation can regulate genes involved in glutaminolysis, crucial for providing intermediates for the TCA cycle and biosynthesis in rapidly proliferating cancer cells [161].

Histone modifications also play a significant role in cancer metabolism. Histones, the protein components of chromatin, undergo various post-translational modifications, including acetylation, methylation, phosphorylation, and ubiquitination, which influence chromatin structure and gene expression. Histone acetylation, mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), generally leads to an open chromatin structure and active transcription [162]. Acetylation of histones at promoters of glycolytic genes enhances their expression, while HDACs can repress genes involved in lipid metabolism, affecting lipid synthesis and oxidation [163]. Similarly, histone methylation can either activate or repress transcription depending on the specific amino acid residues methylated and the number of methyl groups added [164]. This modification can regulate the expression of enzymes involved in the TCA cycle, impacting energy production, biosynthetic precursor availability, and one-carbon metabolism, crucial for nucleotide biosynthesis and methylation reactions [164].

Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are also key players in the post-transcriptional regulation of gene expression in cancer metabolism [165]. miRNAs can degrade mRNA or inhibit its translation, affecting various metabolic pathways [166]. For example, miRNAs can target mRNAs of enzymes in glycolysis and gluconeogenesis, altering glucose uptake and utilization [167]. They can also modulate the expression of key enzymes in lipid biosynthesis and breakdown, influencing lipid availability and membrane synthesis. For example, microRNA-195 inhibits breast cancer cell proliferation, invasion, and metastasis by targeting FASN, HMGCR, ACACA, and CYP27B1 [168]. On the other hand, lncRNAs can act as scaffolds, guides, or decoys for chromatin-modifying complexes, impacting gene expression related to amino acid metabolism and redox balance, which are essential for the metabolic needs of cancer cells [169].

The integration of epigenetic modifications and metabolic pathways in cancer is complex and dynamic [170, 171]. Cancer cells often undergo metabolic reprogramming to meet their increased energy and biosynthetic demands, and epigenetic modifications can facilitate this reprogramming by altering the expression of metabolic enzymes and pathways [152]. For instance, the Warburg effect is supported by the epigenetic silencing of mitochondrial genes and the activation of glycolytic genes, enabling cancer cells to rely on glycolysis for energy production even in the presence of oxygen [172]. Moreover, metabolites themselves can influence epigenetic modifications [173]. For example, α-ketoglutarate, a TCA cycle intermediate, acts as a cofactor for DNA and histone demethylases, linking metabolism directly to epigenetic regulation [174]. S-adenosylmethionine (SAM), a methyl donor for DNA and histone methylation, and NAD+, required for the activity of sirtuins (a class of HDACs), exemplify the direct connection between metabolic intermediates and epigenetic modifications [175].

The therapeutic implications of targeting epigenetic modifications in cancer metabolism are profound. Epigenetic therapies, such as DNA methyltransferase inhibitors (e.g., 5-azacytidine) and HDAC inhibitors (e.g., vorinostat), can reactivate silenced metabolic genes and disrupt the metabolic adaptations of cancer cells [157, 176]. Combining epigenetic drugs with metabolic inhibitors can enhance therapeutic efficacy by targeting the metabolic vulnerabilities of cancer cells [159, 177]. Such as, studies have explored the combination of the histone deacetylase inhibitor vorinostat with different agents in cancer treatment. In one phase I study, vorinostat was safely administered up to 400 mg once daily or 300 mg twice daily with carboplatin and paclitaxel in 28 patients with advanced solid malignancies, demonstrating promising activity [178]. Another phase I study investigated vorinostat combined with pazopanib or ixazomib in patients with metastatic TP53 mutant solid tumors. Results showed that the pazopanib and vorinostat combination yielded significantly higher clinical benefit rates (45% vs. 3.4%; p < 0.001), longer median progression-free survival (3.5 months vs. 1.7 months; p = 0.002), and longer median overall survival (12.7 months vs. 7.3 months; p = 0.24) compared to ixazomib and vorinostat. These findings suggest that antiangiogenesis-based therapy with pazopanib may offer superior clinical outcomes [179]. Additionally, epigenetic modifications can serve as biomarkers for cancer diagnosis, prognosis, and treatment response, providing insights into the metabolic state and potential therapeutic targets in cancer [156, 157]. One example of epigenetic modifications serving as biomarkers in cancer is the role of DNA methylation in CRC. In CRC, specific patterns of DNA methylation, such as hypermethylation of the MLH1 gene promoter, are associated with microsatellite instability (MSI), which is a hallmark of certain CRC subtypes. The presence of MSI can help diagnose and prognosticate CRC, as well as guide treatment decisions [180]. For instance, MSI-high tumors are often more responsive to immune checkpoint inhibitors [181, 182]. Thus, DNA methylation status not only aids in the diagnosis and prognosis of CRC but also provides valuable information for selecting targeted therapies, illustrating how epigenetic modifications can offer insights into cancer’s metabolic state and therapeutic strategies.

Microenvironmental factors

The TME is a complex and dynamic network surrounding cancer cells, composed of various cellular and non-cellular components that significantly influence cancer progression and metastasis [183]. This microenvironment includes stromal cells such as fibroblasts, immune cells like macrophages and lymphocytes, endothelial cells forming blood vessels, and the extracellular matrix (ECM) [184]. Each component interacts with cancer cells through biochemical and mechanical signals, creating a niche that supports tumor growth and resistance to therapies [185].

One of the critical elements in the TME is CAFs, which secrete growth factors, cytokines, and ECM components that facilitate tumor cell proliferation, invasion, and angiogenesis [186]. CAFs also contribute to the remodeling of the ECM, providing structural support for tumor expansion and creating barriers to immune cell infiltration [187]. Similarly, immune cells within the TME can adopt pro-tumorigenic roles [188]. For example, TAMs often display an M2-like phenotype that promotes tissue repair and immunosuppression, aiding in tumor immune evasion [189].

Hypoxia, a common feature of solid tumors due to aberrant vasculature, further complicates the TME [190]. Hypoxic conditions stabilize HIFs, which activate a transcriptional program that promotes angiogenesis, metabolic reprogramming, and EMT [191]. This adaptation enables cancer cells to survive in low-oxygen conditions and increases their metastatic potential [192]. Additionally, the acidic and nutrient-depleted environment of the TME results from altered metabolic activity of cancer cells, influencing the behavior of surrounding stromal and immune cells [193].

The interplay between metabolic pathways and the TME further emphasizes the complexity of cancer metabolism. Nutrient availability, such as glucose and amino acids, in the TME influences the metabolic state of cancer and stromal cells. Moreover, metabolic byproducts like lactate can modulate immune cell function, creating an immunosuppressive microenvironment that favors tumor progression [194]. For example, in CRC, tumor cells undergo metabolic changes that alter the availability of nutrients like glucose and amino acids in the TME. This reprogramming leads to an increased reliance on aerobic glycolysis, commonly referred to as the Warburg effect, where cancer cells preferentially convert glucose to lactate even in the presence of oxygen. This process not only supports rapid tumor growth but also results in the accumulation of lactate in the TME, creating an acidic environment that can suppress immune responses [195, 196]. Targeting these metabolic adaptations presents a promising strategy for cancer therapy, aiming to disrupt the metabolic flexibility of cancer cells and sensitize them to conventional treatments.

Inhibitors for targeting cancer metabolism

Glycolytic inhibitors

Cancer cells often exhibit altered metabolism, characterized by increased glucose uptake and glycolysis, even in the presence of oxygen. This metabolic reprogramming supports rapid cell proliferation and survival. Consequently, targeting glycolysis has emerged as a potential therapeutic strategy in cancer treatment. Various glycolytic inhibitors have been developed to exploit the dependence of cancer cells on this pathway [197]. Table 1 provides an overview of glycolytic inhibitors, their clinical trial phases, status, conditions studied, and respective study periods (Table 1). Table 1 Overview of inhibitors that target glycolysis directly or indirectly

Glycolytic inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
2-deoxy-D-glucose (2DG)	NCT00096707

NCT00633087

NCT00247403

	Phase 1

Phase 1/2

Phase 1

	Complete

Complete

Complete

	Inhibits hexokinase, reducing glycolysis by competing with glucose.	2004–2008

2006–2011

2005–2008

	
STF31	N/A	N/A	Preclinical studies	Inhibits the glucose transporter GLUT1, reducing glucose uptake and glycolysis.	N/A	
Phloretin	N/A	N/A	Preclinical studies	Inhibits glucose transporters GLUT1 and GLUT2, affecting glycolysis indirectly.	N/A	
WZB117	N/A	N/A	Preclinical studies	Inhibits the glucose transporter GLUT1, reducing glucose uptake and glycolysis.	N/A	
3PO (PFKFB3 inhibitor)	N/A	N/A	Preclinical studies	Inhibits PFKFB3, reducing levels of fructose-2,6-bisphosphate and thereby decreasing glycolytic flux.	N/A	
Dichloroacetate (DCA)	NCT05120284

NCT00703859

NCT00540176

NCT01163487

NCT01386632

NCT01111097

NCT01029925

NCT00566410

	Phase 2

Phase 1

Phase 2

Phase 1

Phase 2

Phase 1

Phase 2

Phase 1

	Recruiting

Withdrawn

Completed

Completed

Completed

Completed

Terminated

Completed

	Inhibits pyruvate dehydrogenase kinase (PDK), shifting metabolism from glycolysis to oxidative phosphorylation.	2022–2025

2008–2010

2007–2009

2010–2016

2011–2020

2010–2014

2009–2011

2007–2013

	
Oxamic acid	N/A	N/A	Preclinical studies	Inhibits lactate dehydrogenase (LDH), disrupting the conversion of pyruvate to lactate in glycolysis.	N/A	
Galloflavin	N/A	N/A	Preclinical studies	Inhibits lactate dehydrogenase (LDH).	N/A	
Oxamate	N/A	N/A	Preclinical studies	Inhibits lactate dehydrogenase (LDH).	N/A	
FX11	N/A	N/A	Preclinical studies	Inhibits lactate dehydrogenase A (LDHA).	N/A	
AZD3965	NCT01791595	Phase 1	Completed	Inhibits MCT1, preventing lactate export, leading to intracellular acidification and inhibition of glycolysis. Effective in cancer cells with high glycolytic rates.	2013–2020	
BAY-876	N/A	N/A	Preclinical studies	Inhibits the glucose transporter GLUT1.	N/A	
Iodoacetate	N/A	N/A	Preclinical studies	Inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH).	N/A	
Koningic acid (KA)	N/A	N/A	Preclinical studies	Inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH).	N/A	
3-Bromopyruvate (3-BP)	N/A	N/A	Preclinical studies	Inhibits glycolysis by targeting hexokinase II, disrupting ATP production and causing metabolic stress, particularly in cancer cells.	N/A	
Gossypol	NCT01977209

NCT00848016

NCT00544596

NCT00540722

NCT00666666

NCT00773955

NCT00390403

NCT00286793

NCT00275431

NCT00286806

NCT00561197

NCT06133088

NCT00286780

NCT00397293

NCT00891072

NCT01633541

NCT01285635

NCT00934076

NCT00440388

NCT01003769

NCT05338931

NCT00988169

NCT00544960

NCT02697344

NCT00571675

	Phase 3

Phase 2

Phase 1

Phase 2

Phase 2

Phase 2

Phase 1

Phase 1/2

Phase 2

Phase 1/2

Phase 1/2

Phase 2

Phase 2 Phase 1/2

Phase 1

Phase 2

Phase 2

Phase 1

Phase 2

Phase 1/2

Phase 1/2

Phase 2

Phase 2

Phase 1

Phase 2

	Unknown

Completed

Completed

Completed

Completed

Completed

Completed

Completed

Completed

Completed

Terminated

Recruiting

Completed

Completed

Completed

Completed

Terminated

Withdrawn

Completed

Terminated

Recruiting

Terminated

Completed

Completed

Completed

	Inhibits glycolysis by targeting multiple enzymes, including hexokinase and lactate dehydrogenase, leading to reduced ATP production and metabolic stress, particularly in cancer cells.	2013–2016

2009–2012

2007–2013

2008–2012

2009–2012

2008–2010

2007–2009

2006–2009

2005–2008

2005–2007

2007–2010

2023–2025

2006–2007

2006–2008

2009–2011

2012–2021

2010–2015

2010–2015

2006–2008

2015–2018

2022–2030

2009–2010

2007–2009

2016–2023

2007–2010

	
AZD3965	NCT01791595	Phase 1	Completed	MCT1 inhibitor (indirectly affects glycolysis)	2013–2020	
Syrosingopine	N/A	N/A	Preclinical studies	MCT1/MCT4 inhibitor (indirectly affects glycolysis)	N/A	
PFK158	NCT02044861	Phase 1	Unknown	Targets the PFKFB3	2014–2015	
Shikonin	N/A	N/A	Preclinical studies	Targets the PKM2	N/A	

Hexokinase inhibitors, such as 2-Deoxy-D-glucose (2-DG) and Lonidamine, play a crucial role in disrupting the initial steps of glycolysis. 2-DG is a glucose analog that competes with glucose for phosphorylation by hexokinase, the enzyme responsible for the first step of glycolysis [198]. This competition impairs ATP production, leading to cancer cell death [199]. Lonidamine specifically inhibits hexokinase II (HKII), which is often overexpressed in cancer cells, thereby reducing glycolytic flux and inducing apoptosis [200]. Combination therapies involving these agents offer hope for improving cancer treatment outcomes. For example, the combination of 2-Deoxy-glucose (2-DG) with different therapeutic approaches has yielded contrasting outcomes in cancer therapy. The pairing of 2-DG with fenofibrate (FF) shows significant potential by synergistically inducing energy and endoplasmic reticulum (ER) stress in tumors, leading to energy depletion, inhibition of mTOR, and cancer cell death, highlighting a promising avenue for clinical development [201]. However, the combination of 2-DG with a ketogenic diet (KD) has resulted in significant dose-dependent toxicity, causing acute thrombocytopenia, interstitial pneumonia, and rapid mortality in treated mice, while being well tolerated on a standard diet [202]. Similarly, lonidamine has shown limited cytotoxicity on its own but significantly enhances the efficacy of various chemotherapeutic agents, such as 5-fluorouracil, methotrexate, etoposide, cisplatin, and mitomycin C, in both mouse and human fibrosarcoma cell lines. Its enhancement of drug effectiveness is time- and concentration-dependent, suggesting its potential role in combination therapies to improve cancer treatment outcomes. By targeting energy metabolism pathways, including monocarboxylate transporter (MCT) and mitochondrial pyruvate carrier (MPC) inhibition, lonidamine selectively targets tumors without causing common side effects like alopecia and myelosuppression [203]. Furthermore, it has shown promising synergistic effects when used alongside physical therapies such as radiotherapy, hyperthermia, and photodynamic therapy [204]. This suggests that combination therapies with hexokinase inhibitors like 2-Deoxy-D-glucose (2-DG) and lonidamine can enhance cancer treatment effectiveness. While 2-DG shows promise when paired with fenofibrate, it can cause severe toxicity with a ketogenic diet. Lonidamine enhances the efficacy of various chemotherapeutic agents and physical therapies, offering potential in multidrug strategies, though outcomes depend on the specific combinations used.

Moreover, inhibitors of phosphofructokinase, such as 3-PO, target a rate-limiting enzyme in glycolysis. 3-PO (3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) was initially thought to inhibit PFKFB3, rather than phosphofructokinase-1 (PFK-1) [205, 206]. However, recent research has revealed that 3-PO does not directly bind to or inhibit PFKFB3 [206]. Instead, it reduces glycolytic activity in cancer cells by a different mechanism. 3-PO accumulates lactic acid inside cells, leading to a decrease in intracellular pH and the subsequent inhibition of glycolytic enzymes [206]. This inhibition of glycolysis can impair cancer cell growth and survival [205], but it is not due to the direct inhibition of PFK-1 or PFKFB3 as previously thought [207]. In contrast, koningic acid is a selective inhibitor of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), disrupting the glycolytic pathway, reducing ATP production, and promoting apoptosis in some cancer cells. While 3-PO and koningic acid affect glycolysis, they do so through different mechanisms and target distinct enzymes within the pathway [207].

Furthermore, targeting pyruvate kinase M2 (PKM2), an isoform expressed in cancer cells that promotes aerobic glycolysis, is another strategy [208]. Shikonin and TEPP-46 are notable PKM2 inhibitors. Shikonin disrupts the final step of glycolysis, reducing ATP production and causing cancer cell death [209]. TEPP-46, on the other hand, activates PKM2, shifting it from its less active dimeric form to the more active tetrameric form, thereby impairing cancer cell proliferation. For example, TEPP-46 was investigated as a potential treatment for triple-negative breast cancer (TNBC). PKM2 phosphorylation at S37 was associated with aggressive breast cancer phenotypes. TEPP-46 reduced PKM2 nuclear localization, inhibited tumor growth in a TNBC mouse xenograft model, and synergized with a CDK inhibitor to impair cell invasion and trigger cancer cell death [210].

Lactate dehydrogenase (LDH) inhibitors, such as galloflavin [211] and FX11 [212], prevent the conversion of pyruvate to lactate, a crucial step in glycolysis. By inhibiting LDH, these agents disrupt glycolysis, reducing lactate production and impairing cancer cell growth [212, 213]. These inhibitors are particularly effective in tumors with high glycolytic rates, where they can induce significant metabolic stress.

The mechanisms of action of glycolytic inhibitors encompass various aspects of cancer cell metabolism [52]. These inhibitors cause energy deprivation by reducing ATP production, which is essential for cancer cell survival [214]. They also inhibit biomass production by limiting intermediates for biosynthetic pathways, thus impairing cancer cell growth and proliferation [21]. Disrupting glycolysis can increase reactive oxygen species (ROS) levels, leading to oxidative stress and cell death [154]. Glycolytic inhibitors can also enhance the efficacy of other cancer treatments, such as chemotherapy and radiotherapy, by sensitizing tumors to conventional therapies [215].

Despite their potential, the clinical application of glycolytic inhibitors faces several challenges. Selective targeting of cancer cells without affecting normal cells is crucial to minimize toxicity [59, 60]. This is because normal cells also rely on glycolysis, making it difficult to target cancer cells specifically without harming healthy tissues. Cancer cells can develop resistance to glycolytic inhibitors through various mechanisms, such as upregulation of alternative metabolic pathways, necessitating combination therapies and biomarkers for resistance [59, 216]. For example, cancer cells may adapt by increasing oxidative phosphorylation or glutaminolysis when glycolysis is inhibited. Additionally, the potential toxicity and side effects of glycolytic inhibitors must be carefully managed, particularly in tissues with high glycolytic activity like the brain and muscles. These tissues rely heavily on glucose metabolism for their normal function, and inhibiting glycolysis could lead to serious side effects. Developing effective glycolytic inhibitors with suitable pharmacokinetic properties for clinical use remains a challenge. Many compounds that show promise in preclinical studies may not have the desired properties for use in humans, such as appropriate bioavailability or half-life. Furthermore, the complex interplay between cancer cell metabolism and the immune system needs to be considered when developing glycolytic inhibitors. Inhibiting glycolysis may affect immune cell function, potentially compromising the body’s natural defense against cancer.

Based on metabolic profiling of tumors, personalized medicine approaches can enhance therapeutic efficacy of glycolytic inhibitors by identifying patients most likely to benefit from these treatments. Understanding the metabolic heterogeneity of tumors is crucial for developing effective therapies. By addressing these challenges, glycolytic inhibitors can become a valuable addition to the arsenal of cancer treatments, offering new hope for patients with metabolic vulnerabilities in their tumors.

Glutaminase inhibitors

Cancer metabolism has been a focal point of research due to its critical role in the proliferation and survival of cancer cells. One of the central metabolic pathways by cancer cells is glutamine metabolism [106, 217]. Glutamine, a non-essential amino acid, becomes essential for the rapid growth and survival of cancer cells [106]. This is largely because glutamine serves as a carbon and nitrogen source for nucleotide and amino acid synthesis, which are crucial for the growth of proliferating cells [106, 217]. Glutamine serves as a precursor for various biosynthetic processes, including lipid synthesis and energy production through the TCA cycle [106]. The enzyme glutaminase, which converts glutamine to glutamate, is a key player in this metabolic pathway [106, 218]. Consequently, glutaminase inhibitors have emerged as promising therapeutic targets in cancer treatment (Table 2). Table 2 Overview of glutaminase inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Telaglenastat (CB-839)	NCT04824937

NCT04250545

NCT05521997

NCT03875313

NCT03057600

NCT02771626

NCT03798678

NCT03872427

NCT03163667

NCT03528642

NCT03965845

NCT03428217

NCT03831932

NCT04265534

	Phase 2

Phase 1

Phase 2

Phase 1/2

Phase 2

Phase 1/2

Phase 1

Phase 2

Phase 2

Phase 1

Phase 1/2

Phase 2

Phase 1/2

Phase 2

	Unknown

Active (Not recruiting)

Not recruiting

Terminated

Completed

Terminated

Active (Not recruiting)

Active (Not recruiting)

Completed

Active (Not recruiting)

Completed

Completed

Active (Not recruiting)

Terminated

	Telaglenastat blocks glutaminase, an enzyme overproduced in some cancers that fuels growth. By inhibiting glutaminase.	2021–2021

2020–2025

2024–2030

2019–2020

2017–2019

2016–2020

2019–2025

2019–2024

2017–2020

2019–2024

2019–2021

2018–2021

2020–2025

2020–2022

	
DON	N/A	N/A	Preclinical studies	Inhibits multiple enzymes in glutamine metabolism, including glutaminase.	N/A	
BPTES	N/A	N/A	Preclinical studies	BPTES is a selective non-competitive inhibitor of GLS1, binding to an allosteric site to reduce its activity. This decreases glutamate production, impairing the TCA cycle and biosynthetic processes in cancer cells.	N/A	
986	N/A	N/A	Preclinical studies	968 is a selective glutaminase inhibitor that blocks the enzyme’s active site, preventing the conversion of glutamine to glutamate and limiting glutamate availability for the TCA cycle and other metabolic processes in cancer cells.	N/A	
V-9302	N/A	N/A	Preclinical studies	Targets the glutamine transporter ASCT2 (SLC1A5).	N/A	

Glutaminase exists in two major isoforms in humans: GLS1 (kidney-type glutaminase) and GLS2 (liver-type glutaminase) [100, 219]. GLS1 is predominantly expressed in cancer cells, making it an attractive target for cancer therapy [219]. Inhibition of GLS1 disrupts the conversion of glutamine to glutamate, leading to a reduction in the production of key metabolites required for cell growth and survival [220, 221]. This, in turn, can induce cell death in glutamine-dependent cancer cells [221]. Several studies have demonstrated that glutaminase inhibitors can effectively suppress tumor growth in various cancer models, highlighting their potential as therapeutic agents [100, 220].

One of the most well-known glutaminase inhibitors is CB-839 (Telaglenastat), which selectively inhibits GLS1. Preclinical studies have shown that CB-839 can reduce tumor growth in multiple cancer types [110]. These findings have led to several clinical trials to evaluate the safety and efficacy of CB-839 in cancer patients. Early-phase clinical trials have reported promising results, with CB-839 demonstrating acceptable safety profiles and preliminary evidence of anti-tumor activity. These results have spurred further investigations into the combination of glutaminase inhibitors with other therapeutic agents to enhance their efficacy. For example, in a phase I clinical trial, telaglenastat is being investigated for its safety and efficacy when combined with radiation therapy (RT) and temozolomide (TMZ) in patients with untreated IDH mutant astrocytomas, where it depletes intracellular glutamate and enhances RT efficacy [222]. Similarly, in advanced renal cell carcinoma (mRCC), telaglenastat combined with everolimus demonstrated a favorable safety profile and improved progression-free survival (PFS) in patients previously treated with tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors, suggesting the potential benefit of dual targeting glucose and glutamine metabolism in these cancers [223].

The combination of glutaminase inhibitors with other cancer therapies represents a promising approach to enhance treatment efficacy. Cancer cells often exhibit metabolic flexibility, allowing them to adapt to metabolic stress by switching to alternative pathways. Therefore, combining glutaminase inhibitors with other metabolic inhibitors or standard chemotherapies can create a synthetic lethality scenario, where the simultaneous targeting of multiple pathways overwhelms the cancer cells’ adaptive capacity. For example, combining CB-839 with inhibitors of the PI3K/AKT/mTOR pathway, which is often upregulated in cancer, can improve the therapeutic effects [106, 224].

Despite the promising potential of glutaminase inhibitors, several challenges remain. One major challenge is the heterogeneity of tumors and the metabolic plasticity of cancer cells. Not all tumors are equally dependent on glutamine metabolism, and some may develop resistance to glutaminase inhibition by activating alternative metabolic pathways. Therefore, identifying biomarkers that can predict which tumors are most likely to respond to glutaminase inhibitors is crucial for the successful implementation of this therapeutic strategy. Additionally, understanding the mechanisms underlying resistance to glutaminase inhibition will be essential for developing strategies to overcome resistance and improve patient outcomes.

Inhibitors of the tricarboxylic acid (TCA) cycle

The TCA cycle operates within the mitochondria, where it generates ATP, NADH, and FADH2 through the oxidation of acetyl-CoA derived from carbohydrates, fats, and proteins. These products are essential for the electron transport chain and oxidative phosphorylation. The cycle involves several key enzymes, including citrate synthase, aconitase, isocitrate dehydrogenase (IDH), alpha-ketoglutarate dehydrogenase, succinyl-CoA synthetase, succinate dehydrogenase (SDH), fumarase, and malate dehydrogenase. Dysregulation of these enzymes is often observed in various cancers, making them potential therapeutic targets [225, 226].

Succinate dehydrogenase (SDH), a component of both the TCA cycle and the electron transport chain, is another critical enzyme. Mutations in SDH genes are linked to hereditary paragangliomas, pheochromocytomas, and renal cell carcinoma [227]. Loss of SDH function leads to succinate accumulation, which inhibits alpha-ketoglutarate-dependent dioxygenases and stabilizes HIFs, promoting tumorigenesis [228, 229]. While direct inhibitors of mutant SDH are still under investigation, targeting the metabolic and signaling consequences of SDH loss [230], such as with HIF inhibitors, presents a potential strategy [231]. However, there is a scarcity of clinical trials for the inhibitors of the TCA cycle (Table 3). Table 3 Overview of the tricarboxylic acid (TCA) cycle inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Fluoroacetate	N/A	N/A	Preclinical studies	Fluoroacetate is metabolized to fluorocitrate, which inhibits aconitase, thereby blocking the conversion of citrate to isocitrate.	N/A	
Arsenite	N/A	N/A	Preclinical studies	Arsenite binds to lipoic acid, a cofactor for these enzyme complexes, inhibiting their activity.	N/A	
Malonate	N/A	N/A	Preclinical studies	Malonate is a competitive inhibitor of succinate dehydrogenase, blocking the conversion of succinate to fumarate.	N/A	
Oxaloacetate	NCT04290897	Phase 2	Recruiting	High levels of oxaloacetate can inhibit citrate synthase through feedback inhibition.	2021–2025	
Dimethyl malonate	N/A	N/A	Preclinical studies	Similar to malonate, dimethyl malonate competitively inhibits succinate dehydrogenase.	N/A	
Alpha-cyano-4-hydroxycinnamate (CHC)	N/A	N/A	Preclinical studies	CHC inhibits the mitochondrial pyruvate carrier, reducing the entry of pyruvate into the TCA cycle.	N/A	
Bromopyruvate	N/A	N/A	Preclinical studies	Inhibits hexokinase and pyruvate dehydrogenase, disrupting glycolysis and the TCA cycle and reducing cellular energy production.	N/A	
Oligomycin	N/A	N/A	Preclinical studies	Oligomycin inhibits ATP synthase, leading to a buildup of proton gradient and inhibition of the electron transport chain, which indirectly affects the TCA cycle by reducing NAD + and FAD regeneration.	N/A	

Similarly, mutations in fumarase (FH) are associated with hereditary leiomyomatosis and renal cell cancer [232]. Loss of FH activity results in fumarate accumulation, leading to effects similar to those seen with SDH mutations, including HIF stabilization and epigenetic changes. Direct targeting of FH-deficient tumors often involves exploiting the metabolic vulnerabilities and stress responses induced by fumarate accumulation [38].

Strategies for targeting the TCA cycle in cancer therapy include metabolic flux analysis, synthetic lethality, and combination therapies. Metabolic flux analysis, using stable isotope tracing, maps altered metabolic pathways in cancer cells to identify key vulnerabilities. Exploiting synthetic lethality involves targeting secondary pathways cancer cells rely on due to TCA cycle alterations, such as inhibiting glycolysis in tumors with impaired oxidative phosphorylation. Combination therapies pair TCA cycle inhibitors with treatments like chemotherapy, targeted therapies, or immunotherapy to enhance efficacy and overcome resistance. Challenges include ensuring selectivity to minimize toxicity to normal cells, developing cancer-specific delivery systems, identifying biomarkers for patient stratification, and addressing resistance mechanisms through continuous monitoring and combination strategies. More clinical trials are needed to evaluate the safety and efficacy of TCA cycle inhibitors across various cancer types and develop personalized treatments based on each tumor’s molecular context.

Fatty acid oxidation inhibitors

Cancer cells undergo significant metabolic reprogramming to support their rapid growth and proliferation. One critical metabolic pathway that these cells exploit is fatty acid oxidation (FAO), the process by which fatty acids are broken down in the mitochondria to generate energy. Targeting FAO can disrupt the energy supply and metabolic flexibility of cancer cells, potentially suppressing their growth. As a result, fatty acid oxidation inhibitors (FAO inhibitors) have emerged as promising therapeutic agents in cancer treatment [49, 118] (Table 4). For example, a recent study highlights the metabolic switch from glucose to fatty acid-dependent anabolic and energy metabolism in cisplatin-resistant cancer cells. It demonstrates that inhibition of FAO re-sensitizes these cells to cisplatin treatment, suggesting a combinational therapy of FAO inhibitors and platinum drugs as a potential strategy [233]. Table 4 Overview of the fatty acid oxidation inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Etomoxir	N/A	N/A	Preclinical studies	Inhibits carnitine palmitoyltransferase I (CPT-1), preventing the transport of long-chain fatty acids into the mitochondria for β-oxidation.	N/A	
Perhexiline	N/A	N/A	Preclinical studies	Inhibits both CPT-1 and CPT-2, reducing mitochondrial fatty acid uptake and oxidation, and shifting myocardial energy metabolism from fatty acids to glucose.	N/A	
Trimetazidine	NCT03278444	Phase 3	Unknown	Partially inhibits long-chain 3-ketoacyl-CoA thiolase (LC-3KAT), the last enzyme of the mitochondrial fatty acid β-oxidation pathway, thereby promoting glucose oxidation over fatty acid oxidation.	2017–2021	
Ranexa	NCT01992016	N/A	Completed	Inhibits the late sodium current (INaL) in cardiac cells, which indirectly reduces fatty acid oxidation by altering myocardial energy metabolism.	2014–2018	
Meldonium	N/A	N/A	Preclinical studies	Inhibits gamma-butyrobetaine dioxygenase, leading to reduced carnitine biosynthesis and transport, which in turn decreases fatty acid oxidation.	N/A	
Oxfenicine	N/A	N/A	Preclinical studies	Specifically inhibits CPT-1, similar to etomoxir, reducing the mitochondrial uptake of long-chain fatty acids and their subsequent oxidation.	N/A	
Teglicar	N/A	N/A	Preclinical studies	A potent CPT-1 inhibitor that reduces fatty acid transport into mitochondria, thereby decreasing fatty acid oxidation.	N/A	
4-Hydroxyphenylglycine (HPG)	N/A	N/A	Preclinical studies	Inhibits CPT-1 activity, reducing the transport and oxidation of long-chain fatty acids in mitochondria.	N/A	
HY-65,933	N/A	N/A	Preclinical studies	Inhibiting CPT-1, reducing fatty acid transport into mitochondria.	N/A	
Cerulenin	N/A	N/A	Preclinical studies	Primarily inhibits fatty acid synthase (FAS), which indirectly affects fatty acid oxidation by reducing the availability of newly synthesized fatty acids.	N/A	
Fasentin	N/A	N/A	Preclinical studies	Targets glucose transport and fatty acid metabolism, impacting fatty acid oxidation pathways, though the exact mechanism is less well-characterized. .	N/A	
Bempedoic Acid	N/A	N/A	Preclinical studies	Inhibits ATP-citrate lyase, reducing cholesterol synthesis, which can also impact fatty acid metabolism by decreasing acetyl-CoA availability for fatty acid synthesis and oxidation. .	N/A	

FAO plays a pivotal role in cancer metabolism. While the reliance of cancer cells on glycolysis is well-documented, recent studies have highlighted the importance of FAO in cancer. FAO provides ATP, NADPH, and acetyl-CoA, all of which are crucial for maintaining cellular energy homeostasis, redox balance, and biosynthesis [234, 235]. The ATP generated through FAO supports the high energy demands of proliferating cancer cells, while NADPH helps maintain redox balance, protecting cells from oxidative stress [234, 235]. Additionally, acetyl-CoA produced from FAO is essential for fatty acid and cholesterol synthesis, necessary for membrane formation and signaling molecules [118, 236].

FAO inhibitors target various enzymes in the FAO pathway, reducing the availability of energy and essential metabolites for cancer cells. Key enzymes targeted by these inhibitors include Carnitine Palmitoyltransferase 1 (CPT1), Acyl-CoA Dehydrogenase (ACAD), and 3-Ketoacyl-CoA Thiolase (KAT) [234, 237]. CPT1, the rate-limiting enzyme in the transport of long-chain fatty acids into mitochondria, can be inhibited by drugs like etomoxir, blocking fatty acid entry and subsequent oxidation [118, 238]. ACAD inhibitors prevent the initial step of mitochondrial fatty acid β-oxidation, while KAT inhibitors halt the final step, leading to an accumulation of fatty acid intermediates [234, 237].

The therapeutic potential of FAO inhibitors in cancer treatment is significant. Cancer cells that heavily rely on FAO for energy and biosynthesis are particularly vulnerable to these inhibitors. By targeting FAO, these inhibitors can selectively kill cancer cells without affecting normal cells that rely more on glycolysis [239]. Moreover, FAO inhibitors can be used in combination with other cancer therapies to enhance their efficacy. For instance, combining FAO inhibitors with glycolysis inhibitors can target the metabolic flexibility of cancer cells, making it harder for them to adapt and survive. Furthermore, FAO inhibitors may help overcome drug resistance, which is often a significant challenge in cancer treatment. By targeting the metabolic adaptations that contribute to resistance, FAO inhibitors can improve the effectiveness of conventional therapies.

Examples of FAO inhibitors that have shown potential in cancer therapy include etomoxir, perhexiline, and ranolazine [240, 241]. Etomoxir and perhexiline are CPT1 inhibitors that have demonstrated anticancer activity, particularly against FAO-dependent tumors such as prostate cancer and leukemia [241]. Perhexiline, which inhibits both CPT1 and CPT2, has shown promising results in preclinical cancer studies. It has been found to inhibit proliferation and induce apoptosis in prostate cancer cell lines. Additionally, perhexiline combined with anti-androgen therapies like abiraterone or enzalutamide has demonstrated robust growth inhibition in prostate cancer cell models, including those resistant to enzalutamide [240]. Such as, a previous study highlights the therapeutic potential of co-targeting the androgen receptor (AR) axis and lipid oxidation in metastatic castration-resistant prostate cancer (mCRPC). Inhibition of carnitine palmitoyltransferase 1 A (CPT1A), a key enzyme in lipid oxidation, reduces prostate cancer growth and invasion, with the CPT1A isoform being more abundant in high-grade tumors. Combining CPT1A inhibition with the anti-androgen enzalutamide enhances its efficacy, including in enzalutamide-resistant models, by decreasing AKT activation and increasing AR sensitivity. Fat oxidation inhibitors, such as perhexiline, etomoxir, and ranolazine, in combination with enzalutamide, have shown robust growth inhibition in PCa cell models. Preclinical results further demonstrate significant tumor growth reduction with systemic combination treatment, suggesting that dual targeting of AR and lipid oxidation, including with perhexiline, may offer an effective strategy for mCRPC treatment [242]. It’s important to note that while these FAO inhibitors show promise in preclinical studies, their efficacy and safety in clinical cancer treatment still require further investigation.

Despite the promising potential of FAO inhibitors, several challenges remain. Achieving selectivity for cancer cells while sparing normal cells is a significant hurdle. FAO inhibitors need to be developed with a focus on selective targeting to minimize side effects. Additionally, cancer cells may develop resistance to FAO inhibitors through compensatory metabolic pathways. Understanding these resistance mechanisms will be crucial for developing combination therapies that can overcome them. Translating preclinical findings into clinical success also requires rigorous testing and validation in clinical trials.

Lactate dehydrogenase (LDH) inhibitors

Lactate dehydrogenase (LDH) inhibitors have emerged as a promising therapeutic strategy in cancer metabolism, targeting the altered metabolic pathways that are a hallmark of many malignancies. LDH is a key enzyme in the glycolytic pathway, catalyzing the conversion of pyruvate to lactate with concomitant regeneration of NAD+, a crucial step for maintaining glycolysis under anaerobic conditions [243, 244]. Cancer cells often exhibit increased glycolysis rates, even in the presence of oxygen [216, 245]. This metabolic reprogramming facilitates rapid proliferation and survival in the hypoxic TME [216, 245]. LDH inhibitors aim to disrupt this aberrant glycolytic flux, thereby reducing lactate production, acidification of the TME, and overall cancer cell survival [243, 246]. By inhibiting LDH, these agents can also impair the redox balance within cancer cells, leading to increased oxidative stress and apoptosis [246]. Additionally, targeting LDH can hinder the metabolic flexibility of cancer cells, making them more susceptible to other therapeutic interventions [243, 245]. Research and clinical trials are ongoing to optimize the efficacy and specificity of LDH inhibitors (Table 5), with some compounds showing promising preclinical results in reducing tumor growth and metastasis [243, 244]. For example, the pyrazole-based compound series (such as NCI-006) has been rigorously optimized, resulting in nanomolar IC50 values for lead compounds and demonstrated in vivo target engagement and efficacy with oral availability [216]. LDHB, another isoform of LDH, has also been identified as a potential target. LDHB plays a major role in the metabolic adaptability of cancer cells by controlling lysosomal activity and autophagy, enabling an oxidative phenotype [245]. Inhibition of both LDHA and LDHB could be therapeutically useful, as they participate in tumor-stroma metabolic interactions and the exchange of metabolic fuel. Moreover, combining LDH inhibitors like FX-11 with other agents such as DH348 (a CAIX inhibitor) significantly suppressed metastasis in prostate cancer models. Notably, FX-11 also showed synergy with immune checkpoint blockade (anti-PD-1) in pancreatic cancer models. These results suggest that addressing tumor acidity and lactate production could enhance the effectiveness of immunotherapy [247]. Thus, LDH inhibitors represent a novel and exciting avenue in the metabolic targeting of cancer therapy. However, challenges remain, including the need for improved potency, drug-like properties, and in vivo efficacy of natural product-derived LDH inhibitors. Future research should focus on integrating multiple disciplines, including natural product chemistry, medicinal chemistry, and pharmacology, to enhance the development of effective LDH inhibitors for cancer treatment. Table 5 Overview of the lactate dehydrogenase (LDH) inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
FX11	N/A	N/A	Preclinical studies	FX11 inhibits LDHA, leading to decreased lactate production and an increase in oxidative stress within cancer cells. This inhibition disrupts glycolysis and induces cell death in glycolytic-dependent tumor cells.	N/A	
Galloflavin	N/A	N/A	Preclinical studies	Galloflavin is a non-competitive inhibitor of LDH that binds to the enzyme and inhibits its activity, reducing lactate production. This leads to the accumulation of pyruvate and inhibition of glycolytic flux, ultimately resulting in decreased cancer cell proliferation and increased apoptosis.	N/A	
Oxamate	N/A	N/A	Preclinical studies	Oxamate acts as a pyruvate analog and competes with pyruvate for binding to LDH. By inhibiting LDH activity, oxamate reduces lactate production and glycolysis, which can decrease tumor growth and induce apoptosis in cancer cells.	N/A	
NCI-737	N/A	N/A	Preclinical studies	NCI-737 selectively inhibits LDHA, resulting in reduced lactate production and increased oxidative phosphorylation. This shift in metabolic pathways induces oxidative stress and cell death in cancer cells reliant on glycolysis.	N/A	
Stuartin	N/A	N/A	Preclinical studies	Stuartin is a novel LDH inhibitor that specifically targets LDHA. By inhibiting LDHA, stuartin decreases lactate production and disrupts glycolysis, leading to the death of cancer cells with high glycolytic activity.	N/A	
3-Bromopyruvate (3-BP)	N/A	N/A	Preclinical studies	3-BP is an alkylating agent that inhibits multiple glycolytic enzymes, including LDH. It decreases lactate production, leading to energy depletion and increased oxidative stress in cancer cells, ultimately causing cell death.	N/A	
GNE-140	N/A	N/A	Preclinical studies	GNE-140 inhibits LDHA, reducing the conversion of pyruvate to lactate, leading to pyruvate accumulation and decreased lactate production. This disrupts energy production and metabolic flexibility, making cancer cells less viable, especially in hypoxic tumor conditions.	N/A	

Glucose transport inhibitors

Glucose transport inhibitors are emerging as promising agents in the realm of cancer metabolism therapeutics, targeting the unique metabolic dependencies of cancer cells (Table 6). Cancer cells exhibit a heightened glycolytic rate, known as the Warburg effect, where they predominantly rely on glucose for energy production, even in the presence of oxygen. This metabolic reprogramming supports rapid cell proliferation and survival under adverse conditions. By inhibiting glucose transporters, specifically GLUT1, which is often overexpressed in various cancers, these inhibitors effectively starve cancer cells of their primary energy source [60, 216]. This leads to a reduction in ATP production, disruption of cellular homeostasis, and ultimately, cell death [216, 248]. Moreover, glucose transport inhibitors can synergize with other treatments, such as chemotherapy and radiotherapy, by further sensitizing cancer cells to these interventions [249, 250]. For example, recent studies investigated novel anti-cancer treatments through the application of phloretin in two distinct contexts. First, phloretin-based combinations were tested against hepatocellular carcinoma (HCC), where combination 1 involved inhibiting glycolysis with phloretin and gluconeogenesis with sodium meta-arsenite, while combination 2 involved inhibiting glycolysis with phloretin and inducing gluconeogenesis with dexamethasone. Both combinations significantly regressed malignant tissue in Swiss albino mice with induced HCC, demonstrating effective modulation of glucose metabolism as indicated by changes in GLUT2 and PEPCK expression. Molecular docking studies confirmed strong binding of the drugs to their targets [251]. In the second context, the synergistic effects of phloretin combined with radiotherapy (RT) were explored using a Lewis lung cancer (LLC) xenograft model. Phloretin enhanced RT efficacy, evidenced by increased survival rates, prolonged tumor growth delay, reduced glucose uptake, and higher apoptosis rates. The combination also reduced the proliferation index. These findings collectively suggest that phloretin-based treatments, whether targeting glucose metabolism or combined with RT, offer promising strategies for cancer therapy through enhanced regulation of glucose metabolism, ATP production, and apoptosis induction [252]. The therapeutic potential of these inhibitors is underlined by their ability to selectively target cancer cells while sparing normal cells, thereby minimizing systemic toxicity. Several glucose transporter inhibitors have shown promising results in preclinical studies, including STF-31, Glutor, BAY-876, and WZB117. These compounds have demonstrated efficacy in inhibiting glucose uptake and suppressing tumor growth in various cancer models [216, 248]. However, challenges remain in translating these findings to clinical applications. Many glucose transport inhibitors have faced limitations such as low selectivity, high toxicity, and side effects. To address these issues, researchers are exploring combination therapies and developing more advanced and effective glucose metabolism enzyme-targeted anticancer drugs. Ongoing research and clinical trials are crucial to optimize their efficacy, dosing regimens, and to overcome potential resistance mechanisms, making glucose transport inhibitors a pivotal addition to the arsenal against cancer. Table 6 Overview of the glucose transport inhibitors

Inhibitor	NCT Number	Phase	Status	Mechanism of Action	Year	
Phloretin	N/A	N/A	Preclinical studies	Inhibits glucose transporters GLUT1 and GLUT2 by competing with glucose for the binding site.	N/A	
Fasentin	N/A	N/A	Preclinical studies	Inhibits GLUT1 by binding to an allosteric site, reducing glucose uptake in cells.	N/A	
WZB117	NCT03278444	Phase 3	Unknown	Selectively inhibits GLUT1, disrupting glucose uptake and thereby affecting cellular metabolism and viability.	2017–2021	
STF-31	NCT01992016	N/A	Completed	Inhibits GLUT1, leading to decreased glucose uptake and selectively targeting cells dependent on glucose metabolism, such as renal cell carcinoma.	2014–2018	
BAY-876	N/A	N/A	Preclinical studies	Selective GLUT1 inhibitor, blocking glucose transport and subsequently reducing glycolytic flux in cancer cells.	N/A	
PGG (Penta-O-galloyl-β-D-glucose)	NCT04995094

NCT05159778

NCT03003468

NCT02981303

NCT00912327

NCT02132403

NCT03246685

NCT02086175

NCT01309126

NCT00545545

NCT00874848

NCT00874107

NCT01269385

NCT03555149

	Phase 2

Phase 2

Phase 1/2

Phase 2

N/A

Phase 1

Phase 2

Phase 2

Phase 3

Phase 1/2

Phase 2

Phase 2

Phase 1/2

Phase 1/2

	Withdrawn

Completed

Active (Not recruiting)

Completed

Completed

Terminated

Terminated

Completed

Terminated

Completed

Completed

Completed

Completed

Terminated

	Inhibits GLUT1-mediated glucose transport, thereby reducing glucose uptake and glycolysis in cancer cells.	2021–2023

2021–2023

2017–2025

2017–2020

2009–2012

2014–2015

2017–2018

2014–2021

2011–2017

2007–2009

2009–2015

2009–2016

2011–2015

2018–2022

	
CG-5 (Calcein Green 5)	N/A	N/A	Preclinical studies	Inhibits GLUT1 and GLUT3, reducing glucose uptake and affecting cell survival, particularly in cancer cells.	N/A	
Ritonavir	NCT05334004

NCT03383692

NCT01009437

NCT01095094

NCT04455958

NCT05679388’

NCT00637637

NCT05150691

NCT03147378

NCT01173913

NCT06428045

NCT01165645

NCT02948283

NCT02770378

NCT00003008

NCT00444379

	Phase 1

Phase 1

Phase 1

Phase 2

Phase 2

Phase 1

Phase 2

Phase 1/2

Phase 1

Phase 1

Phase 1

N/A

Phase 1

Phase 1/2

Phase 2

Phase 4

	Recruiting

Completed

Completed

Terminated

Withdrawn

Recruiting

Unknown

Recruiting

Completed

Completed

Not yet recruiting

Withdrawn

Completed

Completed

Completed

Completed

	Inhibits GLUT4, primarily used in adipose tissue and muscle, affecting glucose uptake and insulin sensitivity.	2023–2025

2018–2023

2010–2014

2009–2011

2021–2021

2023–2025

2007–2009

2022–2025

2017–2018

2010–2017

2024–2029

2010–2011

2017–2017

2016–2020

1997–2006

2007–2012

	
Apigenin	N/A	N/A	Preclinical studies	Inhibits GLUT1 and reduces glucose uptake by binding directly to the transporter.	N/A	
Myricetin	N/A	N/A	Preclinical studies	Inhibits GLUT1 and GLUT4, leading to decreased glucose uptake in cancer cells. .	N/A	
Genistein	NCT01985763

NCT02624388

NCT00005827

NCT00546039

NCT00882765

NCT00001696

NCT02766478

NCT00099008

NCT02499861

NCT00769990

NCT01489813

NCT00058266

NCT00290758

NCT01126879

NCT00244933

NCT00276835

NCT00269555

NCT01538316

NCT00584532

NCT01628471

NCT00376948

NCT00118040

NCT01325311

	Phase 1/2

Phase 2

Phase 1

Phase 2

Phase 2

Phase 1

Phase 2

Phase 1

Phase 1/2

Phase 1/2

Phase 2

Phase 2

Phase 2

Phase 2

Phase 2

Phase 1

N/A

N/A

Phase 2/3

Phase 1/2

Phase 2

Phase 2

Phase 2

	Completed

Terminated

Withdrawn

Unknown

Withdrawn

Completed

Terminated

Completed

Completed

Withdrawn

Active (Not recruiting)

Terminated

Completed

Terminated

Completed

Completed

Completed

Unknown

Completed

Completed

Completed

Completed

Completed

	Inhibits GLUT1, reducing glucose transport and inducing metabolic stress in cancer cells. .	2013–2018

2016–2021

1999–2003

2007–2009

2009–2011

1998–2001

2017–2021

2004–2006

2015–2017

2008–2010

2017–2024

2002–2009

2006–2009

2011–2013

2004–2009

2005–2014

2004–2006

2012–2014

2003–2007

2012–2015

2005–2010

2005–2010

2011–2014

	
Quercetin	NCT02989129

NCT05680662

NCT01732393

NCT04733534

NCT03476330

NCT05456022

NCT01538316

NCT05724329

NCT00003365

NCT01912820

NCT06355037

NCT00455416

	Phase 1

Phase 1

Phase 1/2

Phase 2

Phase 2

Phase 2

N/A

Phase 2

N/A

Phase 1

Phase 2

Phase 2

	Withdrawn

Not yet recruiting

Completed

Recruiting

Active (Not recruiting)

Unknown

Unknown

Recruiting

Terminated

Completed

Recruiting

Unknown

	Inhibits GLUT1 and GLUT4, decreasing glucose uptake and affecting cellular metabolism.	2018–2020

2023–2024

2010–2012

2022–2025

2018–2025

2022–2023

2012–2014

2023–2027

1996–2006

2014–2021

2024–2025

2007–2009

	
Silibinin	NCT05793489

NCT05689619

NCT01129570

NCT00487721

NCT02146118

	N/A

N/A

Phase 1

Phase 2

Phase 2

	Recruiting

Recruiting

Completed

Completed

Unknown

	Inhibits GLUT1 and GLUT4, resulting in reduced glucose transport and glycolysis in cancer cells.	2023–2026

2023–2027

2010–2013

2006–2011

2014–2016

	

Monocarboxylate Transporter (MCT) inhibitors

Monocarboxylate Transporter (MCT) inhibitors are emerging as promising agents in the realm of cancer metabolism therapeutics [253, 254] (Table 7). MCTs, particularly MCT1 [255, 256] and MCT4 [257, 258], play crucial roles in the transport of lactate and other monocarboxylates across cell membranes, which is vital for maintaining the metabolic flexibility and survival of cancer cells in the hypoxic tumor microenvironment. Cancer cells often rely on aerobic glycolysis leading to excessive lactate production, and MCTs facilitate the efflux of this lactate to prevent intracellular acidification and sustain glycolytic flux. Inhibiting MCTs can disrupt this metabolic adaptation, leading to intracellular lactate accumulation, reduced glycolysis, and subsequent metabolic stress in cancer cells. This metabolic disruption can potentiate cell death, reduce tumor growth, and enhance the efficacy of other treatments, such as radiotherapy and chemotherapy [216, 259]. Additionally, MCT inhibitors can target the metabolic symbiosis between glycolytic cancer cells and oxidative tumor cells, further hampering tumor progression. Given their selective action on the altered metabolic pathways in cancer cells, MCT inhibitors offer a targeted therapeutic approach with potentially reduced systemic toxicity. Clinical trials are ongoing to evaluate the efficacy and safety of these inhibitors, making them a significant focus in the development of novel anticancer strategies. Moreover, combination therapy using MCT inhibitors shows promise. Recent research reveals potential therapeutic strategies for both non-small cell lung cancer (NSCLC) and multiple myeloma (MM) by repurposing syrosingopine in combination with other metabolic inhibitors—UK-5099 for NSCLC and metformin for MM. In NSCLC, the syrosingopine-UK-5099 combination synergistically induces cell cycle arrest, apoptosis, and mitochondrial damage through lactate accumulation and oxidative stress, mediated by the activation of the integrated stress response (ISR) via heme-regulated inhibitor kinase (HRI) [260]. In MM, the syrosingopine-metformin combination targets metabolic vulnerabilities by inhibiting both glycolysis and oxidative phosphorylation, activating p-AMPKα, reducing protein synthesis, and significantly decreasing tumor burden [261]. Table 7 Overview of the Monocarboxylate Transporter (MCT) inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
AZD3965	NCT01791595	Phase 1	Completed	AZD3965 is a selective inhibitor of MCT1. By inhibiting MCT1, AZD3965 prevents the efflux of lactate from glycolytic cancer cells, leading to intracellular acidification, inhibition of glycolysis, and reduced cell proliferation.	2013–2020	
ARC155858	N/A	N/A	Preclinical studies	ARC155858 is a potent inhibitor of MCT2. It blocks lactate transport, causing a buildup of lactate inside cancer cells, leading to acidification, metabolic stress, and cell death.	N/A	
7ACC2	N/A	N/A	Preclinical studies	7ACC2 is an inhibitor of MCT1. It inhibits lactate transport, resulting in increased intracellular lactate, which disrupts glycolysis and reduces ATP production, leading to cell death.	N/A	
SR13800	N/A	N/A	Preclinical studies	SR13800 selectively inhibits MCT1, reducing lactate efflux and causing metabolic stress and growth inhibition in cancer cells.	N/A	
BAY-8002	N/A	N/A	Preclinical studies	BAY-8002 is a selective MCT4 inhibitor. Inhibition of MCT4 affects lactate export in glycolytic cancer cells, leading to intracellular lactate accumulation, acidification, and inhibition of cancer cell growth.	N/A	
Lonidamine	N/A	N/A	Preclinical studies	Lonidamine inhibits multiple MCTs (including MCT1 and MCT4) and also disrupts mitochondrial function. It impairs lactate export and energy production, leading to apoptosis in cancer cells.	N/A	
Syrosingopine	N/A	N/A	Preclinical studies	Syrosingopine inhibits MCT1 and MCT4, preventing lactate export. This leads to intracellular lactate accumulation, metabolic stress, and cell death.	N/A	
STF-31	N/A	N/A	Preclinical studies	STF-31 targets MCT1 and inhibits glucose transporter GLUT1, leading to impaired lactate transport and glucose uptake, causing metabolic stress and cancer cell death.	N/A	

Amino acid transport inhibitors

Amino acid transport inhibitors represent a promising approach in cancer metabolism therapy by targeting the critical nutrient supply that cancer cells rely on for growth and survival [262, 263] (Table 8). Cancer cells often exhibit increased uptake of amino acids to support their rapid proliferation and metabolic demands. By inhibiting the transporters responsible for amino acid uptake, such as the LAT1 (L-type amino acid transporter 1) and ASCT2 (alanine-serine-cysteine transporter 2), these therapies can effectively starve cancer cells of essential nutrients. This disruption in amino acid supply can lead to impaired protein synthesis, altered cellular metabolism, and the induction of stress responses that may culminate in cell death [262, 263]. Additionally, inhibiting amino acid transport can sensitize cancer cells to other treatments by enhancing metabolic vulnerabilities. As a result, amino acid transport inhibitors are being explored in combination with other therapeutic strategies to achieve more effective cancer control [263, 264]. Such as, a recent study has shown that JPH203 can sensitize cancer cells to radiation therapy by inhibiting radiation-induced amino acid uptake and downregulating mTOR activity, which enhances cellular senescence. This combination of JPH203 and radiation therapy presents a promising approach to cancer treatment, potentially improving the efficacy of radiotherapy while maintaining cellular ATP and GSH levels, indicating minimal toxicity [265]. Ongoing research is focused on identifying specific inhibitors, understanding their mechanisms of action, and optimizing their clinical application to improve patient outcomes in various cancer types. For example, drugs targeting amino acid transporters and related enzymes have transitioned from preclinical research to clinical trials and have demonstrated efficacy in some cases. Clinically, Tamoxifen and Raloxifene block glutamine uptake by inhibiting ASCT2 expression in breast cancer to suppress tumor growth [266]. However, challenges remain in developing selective inhibitors and addressing the metabolic plasticity of cancer cells. Some drugs targeting amino acid metabolism have shown promising effects in animal experiments, but realizing their potential clinically is still difficult. Nevertheless, compared to other therapies, amino acid depletion therapy is generally safer for normal cells, making it an attractive avenue for further research and development in cancer treatment. Table 8 Overview of the amino acid transport inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
CH3-CHL	N/A	N/A	Preclinical studies	Inhibits the system L amino acid transporter LAT1 (SLC7A5), reducing the uptake of essential amino acids like leucine, thereby impairing mTOR signaling and inhibiting cancer cell growth.	N/A	
BCH	N/A	N/A	Preclinical studies	Competitive inhibitor of LAT1, blocking the uptake of large neutral amino acids, leading to reduced protein synthesis and cell proliferation.	N/A	
JPH203	UMIN000034080	Phase 2	Completed	Selective LAT1 inhibitor, reduces leucine uptake, impairs mTOR signaling, and induces cell cycle arrest and apoptosis in cancer cells.	2018	
GPNA	N/A	N/A	Preclinical studies	Inhibits ASCT2, leading to decreased glutamine uptake, impairing nucleotide synthesis, and reducing cancer cell viability.	N/A	
V-9302	N/A	N/A	Preclinical studies	Small molecule inhibitor targeting SLC38A2/SNAT2, reducing glutamine uptake, affecting mTOR signaling, and inducing oxidative stress and apoptosis in cancer cells.	N/A	
Telaglenastat	NCT04824937

NCT04250545

NCT05521997

NCT03875313

NCT03057600

NCT02771626

NCT03798678

NCT03872427

NCT03163667

NCT03528642

NCT03965845

NCT03428217

NCT03831932

NCT04265534

	Phase 2

Phase 1

Phase 2

Phase 1/2

Phase 2

Phase 1/2

Phase 1

Phase 2

Phase 2

Phase 1

Phase 1/2

Phase 2

Phase 1/2

Phase 2

	Unknown

Active (Not recruiting)

Not yet recruiting

Terminated

Completed

Terminated

Active (Not recruiting)

Active (Not recruiting)

Completed

Active (Not recruiting)

Completed

Completed

Active (Not recruiting)

Terminated

	Inhibits glutaminase, an enzyme converting glutamine to glutamate, reducing glutamine utilization in the TCA cycle, and impairing cell growth and survival in glutamine-dependent cancers.	2021–2021

2020–2025

2024–2030

2019–2020

2017–2019

2016–2020

2019–2025

2019–2024

2017–2020

2019–2024

2019–2021

2018–2021

2020–2025

2020–2022

	

Isocitrate dehydrogenase (IDH) inhibitors

Isocitrate Dehydrogenase (IDH) inhibitors represent a promising class of targeted therapies in the realm of cancer metabolism (Table 9). IDH enzymes, specifically IDH1 and IDH2, play crucial roles in the citric acid cycle, catalyzing the conversion of isocitrate to alpha-ketoglutarate (α-KG). Mutations in IDH1 and IDH2 genes, often found in various cancers such as gliomas, AML, and cholangiocarcinoma, result in the production of the oncometabolite 2-hydroxyglutarate (2-HG) [43, 267]. This aberrant metabolite disrupts cellular differentiation and promotes tumorigenesis by inhibiting α-KG-dependent dioxygenases, including those involved in DNA and histone demethylation. IDH inhibitors, such as ivosidenib (AG-120) and enasidenib (AG-221), specifically target these mutant enzymes, reducing 2-HG levels and thereby restoring normal cellular differentiation processes [267, 268]. Clinical trials have demonstrated the efficacy of IDH inhibitors, leading to their approval for treating IDH-mutant cancers. The precision of these inhibitors in targeting metabolic pathways unique to cancer cells underscores their potential to offer a more effective and less toxic alternative to traditional chemotherapies, heralding a new era in cancer treatment focused on metabolic vulnerabilities. Moreover, combining IDH inhibitors with other agents can enhance treatment outcomes. For instance, the FDA recently approved ivosidenib in combination with azacitidine for newly diagnosed IDH1-mutated AML in older adults or those with comorbidities. This approval followed a phase 3 study demonstrating improved event-free survival, overall survival, and complete remission rates with the combination therapy [269]. Table 9 Overview of the Isocitrate dehydrogenase (IDH) inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Ivosidenib (AG-120)	NCT03564821

NCT06291987

NCT04195555

NCT04056910

NCT02073994

NCT04176393

NCT02074839

NCT04955938

NCT03471260

NCT06181734

NCT06081829

NCT05209074

NCT03245424

NCT02989857

NCT06465953

NCT05876754

NCT06127407

NCT04278781

NCT05756777

NCT03173248

NCT03839771

NCT03343197

NCT03503409

NCT04493164

NCT05921760

NCT04088188

NCT04250051

NCT05615818

NCT05907057

NCT06265545

NCT04774393

NCT02677922

NCT05010772

NCT03498521

NCT02632708

NCT06377579

NCT04655391

NCT03680677

NCT06501625

NCT03013998

	Phase 1

Phase 1

Phase 2

Phase 2

Phase 1

Phase 1

Phase 1

Phase 1

Phase 1/2

N/A

Phase 2

Phase 1

N/A

Phase 3

Phase 3

Phase 3

Phase 3

Phase 2

Phase 1

Phase 3

Phase 3

Phase 1

Phase 2

Phase 2

Phase 1/2

Phase 1

Phase 1

Phase 2

Phase 3

N/A

Phase 1/2

Phase 1/2

Phase 1

Phase 2

Phase 1/2

N/A

Phase 1

N/A

Phase 1/2

Phase 1/2

	Completed

Not yet recruiting

Active (Not recruiting)

Completed

Completed

Completed

Recruiting

Withdrawn

Recruiting

Recruiting

Active (Not recruiting)

Recruiting

Approved

Completed

Not yet recruiting

Recruiting

Recruiting

Recruiting

Recruiting

Active (Not recruiting)

Recruiting

Active (Not recruiting)

Active (Not recruiting

Recruiting

Recruiting

Terminated

Recruiting

Recruiting

Recruiting

Not yet recruiting

Recruiting

Active (Not recruiting)

Recruiting

Active (Not recruiting)

Active (Not recruiting)

Not yet recruiting

Withdrawn

Recruiting

Not yet recruiting

Recruiting

	Ivosidenib specifically inhibits the mutant IDH1 enzyme, reducing the production of 2-HG. This inhibition allows for the reactivation of normal cellular differentiation processes that are otherwise blocked by the high levels of 2-HG.	2019–2023

2024–2026

2020–2025

2021–2023

2014–2024

2019–2023

2014–2025

2021–2023

2018–2025

2023–2028

2023–2027

2022–2026

N/A

2017–2021

2024–2028

2023–2025

2024–2030

2020–2026

2023–2025

2017–2026

2019–2033

2018–2025

2019–2025

2020–2025

2023–2026

2021–2023

2020–2028

2024–2028

2023–2026

2024–2026

2021–2024

2016–2024

2021–2026

2018–2024

2015–2024

2024–2025

2022–2023

2018–2025

2024–2030

2016–2026

	
Enasidenib (AG-221)	NCT01915498

NCT04522895

NCT03515512

NCT02273739

NCT06176989

NCT04281498

NCT04092179

NCT05102370

NCT04955938

NCT03728335

NCT03744390

NCT05441514

NCT05756777

NCT03683433

NCT05282459

NCT03881735

NCT04203316

NCT03839771

NCT04075747

NCT03383575

NCT02677922

NCT03825796

NCT04774393

NCT03720366

NCT05010772

NCT02632708

NCT02577406

NCT02813135

NCT03013998

NCT03732703

NCT03878524

	Phase 1/2

Phase 2

Phase 1

Phase 1/2

Phase 2

Phase 2

Phase 1/2

Phase 1

Phase 1

Phase 1

Phase 2

Phase 1

Phase 1

Phase 2

Phase 1/2

Phase 2

Phase 2

Phase 3

Phase 1

Phase 2

Phase 1/2

Phase 2

Phase 1/2

Phase 1

Phase 1

Phase 1

Completed

Phase 1/2

Phase 1/2

Phase 1/2

Phase 1

	Completed

Active (Not recruiting)

Completed

Completed

Recruiting

Completed

Terminated

Active (Not recruiting)

Withdrawn

Recruiting

Active (Not recruiting)

Recruiting

Recruiting

Recruiting

Recruiting

Withdrawn

Recruiting

Recruiting

Completed

Recruiting

Active (Not recruiting)

Active (Not recruiting)

Recruiting

Completed

Recruiting

Active (Not recruiting)

Completed

Recruiting

Recruiting

Uknown

Terminated

	Enasidenib inhibits mutant IDH2, leading to decreased levels of 2-HG, promoting the differentiation of immature myeloid cells, and thereby countering the leukemogenic effects of the IDH2 mutation.	2013–2023

2020–2024

2018–2023

2014–2016

2024–2030

2021–2023

2020–2023

2021–2025

2021–2023

2019–2027

2019–2026

2022–2025

2023–2025

2018–2025

2022–2024

2019–2022

2023–2030

2019–2033

2019–2023

2018–2025

2016–2024

2019–2024

2021–2024

2018–2023

2021–2026

2015–2024

2015–2024

2016–2027

2016–2026

2019–2024

2020–2020

	
Vorasidenib (AG-881)	NCT05592743

NCT05609994

NCT05484622

NCT06478212

NCT04164901

NCT03684811

	N/A

Phase 1

Phase 1

Phase 1/2

Phase 3

Phase 1/2

	Available

Not yet recruiting

Recruiting

Not yet recruiting

Active (Not recruiting)

Completed

	Vorasidenib is a dual inhibitor of both IDH1 and IDH2 mutants, reducing 2-HG levels and potentially targeting tumors with either mutation. It is being investigated for its effects in various solid tumors, including gliomas.	N/A

2024–2027

2023–2027

2024–2028

2020–2027

2018–2022

	
Olutasidenib (FT-2102)	NCT06161974

NCT02719574

	Phase 2

Phase 1/2

	Not yet recruiting

Completed

	Olutasidenib inhibits the mutant IDH1 enzyme, leading to decreased 2-HG levels and reactivating differentiation in affected cells.	2024–2035

2016–2024

	
BAY1436032	NCT02746081

NCT03127735

	Phase 1

Phase 1

	Active (Not recruiting)

Completed

	BAY1436032 inhibits the IDH1 mutant enzyme, reducing 2-HG production and reversing the oncogenic effects associated with the mutation.	2016–2024

2017–2019

	
IDH305	NCT02826642

NCT02977689

NCT02987010

NCT02381886

	Phase 1

Phase 2

Phase 2

Phase 1

	Withdrawn

Withdrawn

Withdrawn

Active (Not recruiting)

	IDH305 selectively targets the IDH1 R132H mutant, inhibiting 2-HG production and restoring normal metabolic and epigenetic functions.	2016–2016

2018–2020

2019–2019

2015–2025

	
IDH-C35	N/A	N/A	Preclinical studies	IDH-C35 is an allosteric inhibitor of the IDH1 R132H mutant, inhibiting the production of 2-HG and offering potential therapeutic benefits in cancers harboring this mutation.	N/A	

Oxidative phosphorylation (OXPHOS) inhibitors

Oxidative phosphorylation (OXPHOS) inhibitors represent a promising approach in cancer metabolism therapy (Table 10), targeting the unique metabolic dependencies of cancer cells [270, 271]. OXPHOS is a critical process occurring in the mitochondria, where cells produce ATP, the primary energy currency, through the electron transport chain and ATP synthase. Cancer cells often exhibit altered metabolic states, including increased reliance on glycolysis even in the presence of oxygen, but many tumors retain or adapt to a dependence on OXPHOS for survival and proliferation, particularly under nutrient-limited or low-oxygen conditions [50, 272]. Inhibiting OXPHOS disrupts ATP production, generating oxidative stress and triggering cell death in OXPHOS-dependent cancer cells [273]. Various agents, such as metformin, phenformin, and IACS-010759, target different components of the mitochondrial electron transport chain, highlighting the heterogeneity of tumor metabolic dependencies and the need for personalized treatment strategies [63, 274]. Additionally, OXPHOS inhibitors can enhance the efficacy of existing therapies, such as chemotherapy and radiotherapy, by sensitizing cancer cells to these treatments [273, 275]. Despite their potential, challenges remain, including the identification of biomarkers to predict responsiveness and managing off-target effects on normal cells, which also rely on OXPHOS for energy production. Combining oxidative phosphorylation inhibitors with other therapeutic agents can enhance their effectiveness in cancer treatment. Recent research has shown that OXPHOS inhibitors can be particularly effective when used in conjunction with other treatments such as chemotherapy, targeted therapies, or immunotherapies. This combinatorial approach can help overcome resistance mechanisms, and improve tumor response [275]. Therefore, ongoing research is crucial to optimize the therapeutic window and enhance the specificity of OXPHOS inhibitors in cancer treatment. Table 10 Overview of the oxidative phosphorylation (OXPHOS) inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Metformin	Several	Various	Various	Although primarily an antidiabetic drug, metformin indirectly inhibits Complex I by reducing mitochondrial oxidative phosphorylation, leading to a decrease in ATP production and energy stress in cancer cells	N/A	
Phenformin	NCT03026517	Phase 1	Active (Not recruiting)	A more potent analog of metformin, phenformin also inhibits Complex I, causing a reduction in ATP production and an increase in reactive oxygen species (ROS).	2017–2025	
IACS-010759	NCT02882321

NCT03291938

	Phase 1

Phase 1

	Terminated

Completed

	A highly specific Complex I inhibitor, IACS-010759 disrupts mitochondrial respiration, leading to energy depletion and increased oxidative stress in tumor cells.	2016–2022

2017–2020

	
BAY 87-2243	NCT01297530	Phase 1	Terminated	BAY 87-2243 is an investigational inhibitor of Complex I that induces mitochondrial dysfunction, leading to the inhibition of tumor growth by altering cellular metabolism.	2011–2012	
Rotenone	N/A	N/A	Preclinical studies	A naturally occurring pesticide that directly inhibits Complex I, leading to the disruption of electron transport and decreased ATP synthesis.	N/A	
Piericidin A	N/A	N/A	N/A	A bacterial metabolite that inhibits Complex I by binding to the quinone binding site, disrupting electron transfer and ATP production.	N/A	
Atpenin A5	N/A	N/A	Preclinical studies	A5 specifically inhibits Complex II by binding to the ubiquinone binding site, blocking the electron transfer from succinate to ubiquinone.	N/A	
TTFA (Thenoyltrifluoroacetone)	N/A	N/A	Preclinical studies	TTFA is a competitive inhibitor of Complex II that binds to the iron-sulfur clusters within succinate dehydrogenase, preventing electron transfer from succinate to ubiquinone.	N/A	
3-Nitropropionic Acid (3-NP)	N/A	N/A	Preclinical studies	3-Nitropropionic acid is an irreversible inhibitor of Complex II that covalently modifies the enzyme, leading to inhibition of electron transfer from succinate to ubiquinone.	N/A	
Malonate	NCT00805636

NCT00696943

	Phase 2

Phase 2

	Unknown

Terminated

	Malonate is a competitive inhibitor of succinate dehydrogenase that resembles succinate and competes for the active site, thereby inhibiting Complex II activity.	2008–2010

2008–2009

	
Carboxin	N/A	N/A	Preclinical studies	Carboxin inhibits Complex II by binding to the quinone reduction site, preventing electron transfer from succinate to ubiquinone.	N/A	
Dimethylmalonate	N/A	N/A	Preclinical studies	Dimethylmalonate is a prodrug that is metabolized into malonate in cells, which then inhibits Complex II by competing with succinate for the active site.	N/A	
Antimycin A	N/A	N/A	Preclinical studies	Antimycin A binds to the Qi site of Complex III, blocking the transfer of electrons from ubiquinol to cytochrome c. This inhibition disrupts the electron transport chain, leading to increased reactive oxygen species (ROS) and apoptosis.	N/A	
Myxothiazol	N/A	N/A	Preclinical studies	Myxothiazol inhibits Complex III by binding to the Qo site, preventing the oxidation of ubiquinol and blocking electron transfer to cytochrome c.	N/A	
Stigmatellin	N/A	N/A	Preclinical studies	Stigmatellin binds to the Qo site of Complex III, inhibiting the transfer of electrons from ubiquinol to cytochrome c and disrupting the mitochondrial electron transport chain.	N/A	
Napthoquinones	N/A	N/A	Preclinical studies	β-Lapachone, a napthoquinone derivative, can inhibit Complex III by inducing the generation of ROS, which disrupts electron transport and leads to mitochondrial dysfunction.	N/A	
MOA-1	N/A	N/A	Preclinical studies	MOA-1 inhibits Complex III, leading to the accumulation of ROS and mitochondrial dysfunction, which can induce apoptosis in cancer cells.	N/A	
Azide	N/A	N/A	Preclinical studies	Azide inhibits Complex IV by binding to the cytochrome a3 subunit, blocking electron transfer and oxygen reduction, leading to impaired oxidative phosphorylation.	N/A	
Oligomycin	N/A	N/A	Preclinical studies	Oligomycin binds to the Fo subunit of ATP synthase, inhibiting proton flow through the enzyme and thereby preventing ATP synthesis.	N/A	
Bedaquiline	N/A	N/A	Preclinical studies	Bedaquiline, an antibiotic used to treat multidrug-resistant tuberculosis, inhibits the c subunit of ATP synthase, disrupting proton flow and ATP production.	N/A	
Venturicidin	N/A	N/A	Preclinical studies	Venturicidin is a potent inhibitor of ATP synthase that binds to the Fo subunit, blocking proton translocation and ATP synthesis.	N/A	
Bongkrekic Acid	N/A	N/A	Preclinical studies	Bongkrekic acid inhibits the adenine nucleotide translocator (ANT) in mitochondria, indirectly affecting ATP synthase by disrupting ATP/ADP exchange across the mitochondrial membrane.	N/A	
Dicyclohexylcarbodiimide	N/A	N/A	Preclinical studies	DCCD inhibits ATP synthase by binding to the Fo subunit, blocking proton translocation and thereby preventing ATP production.	N/A	
Efrapeptin	N/A	N/A	Preclinical studies	Efrapeptin inhibits ATP synthase by binding to the Fo subunit, preventing proton flow and ATP synthesis.	N/A	
Aurovertin B:	N/A	N/A	Preclinical studies	Aurovertin B inhibits the F1 ATPase domain of ATP synthase, blocking ATP synthesis and reducing mitochondrial efficiency.	N/A	
Clinical tials for Metformin: https://clinicaltrials.gov/search?cond=Cancer&intr=Metformin

Fatty acid synthesis inhibitors

Fatty acid synthesis inhibitors represent a promising avenue in cancer metabolism therapy, targeting the metabolic reprogramming characteristic of many cancers [118, 276] (Table 11). Cancer cells often exhibit increased de novo lipogenesis, crucial for rapid cell proliferation and survival [118, 277]. This enhanced fatty acid synthesis is driven by upregulated expression of key enzymes, such as fatty acid synthase (FASN), which catalyzes the formation of palmitate from acetyl-CoA and malonyl-CoA. Inhibiting FASN disrupts the production of fatty acids necessary for membrane biosynthesis, energy storage, and signaling molecule generation, thereby impeding tumor growth and inducing apoptosis [118]. Various FASN inhibitors, including natural products like orlistat and synthetic molecules such as TVB-2640, have demonstrated efficacy in preclinical studies by selectively targeting cancer cells while sparing normal cells, which rely more on dietary fatty acids [118, 278]. By exploiting the metabolic vulnerabilities of cancer cells, fatty acid synthesis inhibitors offer a targeted therapeutic approach that can potentially enhance the efficacy of existing treatments and overcome resistance mechanisms in various malignancies. Table 11 Overview of the fatty acid synthesis inhibitors

Inhibitors	NCT Number	Phase	Status	Mechanism of Action	Year	
Orlistat	N/A	N/A	N/A	Irreversible inhibitor of FASN, blocking the synthesis of palmitate.	N/A	
BCH	N/A	N/A	Preclinical studies	Competitive inhibitor of LAT1, blocking the uptake of large neutral amino acids, leading to reduced protein synthesis and cell proliferation.	N/A	
C75	N/A	N/A	N/A	Inhibits FASN activity and induces apoptosis in cancer cells.	N/A	
Cerulenin	N/A	N/A	N/A	Covalently binds to the ketoacyl synthase domain of FASN, inhibiting its function.	N/A	
Firsocostat (GS-0976)	N/A	N/A	Preclinical studies	Inhibits ACC, reducing fatty acid synthesis.	N/A	
TVB-2640	NCT02223247

NCT02980029

NCT03808558

NCT05743621

NCT03032484

NCT03179904

	Phase

Phase 1

Phase 2

Phase 1

Phase 2

Phase 2

	Completed

Recruiting

Recruiting

Recruiting

Completed

Active (Not recruiting)

	Small molecule inhibitor of FASN, blocking lipid biosynthesis in cancer cells.	2013–2017

2017–2024

2019–2026

2023–2027

2017–2021

2017–2024

	
Triclosan	N/A	N/A	Preclinical studies	Inhibits enoyl-ACP reductase, an enzyme involved in fatty acid synthesis.	N/A	
Platensimycin	N/A	N/A	Preclinical studies	Inhibits the condensation step of fatty acid synthesis.	N/A	
Soraphen A	N/A	N/A	Preclinical studies	Inhibits ACC, disrupting fatty acid synthesis.	N/A	
TOFA (5-(Tetradecyloxy)-2-furoic acid)	N/A	N/A	Preclinical studies	Inhibits ACC and thus fatty acid synthesis.	N/A	

Challenges and future directions

There are several challenges associated with cancer metabolism, but various strategies can be implemented to address these issues effectively (Fig. 6). One of the significant challenges in targeting cancer metabolism is overcoming the metabolic plasticity of cancer cells. These cells can dynamically adapt to various microenvironmental stresses such as nutrient deprivation and hypoxia, making it difficult to target a single metabolic pathway effectively [70]. This adaptability is achieved through metabolic flexibility (the ability to use different nutrients) and plasticity (the ability to process metabolic substrates in different ways). Furthermore, metabolic heterogeneity within and between tumors adds another layer of complexity. Different cancer cells within the same tumor may rely on distinct metabolic pathways, complicating the development of universal metabolic inhibitors [70, 279]. This heterogeneity is influenced by factors such as the tissue of origin, driving mutations, and the tumor microenvironment. Redundancy and compensation in metabolic pathways also pose a challenge, as cancer cells can bypass metabolic blockades by upregulating alternative pathways or utilizing neighboring stromal cells to supply essential nutrients, undermining the efficacy of targeted therapies [280, 281]. This ability to switch between different metabolic modes allows cancer cells to maintain growth even during glucose or amino acid deprivation. Additionally, the tumor microenvironment significantly influences cancer metabolism. Interactions between cancer cells and stromal cells, immune cells, and extracellular matrix components can modify metabolic pathways, making it challenging to predict therapeutic outcomes [279, 281]. The architectural and mechanical properties of the tumor environment play a crucial role in controlling metabolic plasticity.Fig. 6 The flow chart illustrates the multifaceted challenges and future directions in overcoming metabolic plasticity in cancer cells. The left section highlights the primary challenges, including metabolic plasticity, metabolic heterogeneity within and between tumors, redundancy and compensation in metabolic pathways, influence of the tumor microenvironment and the difficulty in effectively targeting single metabolic pathways. The right section outlines future directions, such as comprehensive profiling of cancer metabolism at single-cell resolution using advanced omics technologies, targeting multiple pathways with combination therapies, modulating the tumor microenvironment to reduce metabolic adaptability, and understanding the temporal dynamics of metabolic changes to develop phase-specific therapies

To address these challenges, future directions include comprehensive profiling of cancer metabolism at single-cell resolution using advanced omics technologies (genomics, proteomics, metabolomics). This approach can help identify key metabolic vulnerabilities. Targeting multiple pathways simultaneously with combination therapies could overcome the redundancy and compensation seen in cancer metabolism. Modulating the tumor microenvironment, such as normalizing blood supply or altering the extracellular matrix, may reduce the metabolic adaptability of cancer cells and enhance the efficacy of metabolic inhibitors. Understanding the temporal dynamics of metabolic changes in cancer cells could lead to therapies that target specific metabolic states or phases of the cell cycle, reducing the likelihood of adaptation.

Combination therapies present another set of challenges in targeting cancer metabolism [154]. One major challenge is the increased risk of toxicity and adverse side effects, which can limit the doses that can be safely administered [282]. Unanticipated interactions between drugs can also affect their efficacy and safety profiles, complicating the design of combination regimens [283]. Optimizing the dosing and scheduling for combination therapies is complex and requires extensive preclinical and clinical testing [284]. Despite these efforts, cancer cells may still develop resistance to combination therapies through various mechanisms, including genetic mutations and epigenetic alterations [285].

To enhance the efficacy of combination therapies, future directions include the rational design of combinations based on mechanistic insights into cancer metabolism and signaling pathways, which can improve efficacy and reduce toxicity. Identifying synergistic drug combinations through high-throughput screening and computational modeling can enhance therapeutic outcomes while minimizing side effects. Adaptive therapy strategies that dynamically adjust treatment based on tumor response and resistance patterns may prolong the efficacy of combination treatments and delay resistance. Personalizing combination therapies to individual patients based on their unique genetic and metabolic profiles can optimize efficacy and reduce adverse effects, leading to more effective and tailored treatment approaches.

Identifying reliable biomarkers for metabolic targeting poses several challenges. One of the primary challenges is the identification and validation of biomarkers that accurately reflect metabolic changes in cancer cells. This requires extensive clinical testing to ensure sensitivity, specificity, and reproducibility [286]. This process is complex and time-consuming, as it involves rigorous evaluation of potential biomarkers across diverse patient populations. Tumor heterogeneity can lead to variability in biomarker expression, complicating their use in predicting therapeutic responses [216]. Additionally, metabolic biomarkers may change dynamically in response to therapy and disease progression, necessitating the development of robust methods for real-time monitoring [287]. Some metabolic biomarkers may also be difficult to measure non-invasively, limiting their clinical utility.

Future directions in this area include developing liquid biopsy techniques to measure circulating metabolites, exosomes, or other biomarkers, providing minimally invasive methods for monitoring cancer metabolism and treatment response. Integrating multi-omics data (e.g., genomics, proteomics, metabolomics) can help identify comprehensive biomarker signatures that reflect the metabolic state of cancer cells. Advances in imaging technologies and biosensors can enable real-time monitoring of metabolic changes in tumors, aiding in the timely adjustment of therapeutic strategies. Developing predictive biomarkers that can identify patients most likely to benefit from specific metabolic therapies can enhance personalized treatment approaches and improve outcomes. By addressing these challenges and pursuing these future directions, researchers can make significant strides in the effective targeting of cancer metabolism.

Conclusion

The study of altered metabolism in cancer has unveiled crucial energy pathways driving tumor growth and survival, highlighting therapeutic opportunities. Key metabolic mechanisms include the Warburg effect, where cancer cells prefer glycolysis even in oxygen-rich conditions, alongside oxidative phosphorylation, glutaminolysis, and lipid metabolism. These processes, regulated by oncogenes, tumor suppressors, epigenetic changes, and the tumor microenvironment, offer targets for therapy. Potential interventions include glycolysis inhibitors like 2-deoxy-D-glucose, oxidative phosphorylation inhibitors, glutamine metabolism inhibitors such as CB-839, and fatty acid synthase inhibitors. Additionally, modulating key regulators like the mTOR and PI3K/AKT pathways expands therapeutic options. However, cancer cells’ metabolic plasticity challenges single-agent therapies, suggesting that combination therapies may enhance efficacy. Identifying biomarkers for metabolic targeting will aid in patient selection and treatment monitoring. Future research should explore the interplay between metabolic pathways and their regulation by the tumor microenvironment to develop effective treatments. Integrating metabolic inhibitors with conventional therapies promises to transform cancer treatment, offering hope for improved patient outcomes. Overall, studying altered cancer metabolism provides critical insights and paves the way for innovative and precise therapeutic strategies.

Abbreviations

TME Tumor microenvironment

HIFs Hypoxia-inducible factors

AMPK AMP-activated protein kinase

LUAD Lung adenocarcinoma

LDHA Lactate dehydrogenase A

OXPHOS Oxidative phosphorylation

ETC Electron transport chain

AML Acute myeloid leukemia

LSCs Leukemic stem cells

ROS Reactive oxygen species

MMPs Matrix metalloproteinases

EMT Epithelial-mesenchymal transition

CSCs Cancer stem cells

TCA Tricarboxylic acid

GDH Glutamate dehydrogenase

FAO Fatty acid oxidation

PI3K Phosphatidylinositol 3-kinase

PIP3 Phosphatidylinositol (3,4,5)-trisphosphate

CAFs Cancer-associated fibroblasts

TAMs Tumor-associated macrophages

VEGF Vascular endothelial growth factor

HATs Histone acetyltransferases

HDACs Histone deacetylases

miRNAs microRNAs

lncRNAs Long non-coding RNAs

ECM Extracellular matrix

PKM2 Pyruvate kinase M2

LDH Lactate dehydrogenase

IDH Isocitrate dehydrogenase

CPT1 Carnitine Palmitoyltransferase 1

ACAD Acyl-CoA Dehydrogenase

MCT Monocarboxylate Transporter

HK2 Hexokinase 2

PFK Phosphofructokinase

GLUT Glucose Transporters

TIGAR TP53-Induced Glycolysis and Apoptosis Regulator

SCO2 Synthesis of Cytochrome c Oxidase 2

PTEN Phosphatase and Tensin Homolog

LKB1 Liver Kinase B1

Acknowledgements

Not applicable.

Authors’ contributions

Muhammad Tufail: Conceptualization, Original Drafting, Visualization, Writing - Review & Editing. Can-Hua Jian: Review and editing. Ning Li: Supervision, reviewed, and editing. All authors have reviewed and approved the final manuscript for publication.

Funding

This work was supported by the National Natural Sciences Foundation of China (Grant No. 82170974) and the Central South University Research Program of Advanced Interdisciplinary Studies (Grant No. 2023QYJC038).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have given consent for publication.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Sedeta E Sung H Laversanne M Bray F Jemal A Recent mortality patterns and time trends for the major cancers in 47 countries worldwide Cancer Epidemiol Biomarkers Prev 2023 32 894 905 10.1158/1055-9965.EPI-22-1133 37195435
Sedeta E, Sung H, Laversanne M, Bray F, Jemal A. Recent mortality patterns and time trends for the major cancers in 47 countries worldwide. Cancer Epidemiol Biomarkers Prev. 2023;32:894–905.37195435
2. Han B Zheng R Zeng H Wang S Sun K Chen R Li L Wei W He J Cancer incidence and mortality in China, 2022 J Natl Cancer Cent 2024 4 47 53 10.1016/j.jncc.2024.01.006 39036382
Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53.39036382
3. Yang J Shay C Saba NF Teng Y Cancer metabolism and carcinogenesis Exp Hematol Oncol 2024 13 10 10.1186/s40164-024-00482-x 38287402
Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13:10.38287402
4. Kim Y Jang Y Kim MS Kang C Metabolic remodeling in cancer and senescence and its therapeutic implications Trends Endocrinol Metab. 2024 35 744 10.1016/j.tem.2024.02.008
Kim Y, Jang Y, Kim MS, Kang C. Metabolic remodeling in cancer and senescence and its therapeutic implications. Trends Endocrinol Metab. 2024;35:744.
5. Akter R Awais M Boopathi V Ahn JC Yang DC Kang SC Yang DU Jung S-K Inversion of the Warburg effect: unraveling the metabolic Nexus between obesity and cancer ACS Pharmacol Trans Sci 2024 7 560 569 10.1021/acsptsci.3c00301
Akter R, Awais M, Boopathi V, Ahn JC, Yang DC, Kang SC, Yang DU, Jung S-K. Inversion of the Warburg effect: unraveling the metabolic Nexus between obesity and cancer. ACS Pharmacol Trans Sci. 2024;7:560–9.
6. Lam Wong KK Verheyen EM Metabolic reprogramming in cancer: mechanistic insights from Drosophila Dis Models Mech 2021 14 dmm048934 10.1242/dmm.048934
Lam Wong KK, Verheyen EM. Metabolic reprogramming in cancer: mechanistic insights from Drosophila. Dis Models Mech. 2021;14:dmm048934.
7. Yoshida GJ Metabolic reprogramming: the emerging concept and associated therapeutic strategies J Exp Clin Cancer Res 2015 34 111 10.1186/s13046-015-0221-y 26445347
Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.26445347
8. Liefwalker DF Ryan M Wang Z Pathak KV Plaisier S Shah V Babra B Dewson GS Lai IK Mosley AR Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies Cancer Metabolism 2021 9 31 10.1186/s40170-021-00263-8 34399819
Liefwalker DF, Ryan M, Wang Z, Pathak KV, Plaisier S, Shah V, Babra B, Dewson GS, Lai IK, Mosley AR, et al. Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. Cancer Metabolism. 2021;9:31.34399819
9. Stein BD Ferrarone JR Gardner EE Chang JW Wu D Hollstein PE Liang RJ Yuan M Chen Q Coukos JS LKB1-Dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma Cancer Discov 2023 13 1002 1025 10.1158/2159-8290.CD-22-0805 36715544
Stein BD, Ferrarone JR, Gardner EE, Chang JW, Wu D, Hollstein PE, Liang RJ, Yuan M, Chen Q, Coukos JS, et al. LKB1-Dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma. Cancer Discov. 2023;13:1002–25.36715544
10. Ciccarese F Zulato E Indraccolo S LKB1/AMPK pathway and drug response in cancer: a therapeutic perspective Oxidative Med Cell Longevity 2019 2019 8730816 10.1155/2019/8730816
Ciccarese F, Zulato E, Indraccolo S. LKB1/AMPK pathway and drug response in cancer: a therapeutic perspective. Oxidative Med Cell Longevity. 2019;2019:8730816.
11. Wicks EE Semenza GL Hypoxia-inducible factors: cancer progression and clinical translation J Clin Investig 2022 132 132 10.1172/JCI159839
Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Investig. 2022;132:132.
12. Mucaj V Shay JES Simon MC Effects of hypoxia and HIFs on cancer metabolism Int J Hematol 2012 95 464 470 10.1007/s12185-012-1070-5 22539362
Mucaj V, Shay JES, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. 2012;95:464–70.22539362
13. Sadria M Seo D Layton AT The mixed blessing of AMPK signaling in Cancer treatments BMC Cancer 2022 22 105 10.1186/s12885-022-09211-1 35078427
Sadria M, Seo D, Layton AT. The mixed blessing of AMPK signaling in Cancer treatments. BMC Cancer. 2022;22:105.35078427
14. Novikova DS Garabadzhiu AV Melino G Barlev NA Tribulovich VG AMP-activated protein kinase: structure, function, and role in pathological processes Biochem (Moscow) 2015 80 127 144 10.1134/S0006297915020017
Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG. AMP-activated protein kinase: structure, function, and role in pathological processes. Biochem (Moscow). 2015;80:127–44.
15. Zou Z Tao T Li H Zhu X mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges Cell Biosci 2020 10 31 10.1186/s13578-020-00396-1 32175074
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31.32175074
16. Zhao H Li Y Cancer metabolism and intervention therapy Mol Biomed 2021 2 5 10.1186/s43556-020-00012-1 35006438
Zhao H, Li Y. Cancer metabolism and intervention therapy. Mol Biomed. 2021;2:5.35006438
17. Trajkovic-Arsic M Subramani E Is metabolism the magic bullet for targeted cancer therapy? BMC Cancer 2023 23 484 10.1186/s12885-023-10999-9 37254076
Trajkovic-Arsic M, Subramani E. Is metabolism the magic bullet for targeted cancer therapy? BMC Cancer. 2023;23:484.37254076
18. Huldani H Malviya J Rodrigues P Hjazi A Deorari MM Al-Hetty HRAK Qasim QA Alasheqi MQ Ihsan A Discovering the strength of immunometabolism in cancer therapy: employing metabolic pathways to enhance immune responses Cell Biochem Funct 2024 42 e3934 10.1002/cbf.3934 38379261
Huldani H, Malviya J, Rodrigues P, Hjazi A, Deorari MM, Al-Hetty HRAK, Qasim QA, Alasheqi MQ, Ihsan A. Discovering the strength of immunometabolism in cancer therapy: employing metabolic pathways to enhance immune responses. Cell Biochem Funct. 2024;42:e3934.38379261
19. Latham BD Geffert RM Jackson KD Kinase inhibitors FDA approved 2018–2023: drug targets, metabolic pathways, and drug-induced toxicities Drug Metab Dispos 2024 52 479 492 10.1124/dmd.123.001430 38286637
Latham BD, Geffert RM, Jackson KD. Kinase inhibitors FDA approved 2018–2023: drug targets, metabolic pathways, and drug-induced toxicities. Drug Metab Dispos. 2024;52:479–92.38286637
20. Nath S Balling R The Warburg effect reinterpreted 100 year on: a first-principles stoichiometric analysis and interpretation from the perspective of ATP metabolism in cancer cells Function 2024 5 zqae008 10.1093/function/zqae008 38706962
Nath S, Balling R. The Warburg effect reinterpreted 100 year on: a first-principles stoichiometric analysis and interpretation from the perspective of ATP metabolism in cancer cells. Function. 2024;5:zqae008.38706962
21. Vander Heiden MG Cantley LC Thompson CB Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009 324 1029 1033 10.1126/science.1160809 19460998
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.19460998
22. Zheng J Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review) Oncol Lett 2012 4 1151 7 10.3892/ol.2012.928 23226794
Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett. 2012;4:1151–7.23226794
23. Shiratori R Furuichi K Yamaguchi M Miyazaki N Aoki H Chibana H Ito K Aoki S Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner Sci Rep 2019 9 18699 10.1038/s41598-019-55296-3 31822748
Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, Ito K, Aoki S. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep. 2019;9:18699.31822748
24. Kim J-w Dang CV Cancer’s Molecular Sweet tooth and the Warburg Effect Cancer Res 2006 66 8927 8930 10.1158/0008-5472.CAN-06-1501 16982728
Kim J-w, Dang CV. Cancer’s Molecular Sweet tooth and the Warburg Effect. Cancer Res. 2006;66:8927–30.16982728
25. Lv X-b Liu L Cheng C Yu B Xiong L Hu K Tang J Zeng L Sang Y SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer Sci Rep 2015 5 17940 10.1038/srep17940 26658802
Lv X-b, Liu L, Cheng C, Yu B, Xiong L, Hu K, Tang J, Zeng L, Sang Y. SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer. Sci Rep. 2015;5:17940.26658802
26. Zhang C Liu J Liang Y Wu R Zhao Y Hong X Lin M Yu H Liu L Levine AJ Tumour-associated mutant p53 drives the Warburg effect Nat Commun 2013 4 2935 10.1038/ncomms3935 24343302
Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.24343302
27. Wang B Pei J Xu S Liu J Yu J A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle J Exp Clin Cancer Res 2024 43 74 10.1186/s13046-024-02994-0 38459595
Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024;43:74.38459595
28. Nguyen T-L Durán RV Glutamine metabolism in cancer therapy Cancer Drug Resist 2018 1 126 138
Nguyen T-L, Durán RV. Glutamine metabolism in cancer therapy. Cancer Drug Resist. 2018;1:126–38.
29. Yoo HC Yu YC Sung Y Han JM Glutamine reliance in cell metabolism Exp Mol Med 2020 52 1496 1516 10.1038/s12276-020-00504-8 32943735
Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52:1496–516.32943735
30. Li T Copeland C Le A Le A Glutamine Metabolism in Cancer The Heterogeneity of Cancer Metabolism 2021 Cham Springer International Publishing 17 38
Li T, Copeland C, Le A. Glutamine Metabolism in Cancer. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2021. p. 17–38.
31. Setton J Zinda M Riaz N Durocher D Zimmermann M Koehler M Reis-Filho JS Powell SN Synthetic lethality in cancer therapeutics: the next generation Cancer Discov 2021 11 1626 1635 10.1158/2159-8290.CD-20-1503 33795234
Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 2021;11:1626–35.33795234
32. Li S Topatana W Juengpanich S Cao J Hu J Zhang B Ma D Cai X Chen M Development of synthetic lethality in cancer: molecular and cellular classification Signal Transd Target Ther 2020 5 241 10.1038/s41392-020-00358-6
Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transd Target Ther. 2020;5:241.
33. Dalla Pozza E Dando I Pacchiana R Liboi E Scupoli MT Donadelli M Palmieri M Regulation of succinate dehydrogenase and role of succinate in cancer Semin Cell Dev Biol 2020 98 4 14 10.1016/j.semcdb.2019.04.013 31039394
Dalla Pozza E, Dando I, Pacchiana R, Liboi E, Scupoli MT, Donadelli M, Palmieri M. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol. 2020;98:4–14.31039394
34. Aghamir SMK Heshmat R Ebrahimi M Ketabchi SE Parichehreh Dizaji S Khatami F The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review Onco Targets Ther 2019 12 7929 40 10.2147/OTT.S207460 31579262
Aghamir SMK, Heshmat R, Ebrahimi M, Ketabchi SE, Parichehreh Dizaji S, Khatami F. The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review. Onco Targets Ther. 2019;12:7929–40.31579262
35. Pliszka M Szablewski L Glucose transporters as a target for anticancer therapy Cancers 2021 13 4184 10.3390/cancers13164184 34439338
Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021;13: 4184.34439338
36. Sarkadi B Meszaros K Krencz I Canu L Krokker L Zakarias S Barna G Sebestyen A Papay J Hujber Z Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas Cancers (Basel) 2020 12 12 10.3390/cancers12030599
Sarkadi B, Meszaros K, Krencz I, Canu L, Krokker L, Zakarias S, Barna G, Sebestyen A, Papay J, Hujber Z, et al. Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas. Cancers (Basel). 2020;12:12.
37. Kitazawa S Ebara S Ando A Baba Y Satomi Y Soga T Hara T Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors Oncotarget 2017 8 28922 28938 10.18632/oncotarget.15959 28423651
Kitazawa S, Ebara S, Ando A, Baba Y, Satomi Y, Soga T, Hara T. Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Oncotarget. 2017;8:28922–38.28423651
38. Valcarcel-Jimenez L Frezza C Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism Br J Cancer 2023 129 1546 1557 10.1038/s41416-023-02412-w 37689804
Valcarcel-Jimenez L, Frezza C. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism. Br J Cancer. 2023;129:1546–57.37689804
39. Lindner AK Tulchiner G Seeber A Siska PJ Thurnher M Pichler R Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma Front Oncol 2022 12 906014 10.3389/fonc.2022.906014 35912170
Lindner AK, Tulchiner G, Seeber A, Siska PJ, Thurnher M, Pichler R. Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front Oncol. 2022;12:906014.35912170
40. Ahmad IM Dafferner AJ Salloom RJ Abdalla MY Heme Oxygenase-1 Inhibition modulates autophagy and augments arsenic trioxide cytotoxicity in pancreatic cancer cells Biomedicines. 2023 11 2580 10.3390/biomedicines11092580 37761021
Ahmad IM, Dafferner AJ, Salloom RJ, Abdalla MY. Heme Oxygenase-1 Inhibition modulates autophagy and augments arsenic trioxide cytotoxicity in pancreatic cancer cells. Biomedicines. 2023;11:2580.37761021
41. Romeo G Ciaffaglione V Amata E Dichiara M Calabrese L Vanella L Sorrenti V Grosso S D’Amico AG D’Agata V Combination of Heme Oxygenase-1 inhibition and sigma receptor modulation for anticancer activity Molecules. 2021 26 3860 10.3390/molecules26133860 34202711
Romeo G, Ciaffaglione V, Amata E, Dichiara M, Calabrese L, Vanella L, Sorrenti V, Grosso S, D’Amico AG, D’Agata V, et al. Combination of Heme Oxygenase-1 inhibition and sigma receptor modulation for anticancer activity. Molecules. 2021;26:3860.34202711
42. Parker SJ Metallo CM Metabolic consequences of oncogenic IDH mutations Pharmacol Ther 2015 152 54 62 10.1016/j.pharmthera.2015.05.003 25956465
Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54–62.25956465
43. Hvinden IC Cadoux-Hudson T Schofield CJ McCullagh JSO Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations Cell Rep Med 2021 2 100469 10.1016/j.xcrm.2021.100469 35028610
Hvinden IC, Cadoux-Hudson T, Schofield CJ, McCullagh JSO. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Rep Med. 2021;2:100469.35028610
44. Tateishi K Wakimoto H Iafrate AJ Tanaka S Loebel F Lelic N Wiederschain D Bedel O Deng G Zhang B Extreme vulnerability of IDH1 mutant cancers to NAD + depletion Cancer Cell 2015 28 773 784 10.1016/j.ccell.2015.11.006 26678339
Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, et al. Extreme vulnerability of IDH1 mutant cancers to NAD + depletion. Cancer Cell. 2015;28:773–84.26678339
45. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015;28(6):773–84. 10.1016/j.ccell.2015.11.006. 
46. Garrett M Sperry J Braas D Yan W Le TM Mottahedeh J Ludwig K Eskin A Qin Y Levy R Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities Cancer Metab 2018 6 4 10.1186/s40170-018-0177-4 29692895
Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, et al. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018;6:4.29692895
47. Marcucci F Rumio C On the role of Glycolysis in early tumorigenesis—permissive and Executioner effects Cells 2023 12 1124 10.3390/cells12081124 37190033
Marcucci F, Rumio C. On the role of Glycolysis in early tumorigenesis—permissive and Executioner effects. Cells. 2023;12: 1124.37190033
48. Li C Liu F-Y Shen Y Tian Y Han F-J Research progress on the mechanism of glycolysis in ovarian cancer Front Immunol 2023 14 1284853 10.3389/fimmu.2023.1284853 38090580
Li C, Liu F-Y, Shen Y, Tian Y, Han F-J. Research progress on the mechanism of glycolysis in ovarian cancer. Front Immunol. 2023;14:1284853.38090580
49. Nong S Han X Xiang Y Qian Y Wei Y Zhang T Tian K Shen K Yang J Ma X Metabolic reprogramming in cancer: mechanisms and therapeutics MedComm 2023 4 e218 10.1002/mco2.218 36994237
Nong S, Han X, Xiang Y, Qian Y, Wei Y, Zhang T, Tian K, Shen K, Yang J, Ma X. Metabolic reprogramming in cancer: mechanisms and therapeutics. MedComm. 2023;4:e218.36994237
50. Yang F Hilakivi-Clarke L Shaha A Wang Y Wang X Deng Y Lai J Kang N Metabolic reprogramming and its clinical implication for liver cancer Hepatology 2023 78 1602 24 10.1097/HEP.0000000000000005 36626639
Yang F, Hilakivi-Clarke L, Shaha A, Wang Y, Wang X, Deng Y, Lai J, Kang N. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78:1602–24.36626639
51. Yu L Chen X Sun X Wang L Chen S The glycolytic switch in tumors: how many players are involved? J Cancer 2017 8 3430 3440 10.7150/jca.21125 29151926
Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how many players are involved? J Cancer. 2017;8:3430–40.29151926
52. Ganapathy-Kanniappan S Geschwind J-FH Tumor glycolysis as a target for cancer therapy: progress and prospects Mol Cancer 2013 12 152 10.1186/1476-4598-12-152 24298908
Ganapathy-Kanniappan S, Geschwind J-FH. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.24298908
53. Zhou Z Li Y Chen S Xie Z Du Y Liu Y Shi Y Lin X Zeng X Zhao H Chen G GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma Cell Commun Signal 2024 22 303 10.1186/s12964-024-01678-8 38831321
Zhou Z, Li Y, Chen S, Xie Z, Du Y, Liu Y, Shi Y, Lin X, Zeng X, Zhao H, Chen G. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma. Cell Commun Signal. 2024;22:303.38831321
54. Taylor CT Scholz CC The effect of HIF on metabolism and immunity Nat Rev Nephrol 2022 18 573 87 10.1038/s41581-022-00587-8 35726016
Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol. 2022;18:573–87.35726016
55. Kim JW Gao P Liu YC Semenza GL Dang CV Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1 Mol Cell Biol 2007 27 7381 7393 10.1128/MCB.00440-07 17785433
Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381–93.17785433
56. Wiese W Barczuk J Racinska O Siwecka N Rozpedek-Kaminska W Slupianek A Sierpinski R Majsterek I PI3K/Akt/mTOR signaling pathway in blood malignancies-new therapeutic possibilities Cancers (Basel) 2023 15 5297 10.3390/cancers15215297 37958470
Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, Sierpinski R, Majsterek I. PI3K/Akt/mTOR signaling pathway in blood malignancies-new therapeutic possibilities. Cancers (Basel). 2023;15:5297.37958470
57. Hoxhaj G Manning BD The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism Nat Rev Cancer 2020 20 74 88 10.1038/s41568-019-0216-7 31686003
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.31686003
58. Deng H Chen Y Li P Hang Q Zhang P Jin Y Chen M PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer Cancer Pathog Ther 2023 1 56 66 10.1016/j.cpt.2022.09.001 38328610
Deng H, Chen Y, Li P, Hang Q, Zhang P, Jin Y, Chen M. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer. Cancer Pathog Ther. 2023;1:56–66.38328610
59. Chelakkot C Chelakkot VS Shin Y Song K Modulating glycolysis to improve cancer therapy Int J Mol Sci 2023 24 2606 10.3390/ijms24032606 36768924
Chelakkot C, Chelakkot VS, Shin Y, Song K. Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 2023;24:2606.36768924
60. Zhang Y Li Q Huang Z Li B Nice EC Huang C Wei L Zou B Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies Cancers (Basel) 2022 14 14
Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C, Wei L, Zou B. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers (Basel). 2022;14:14.
61. Abdel-Wahab AF Mahmoud W Al-Harizy RM Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy Pharmacol Res 2019 150 104511 10.1016/j.phrs.2019.104511 31678210
Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.31678210
62. Hamanaka RB Chandel NS Targeting glucose metabolism for cancer therapy J Exp Med 2012 209 211 215 10.1084/jem.20120162 22330683
Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med. 2012;209:211–5.22330683
63. Ashton TM McKenna WG Kunz-Schughart LA Higgins GS Oxidative phosphorylation as an emerging target in cancer therapy Clin Cancer Res 2018 24 2482 2490 10.1158/1078-0432.CCR-17-3070 29420223
Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482–90.29420223
64. Qiu X Li Y Zhang Z Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection Cell Oncol 2023 46 847 865 10.1007/s13402-023-00801-0
Qiu X, Li Y, Zhang Z. Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection. Cell Oncol. 2023;46:847–65.
65. Zhao Z Mei Y Wang Z He W The effect of oxidative phosphorylation on cancer drug resistance Cancers 2023 15 62 10.3390/cancers15010062
Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers. 2023;15:62.
66. Chen C Hao X Lai X Liu L Zhu J Shao H Huang D Gu H Zhang T Yu Z Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia Sci Adv 2021 7 7
Chen C, Hao X, Lai X, Liu L, Zhu J, Shao H, Huang D, Gu H, Zhang T, Yu Z, et al. Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia. Sci Adv. 2021;7:7.
67. de Beauchamp L Himonas E Helgason GV Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia Leukemia 2022 36 1 12 10.1038/s41375-021-01416-w 34561557
de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36:1–12.34561557
68. Peng M Huang Y Zhang L Zhao X Hou Y Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells Front Oncol 2022 12 899502 10.3389/fonc.2022.899502 35574326
Peng M, Huang Y, Zhang L, Zhao X, Hou Y. Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells. Front Oncol. 2022;12:899502.35574326
69. Nelson MAM McLaughlin KL Hagen JT Coalson HS Schmidt C Kassai M Kew KA McClung JM Neufer PD Brophy P Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia eLife 2021 10 e63104 10.7554/eLife.63104 34132194
Nelson MAM, McLaughlin KL, Hagen JT, Coalson HS, Schmidt C, Kassai M, Kew KA, McClung JM, Neufer PD, Brophy P, et al. Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia. eLife. 2021;10:e63104.34132194
70. Fendt SM Frezza C Erez A Targeting metabolic plasticity and Flexibility dynamics for Cancer Therapy Cancer Discov 2020 10 1797 1807 10.1158/2159-8290.CD-20-0844 33139243
Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and Flexibility dynamics for Cancer Therapy. Cancer Discov. 2020;10:1797–807.33139243
71. Grasmann G Mondal A Leithner K Flexibility and adaptation of cancer cells in a heterogenous metabolic microenvironment Int J Mol Sci. 2021 22 1476 10.3390/ijms22031476 33540663
Grasmann G, Mondal A, Leithner K. Flexibility and adaptation of cancer cells in a heterogenous metabolic microenvironment. Int J Mol Sci. 2021;22:1476.33540663
72. Olson KA Schell JC Rutter J Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies Trends Biochem Sci 2016 41 219 230 10.1016/j.tibs.2016.01.002 26873641
Olson KA, Schell JC, Rutter J. Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies. Trends Biochem Sci. 2016;41:219–30.26873641
73. Ma Y Wang L Jia R The role of mitochondrial dynamics in human cancers Am J Cancer Res 2020 10 1278 93 32509379
Ma Y, Wang L, Jia R. The role of mitochondrial dynamics in human cancers. Am J Cancer Res. 2020;10:1278–93.32509379
74. Chen W Zhao H Li Y Mitochondrial dynamics in health and disease: mechanisms and potential targets Signal Transd Target Ther 2023 8 333 10.1038/s41392-023-01547-9
Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transd Target Ther. 2023;8:333.
75. Punter KB Chu C Chan EYW Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer Endocr Relat Cancer 2023 30 e220229 10.1530/ERC-22-0229 36356297
Punter KB, Chu C, Chan EYW. Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer. Endocr Relat Cancer. 2023;30:e220229.36356297
76. Goda N Kanai M Hypoxia-inducible factors and their roles in energy metabolism Int J Hematol 2012 95 457 463 10.1007/s12185-012-1069-y 22535382
Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol. 2012;95:457–63.22535382
77. Brian MO Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity BMJ Oncol 2024 3 e000154 10.1136/bmjonc-2023-000154
Brian MO. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024;3:e000154.
78. Elzakra N Kim Y Hu S HIF-1α Metabolic Pathways in Human Cancer Cancer Metabolomics: Methods and Applications 2021 Cham Springer International Publishing 243 260
Elzakra N, Kim Y. HIF-1α Metabolic Pathways in Human Cancer. In: Hu S, editor. Cancer Metabolomics: Methods and Applications. Cham: Springer International Publishing; 2021. p. 243–60.
79. Sato T Ichise N Kobayashi T Fusagawa H Yamazaki H Kudo T Tohse N Enhanced glucose metabolism through activation of HIF-1α covers the energy demand in a rat embryonic heart primordium after heartbeat initiation Sci Rep 2022 12 74 10.1038/s41598-021-03832-5 34996938
Sato T, Ichise N, Kobayashi T, Fusagawa H, Yamazaki H, Kudo T, Tohse N. Enhanced glucose metabolism through activation of HIF-1α covers the energy demand in a rat embryonic heart primordium after heartbeat initiation. Sci Rep. 2022;12:74.34996938
80. Carroll VA Ashcroft M Role of Hypoxia-Inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF Target genes in response to Hypoxia, insulin-like Growth Factor-I, or loss of Von Hippel-Lindau function: implications for targeting the HIF pathway Cancer Res 2006 66 6264 6270 10.1158/0008-5472.CAN-05-2519 16778202
Carroll VA, Ashcroft M. Role of Hypoxia-Inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF Target genes in response to Hypoxia, insulin-like Growth Factor-I, or loss of Von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 2006;66:6264–70.16778202
81. Song I-S Wang A-G Yoon SY Kim J-M Kim JH Lee D-S Kim N-S Regulation of glucose metabolism-related genes and VEGF by HIF-1α and HIF-1β, but not HIF-2α, in gastric cancer Exp Mol Med 2009 41 51 58 10.3858/emm.2009.41.1.007 19287200
Song I-S, Wang A-G, Yoon SY, Kim J-M, Kim JH, Lee D-S, Kim N-S. Regulation of glucose metabolism-related genes and VEGF by HIF-1α and HIF-1β, but not HIF-2α, in gastric cancer. Exp Mol Med. 2009;41:51–8.19287200
82. Liou GY Storz P Reactive oxygen species in cancer Free Radic Res 2010 44 479 496 10.3109/10715761003667554 20370557
Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44:479–96.20370557
83. Perillo B Di Donato M Pezone A Di Zazzo E Giovannelli P Galasso G Castoria G Migliaccio A ROS in cancer therapy: the bright side of the moon Exp Mol Med 2020 52 192 203 10.1038/s12276-020-0384-2 32060354
Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192–203.32060354
84. Arfin S Jha NK Jha SK Kesari KK Ruokolainen J Roychoudhury S Rathi B Kumar D Oxidative stress in cancer cell metabolism Antioxidants 2021 10 5 642 10.3390/antiox10050642 33922139
Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B, Kumar D. Oxidative stress in cancer cell metabolism. Antioxidants. 2021;10(5):642.33922139
85. Liao Z Chua D Tan NS Reactive oxygen species: a volatile driver of field cancerization and metastasis Mol Cancer 2019 18 65 10.1186/s12943-019-0961-y 30927919
Liao Z, Chua D, Tan NS. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol Cancer. 2019;18:65.30927919
86. Jing Q Zhou C Zhang J Zhang P Wu Y Zhou J Tong X Li Y Du J Wang Y Role of reactive oxygen species in myelodysplastic syndromes Cell Mol Biol Lett 2024 29 53 10.1186/s11658-024-00570-0 38616283
Jing Q, Zhou C, Zhang J, Zhang P, Wu Y, Zhou J, Tong X, Li Y, Du J, Wang Y. Role of reactive oxygen species in myelodysplastic syndromes. Cell Mol Biol Lett. 2024;29:53.38616283
87. Manoharan RR Prasad A Pospíšil P Kzhyshkowska J ROS signaling in innate immunity via oxidative protein modifications Front Immunol 2024 15 15 10.3389/fimmu.2024.1359600
Manoharan RR, Prasad A, Pospíšil P, Kzhyshkowska J. ROS signaling in innate immunity via oxidative protein modifications. Front Immunol. 2024;15:15.
88. Huang T Song X Xu D Tiek D Goenka A Wu B Sastry N Hu B Cheng SY Stem cell programs in cancer initiation, progression, and therapy resistance Theranostics 2020 10 8721 8743 10.7150/thno.41648 32754274
Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721–43.32754274
89. Zhou H-M Zhang J-G Zhang X Li Q Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents Signal Transd Target Ther 2021 6 62 10.1038/s41392-020-00430-1
Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transd Target Ther. 2021;6:62.
90. Alcalá S Villarino L Ruiz-Cañas L Couceiro JR Martínez-Calvo M Palencia-Campos A Navarro D Cabezas-Sainz P Rodriguez-Arabaolaza I Cordero-Barreal A Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy J Exp Clin Cancer Res 2024 43 33 10.1186/s13046-023-02931-7 38281027
Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, et al. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy. J Exp Clin Cancer Res. 2024;43:33.38281027
91. Jones CL Inguva A Jordan CT Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors Cell Stem Cell 2021 28 378 393 10.1016/j.stem.2021.02.013 33667359
Jones CL, Inguva A, Jordan CT. Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors. Cell Stem Cell. 2021;28:378–93.33667359
92. Beerkens APM Boreel DF Nathan JA Neuzil J Cheng G Kalyanaraman B Hardy M Adema GJ Heskamp S Span PN Bussink J Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging Cancer Metab 2024 12 13 10.1186/s40170-024-00342-6 38702787
Beerkens APM, Boreel DF, Nathan JA, Neuzil J, Cheng G, Kalyanaraman B, Hardy M, Adema GJ, Heskamp S, Span PN, Bussink J. Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging. Cancer Metab. 2024;12:13.38702787
93. Kosaisawe N Sparta B Pargett M Teragawa CK Albeck JG Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells Cell Metab 2021 33 649 e665648 10.1016/j.cmet.2021.01.014 33561427
Kosaisawe N, Sparta B, Pargett M, Teragawa CK, Albeck JG. Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells. Cell Metab. 2021;33:649–e665648.33561427
94. Janku F Beom S-H Moon YW Kim TW Shin YG Yim D-S Kim GM Kim HS Kim SY Cheong J-H First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors Investig New Drugs 2022 40 1001 1010 10.1007/s10637-022-01277-9 35802288
Janku F, Beom S-H, Moon YW, Kim TW, Shin YG, Yim D-S, Kim GM, Kim HS, Kim SY, Cheong J-H, et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2022;40:1001–10.35802288
95. Adamczuk G Humeniuk E Adamczuk K Grabarska A Dudka J 2,4-Dinitrophenol as an uncoupler augments the anthracyclines toxicity against prostate cancer cells Molecules 2022 27 7227 10.3390/molecules27217227 36364051
Adamczuk G, Humeniuk E, Adamczuk K, Grabarska A, Dudka J. 2,4-Dinitrophenol as an uncoupler augments the anthracyclines toxicity against prostate cancer cells. Molecules. 2022;27:7227.36364051
96. Bobba KN Binoy A Koo S Nedungadi D Podder A Sharma A Mishra N Kim JS Bhuniya S Direct readout protonophore induced selective uncoupling and dysfunction of individual mitochondria within cancer cells Chem Commun 2019 55 6429 6432 10.1039/C9CC01483G
Bobba KN, Binoy A, Koo S, Nedungadi D, Podder A, Sharma A, Mishra N, Kim JS, Bhuniya S. Direct readout protonophore induced selective uncoupling and dysfunction of individual mitochondria within cancer cells. Chem Commun. 2019;55:6429–32.
97. Rai Y Singh S Pandey S Sah D Sah RK Roy BG Dwarakanath BS Bhatt AN Mitochondrial uncoupler DNP induces coexistence of dual-state hyper-energy metabolism leading to tumor growth advantage in human glioma xenografts Front Oncol 2022 12 1063531 10.3389/fonc.2022.1063531 36591481
Rai Y, Singh S, Pandey S, Sah D, Sah RK, Roy BG, Dwarakanath BS, Bhatt AN. Mitochondrial uncoupler DNP induces coexistence of dual-state hyper-energy metabolism leading to tumor growth advantage in human glioma xenografts. Front Oncol. 2022;12:1063531.36591481
98. Shrestha R Johnson E Byrne FL Exploring the therapeutic potential of mitochondrial uncouplers in cancer Mol Metab 2021 51 101222 10.1016/j.molmet.2021.101222 33781939
Shrestha R, Johnson E, Byrne FL. Exploring the therapeutic potential of mitochondrial uncouplers in cancer. Mol Metab. 2021;51:101222.33781939
99. Jin L Alesi GN Kang S Glutaminolysis as a target for cancer therapy Oncogene 2016 35 3619 3625 10.1038/onc.2015.447 26592449
Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35:3619–25.26592449
100. Wang Z Liu F Fan N Zhou C Li D Macvicar T Dong Q Bruns CJ Zhao Y Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies Front Oncol 2020 10 589508 10.3389/fonc.2020.589508 33194749
Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. Targeting glutaminolysis: New perspectives to understand Cancer Development and Novel strategies for potential target therapies. Front Oncol 2020, 10:589508.33194749
101. Zhang J Wang G Mao Q Li S Xiong W Lin Y Ge J Glutamate dehydrogenase (GDH) regulates bioenergetics and redox homeostasis in human glioma Oncotarget 2016 Advance Online Publications 5
Zhang J, Wang G, Mao Q, Li S, Xiong W, Lin Y, Ge J. Glutamate dehydrogenase (GDH) regulates bioenergetics and redox homeostasis in human glioma. Oncotarget. 2016;Advance Online Publications:5.
102. Legendre F MacLean A Appanna VP Appanna VD Biochemical pathways to α-ketoglutarate, a multi-faceted metabolite World J Microbiol Biotechnol 2020 36 123 10.1007/s11274-020-02900-8 32686016
Legendre F, MacLean A, Appanna VP, Appanna VD. Biochemical pathways to α-ketoglutarate, a multi-faceted metabolite. World J Microbiol Biotechnol. 2020;36:123.32686016
103. Altman BJ Stine ZE Dang CV From Krebs to clinic: glutamine metabolism to cancer therapy Nat Rev Cancer 2016 16 619 634 10.1038/nrc.2016.71 27492215
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–34.27492215
104. Lane AN Fan TW Regulation of mammalian nucleotide metabolism and biosynthesis Nucleic Acids Res 2015 43 2466 2485 10.1093/nar/gkv047 25628363
Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43:2466–85.25628363
105. Carr EL Kelman A Wu GS Gopaul R Senkevitch E Aghvanyan A Turay AM Frauwirth KA Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation J Immunol 2010 185 1037 1044 10.4049/jimmunol.0903586 20554958
Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, Turay AM, Frauwirth KA. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185:1037–44.20554958
106. Jin J Byun JK Choi YK Park KG Targeting glutamine metabolism as a therapeutic strategy for cancer Exp Mol Med 2023 55 706 15 10.1038/s12276-023-00971-9 37009798
Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55:706–15.37009798
107. Choi YK Park KG Targeting glutamine metabolism for cancer treatment Biomol Ther (Seoul) 2018 26 19 28 10.4062/biomolther.2017.178 29212303
Choi YK, Park KG. Targeting glutamine metabolism for Cancer Treatment. Biomol Ther (Seoul). 2018;26:19–28.29212303
108. Li X Peng X Li Y Wei S He G Liu J Li X Yang S Li D Lin W Glutamine addiction in tumor cell: oncogene regulation and clinical treatment Cell Commun Signal 2024 22 12 10.1186/s12964-023-01449-x 38172980
Li X, Peng X, Li Y, Wei S, He G, Liu J, Li X, Yang S, Li D, Lin W, et al. Glutamine addiction in tumor cell: oncogene regulation and clinical treatment. Cell Communication Signal. 2024;22:12.38172980
109. Gross MI Demo SD Dennison JB Chen L Chernov-Rogan T Goyal B Janes JR Laidig GJ Lewis ER Li J Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer Mol Cancer Ther 2014 13 890 901 10.1158/1535-7163.MCT-13-0870 24523301
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890–901.24523301
110. Wicker CA Hunt BG Krishnan S Aziz K Parajuli S Palackdharry S Elaban WR Wise-Draper TM Mills GB Waltz SE Takiar V Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models Cancer Lett 2021 502 180 188 10.1016/j.canlet.2020.12.038 33450358
Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Lett. 2021;502:180–8.33450358
111. Vogel FCE Chaves-Filho AB Schulze A Lipids as mediators of cancer progression and metastasis Nat Cancer 2024 5 16 29 10.1038/s43018-023-00702-z 38273023
Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024;5:16–29.38273023
112. Wang W Bai L Li W Cui J The lipid metabolic landscape of cancers and new therapeutic perspectives Front Oncol 2020 10 605154 10.3389/fonc.2020.605154 33364199
Wang W, Bai L, Li W, Cui J. The lipid metabolic landscape of cancers and new therapeutic perspectives. Front Oncol. 2020;10:605154.33364199
113. Jeong D-W Lee S Chun Y-S How cancer cells remodel lipid metabolism: strategies targeting transcription factors Lipids Health Dis 2021 20 163 10.1186/s12944-021-01593-8 34775964
Jeong D-W, Lee S, Chun Y-S. How cancer cells remodel lipid metabolism: strategies targeting transcription factors. Lipids Health Dis. 2021;20:163.34775964
114. Wu Y Pu X Wang X Xu M Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy Lipids Health Dis 2024 23 35 10.1186/s12944-024-02024-0 38302980
Wu Y, Pu X, Wang X, Xu M. Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy. Lipids Health Dis. 2024;23:35.38302980
115. Simeone P Tacconi S Longo S Lanuti P Bravaccini S Pirini F Ravaioli S Dini L Giudetti AM Expanding roles of de novo lipogenesis in breast cancer Int J Environ Res Public Health 2021 18 7 3575 10.3390/ijerph18073575 33808259
Simeone P, Tacconi S, Longo S, Lanuti P, Bravaccini S, Pirini F, Ravaioli S, Dini L, Giudetti AM. Expanding roles of de novo lipogenesis in breast cancer. Int J Environ Res Public Health. 2021;18(7):3575.33808259
116. Mounier C Bouraoui L Rassart E Lipogenesis in cancer progression (review) Int J Oncol 2014 45 485 492 10.3892/ijo.2014.2441 24827738
Mounier C, Bouraoui L, Rassart E. Lipogenesis in cancer progression (review). Int J Oncol. 2014;45:485–92.24827738
117. Lounis MA Péant B Leclerc-Desaulniers K Ganguli D Daneault C Ruiz M Zoubeidi A Mes-Masson AM Saad F Modulation of de novo lipogenesis improves response to enzalutamide treatment in prostate cancer Cancers 2020 12 3339 10.3390/cancers12113339 33187317
Lounis MA, Péant B, Leclerc-Desaulniers K, Ganguli D, Daneault C, Ruiz M, Zoubeidi A, Mes-Masson AM, Saad F. Modulation of de novo lipogenesis improves response to enzalutamide treatment in prostate cancer. Cancers. 2020;12:3339.33187317
118. Koundouros N Poulogiannis G Reprogramming of fatty acid metabolism in cancer Br J Cancer 2020 122 4 22 10.1038/s41416-019-0650-z 31819192
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.31819192
119. Nagarajan SR Butler LM Hoy AJ The diversity and breadth of cancer cell fatty acid metabolism Cancer Metab 2021 9 2 10.1186/s40170-020-00237-2 33413672
Nagarajan SR, Butler LM, Hoy AJ. The diversity and breadth of cancer cell fatty acid metabolism. Cancer Metab. 2021;9:2.33413672
120. Aoki T Kinoshita J Munesue S Hamabe-Horiike T Yamaguchi T Nakamura Y Okamoto K Moriyama H Nakamura K Harada S Hypoxia-Induced CD36 expression in gastric Cancer cells promotes peritoneal metastasis via fatty acid uptake Ann Surg Oncol 2023 30 3125 3136 10.1245/s10434-022-12465-5 36042102
Aoki T, Kinoshita J, Munesue S, Hamabe-Horiike T, Yamaguchi T, Nakamura Y, Okamoto K, Moriyama H, Nakamura K, Harada S, et al. Hypoxia-Induced CD36 expression in gastric Cancer cells promotes peritoneal metastasis via fatty acid uptake. Ann Surg Oncol. 2023;30:3125–36.36042102
121. Schiliro C Firestein BL Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation Cells 2021 10 5 1056 10.3390/cells10051056 33946927
Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021;10(5):1056.33946927
122. Luo J Manning BD Cantley LC Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 2003 4 257 262 10.1016/S1535-6108(03)00248-4 14585353
Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62.14585353
123. Corsetto PA Zava S Rizzo AM Colombo I The critical impact of sphingolipid metabolism in breast cancer progression and drug response Int J Mol Sci 2023 24 2107 10.3390/ijms24032107 36768427
Corsetto PA, Zava S, Rizzo AM, Colombo I. The critical impact of sphingolipid metabolism in breast cancer progression and drug response. Int J Mol Sci. 2023;24:2107.36768427
124. Wang Q Zheng C Hou H Bao X Tai H Huang X Li Z Li Z Wang Q Pan Q Interplay of Sphingolipid metabolism in predicting prognosis of gbm patients: towards precision immunotherapy J Cancer 2024 15 275 10.7150/jca.89338 38164288
Wang Q, Zheng C, Hou H, Bao X, Tai H, Huang X, Li Z, Li Z, Wang Q, Pan Q. Interplay of Sphingolipid Metabolism in Predicting Prognosis of GBM patients: towards Precision Immunotherapy. J Cancer. 2024;15:275.38164288
125. Alizadeh J da Silva Rosa SC Weng X Jacobs J Lorzadeh S Ravandi A Vitorino R Pecic S Zivkovic A Stark H Ceramides and ceramide synthases in cancer: focus on apoptosis and autophagy Eur J Cell Biol 2023 102 151337 10.1016/j.ejcb.2023.151337 37392580
Alizadeh J, da Silva Rosa SC, Weng X, Jacobs J, Lorzadeh S, Ravandi A, Vitorino R, Pecic S, Zivkovic A, Stark H. Ceramides and ceramide synthases in cancer: focus on apoptosis and autophagy. Eur J Cell Biol. 2023;102:151337.37392580
126. Pilátová MB Solárová Z Mezencev R Solár P Ceramides and their roles in programmed cell death Adv Med Sci 2023 68 417 425 10.1016/j.advms.2023.10.004 37866204
Pilátová MB, Solárová Z, Mezencev R, Solár P. Ceramides and their roles in programmed cell death. Adv Med Sci. 2023;68:417–25.37866204
127. Qiao X Hu Z Xiong F Yang Y Peng C Wang D Li X Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy Lipids Health Dis 2023 22 45 10.1186/s12944-023-01807-1 37004014
Qiao X, Hu Z, Xiong F, Yang Y, Peng C, Wang D, Li X. Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids Health Dis. 2023;22:45.37004014
128. Bian X Liu R Meng Y Xing D Xu D Lu Z Lipid metabolism and cancer J Exp Med 2020 218 e20201606 10.1084/jem.20201606
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2020;218:e20201606.
129. Zipinotti dos Santos D de Souza JC Pimenta TM da Silva Martins B Junior RSR Butzene SMS Tessarolo NG Cilas PML Silva IV Rangel LBA The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape Cell Commun Signal 2023 21 161 10.1186/s12964-023-01178-1 37370164
Zipinotti dos Santos D, de Souza JC, Pimenta TM, da Silva Martins B, Junior RSR, Butzene SMS, Tessarolo NG, Cilas PML, Silva IV, Rangel LBA. The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape. Cell Commun Signal. 2023;21:161.37370164
130. Jin H-R Wang J Wang Z-J Xi M-J Xia B-H Deng K Yang J-L Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics J Hematol Oncol 2023 16 103 10.1186/s13045-023-01498-2 37700339
Jin H-R, Wang J, Wang Z-J, Xi M-J, Xia B-H, Deng K, Yang J-L. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16:103.37700339
131. Lasorsa F di Meo NA Rutigliano M Ferro M Terracciano D Tataru OS Battaglia M Ditonno P Lucarelli G Emerging hallmarks of metabolic reprogramming in prostate cancer Int J Mol Sci 2023 24 910 10.3390/ijms24020910 36674430
Lasorsa F, di Meo NA, Rutigliano M, Ferro M, Terracciano D, Tataru OS, Battaglia M, Ditonno P, Lucarelli G. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int J Mol Sci. 2023;24:910.36674430
132. Landa I Cabanillas ME Genomic alterations in thyroid cancer: biological and clinical insights Nat Reviews Endocrinol 2024 20 93 110 10.1038/s41574-023-00920-6
Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Reviews Endocrinol. 2024;20:93–110.
133. Murali R Balasubramaniam V Srinivas S Sundaram S Venkatraman G Warrier S Dharmarajan A Gandhirajan RK Deregulated metabolic pathways in ovarian cancer: cause and consequence Metabolites 2023 13 560 10.3390/metabo13040560 37110218
Murali R, Balasubramaniam V, Srinivas S, Sundaram S, Venkatraman G, Warrier S, Dharmarajan A, Gandhirajan RK. Deregulated metabolic pathways in ovarian cancer: cause and consequence. Metabolites. 2023;13:560.37110218
134. Bitla S, Thakur S, Volety P, Munirathinam G. An overview of the potent role of proto-oncogenes in tissue-specific stem cells. Cancer Stem Cells Signal Pathways. 2024:531–47.
135. Elalfy MM Elhadidy MG El Nashar EM Proto-oncogenes crosstalk, feedback and expression, and anticancer drugs resistance Scientific Archives 2023 5 18 21
Elalfy MM, Elhadidy MG, El Nashar EM. Proto-oncogenes crosstalk, feedback and expression, and anticancer drugs resistance. Scientific Archives. 2023;5:18–21.
136. Wise DR DeBerardinis RJ Mancuso A Sayed N Zhang X-Y Pfeiffer HK Nissim I Daikhin E Yudkoff M McMahon SB Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc Natl Acad Sci 2008 105 18782 18787 10.1073/pnas.0810199105 19033189
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci. 2008;105:18782–7.19033189
137. Gouw AM Hsieh AL Stine ZE Dang CV Mazurek S Shoshan M MYC Regulation of Metabolism and Cancer Tumor Cell Metabolism: Pathways, Regulation and Biology 2015 Vienna Springer Vienna 101 122
Gouw AM, Hsieh AL, Stine ZE, Dang CV. MYC Regulation of Metabolism and Cancer. In: Mazurek S, Shoshan M, editors. Tumor Cell Metabolism: Pathways, Regulation and Biology. Vienna: Springer Vienna; 2015. p. 101–22.
138. Jones RG Thompson CB Tumor suppressors and cell metabolism: a recipe for cancer growth Genes Dev 2009 23 537 548 10.1101/gad.1756509 19270154
Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537–48.19270154
139. Wang W Shi B Cong R Hao M Peng Y Yang H Song J Feng D Zhang N Li D RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism Cell Death Disc 2022 8 372 10.1038/s41420-022-01162-7
Wang W, Shi B, Cong R, Hao M, Peng Y, Yang H, Song J, Feng D, Zhang N, Li D. RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism. Cell Death Disc. 2022;8:372.
140. Yu JSL Cui W Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination Development 2016 143 3050 60 10.1242/dev.137075 27578176
Yu JSL, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143:3050–60.27578176
141. Fontana F Giannitti G Marchesi S Limonta P The PI3K/Akt pathway and glucose metabolism: a dangerous Liaison in Cancer Int J Biol Sci 2024 20 3113 10.7150/ijbs.89942 38904014
Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113.38904014
142. Tufail M Hu JJ Liang J He CY Wan WD Huang YQ Jiang CH Wu H Li N Hallmarks of cancer resistance iScience 2024 27 109979 10.1016/j.isci.2024.109979 38832007
Tufail M, Hu JJ, Liang J, He CY, Wan WD, Huang YQ, Jiang CH, Wu H, Li N. Hallmarks of cancer resistance. iScience. 2024;27:109979.38832007
143. Gregory GL Copple IM Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer Mol Ther-Nucleic Acids 2023 31 211 223 10.1016/j.omtn.2022.12.016 36700046
Gregory GL, Copple IM. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Mol Therapy-Nucleic Acids. 2023;31:211–23.36700046
144. Lane DP p53, guardian of the genome Nature 1992 358 15 6 10.1038/358015a0 1614522
Lane DP. p53, guardian of the genome. Nature. 1992;358:15–6.1614522
145. Matoba S Kang J-G Patino WD Wragg A Boehm M Gavrilova O Hurley PJ Bunz F Hwang PM p53 regulates mitochondrial respiration Science 2006 312 1650 1653 10.1126/science.1126863 16728594
Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3.16728594
146. Bensaad K Tsuruta A Selak MA Vidal MNC Nakano K Bartrons R Gottlieb E Vousden KH TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis Cell 2006 126 107 120 10.1016/j.cell.2006.05.036 16839880
Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis. Cell. 2006;126:107–20.16839880
147. Keerthana CK Rayginia TP Shifana SC Anto NP Kalimuthu K Isakov N Anto RJ The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment Front Immunol 2023 14 1114582 10.3389/fimmu.2023.1114582 36875093
Keerthana CK, Rayginia TP, Shifana SC, Anto NP, Kalimuthu K, Isakov N, Anto RJ. The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. Front Immunol. 2023;14:1114582.36875093
148. Steinberg GR Hardie DG New insights into activation and function of the AMPK Nat Rev Mol Cell Biol 2023 24 255 272 10.1038/s41580-022-00547-x 36316383
Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24:255–72.36316383
149. Mihaylova MM Shaw RJ The AMPK signalling pathway coordinates cell growth, autophagy and metabolism Nat Cell Biol 2011 13 1016 1023 10.1038/ncb2329 21892142
Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13:1016–23.21892142
150. Inoki K Kim J Guan K-L AMPK and mTOR in cellular energy homeostasis and drug targets Annu Rev Pharmacol Toxicol 2012 52 381 400 10.1146/annurev-pharmtox-010611-134537 22017684
Inoki K, Kim J, Guan K-L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381–400.22017684
151. Shackelford DB Shaw RJ The LKB1–AMPK pathway: metabolism and growth control in tumour suppression Nat Rev Cancer 2009 9 563 575 10.1038/nrc2676 19629071
Shackelford DB, Shaw RJ. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75.19629071
152. Pavlova Natalya N Thompson Craig B The emerging hallmarks of cancer metabolism Cell Metabol 2016 23 27 47 10.1016/j.cmet.2015.12.006
Pavlova Natalya N, Thompson Craig B. The emerging hallmarks of cancer metabolism. Cell Metabol. 2016;23:27–47.
153. Nagarajan A Malvi P Wajapeyee N Oncogene-directed alterations in cancer cell metabolism Trends Cancer 2016 2 365 77 10.1016/j.trecan.2016.06.002 27822561
Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer. 2016;2:365–77.27822561
154. Zhao Y Butler EB Tan M Targeting cellular metabolism to improve cancer therapeutics Cell Death Dis 2013 4 e532 532 10.1038/cddis.2013.60 23470539
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532–532.23470539
155. Hardie DG Ross FA Hawley SA AMPK: a nutrient and energy sensor that maintains energy homeostasis Nat Rev Mol Cell Biol 2012 13 251 262 10.1038/nrm3311 22436748
Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62.22436748
156. Huo M Zhang J Huang W Wang Y Interplay among metabolism, epigenetic modifications, and gene expression in cancer Front Cell Dev Biol 2021 9 793428 10.3389/fcell.2021.793428 35004688
Huo M, Zhang J, Huang W, Wang Y. Interplay among metabolism, epigenetic modifications, and Gene expression in Cancer. Front Cell Dev Biol. 2021;9:793428.35004688
157. Xu X Peng Q Jiang X Tan S Yang Y Yang W Han Y Chen Y Oyang L Lin J Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential Exp Mol Med 2023 55 1357 1370 10.1038/s12276-023-01020-1 37394582
Xu X, Peng Q, Jiang X, Tan S, Yang Y, Yang W, Han Y, Chen Y, Oyang L, Lin J, et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med. 2023;55:1357–70.37394582
158. Morrison AJ Cancer cell metabolism connects epigenetic modifications to transcriptional regulation FEBS J 2022 289 1302 1314 10.1111/febs.16032 34036737
Morrison AJ. Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS J. 2022;289:1302–14.34036737
159. Wang G Han JJ Connections between metabolism and epigenetic modifications in cancer Med Rev 2021 1 199 221 10.1515/mr-2021-0015
Wang G, Han JJ. Connections between metabolism and epigenetic modifications in cancer. Med Rev. 2021;1:199–221.
160. Liu Q Liu L Zhao Y Zhang J Wang D Chen J He Y Wu J Zhang Z Liu Z Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in Hepatoma cells Mol Cancer Ther 2011 10 1113 1123 10.1158/1535-7163.MCT-10-1010 21460102
Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, He Y, Wu J, Zhang Z, Liu Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in Hepatoma cells. Mol Cancer Ther. 2011;10:1113–23.21460102
161. Ren J-H He W-S Nong L Zhu Q-Y Hu K Zhang R-G Huang L-L Zhu F Wu G Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy Cancer Biother Radiopharmaceut 2010 25 75 80 10.1089/cbr.2009.0701
Ren J-H, He W-S, Nong L, Zhu Q-Y, Hu K, Zhang R-G, Huang L-L, Zhu F, Wu G. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharmaceut. 2010;25:75–80.
162. Zhao Z Shilatifard A Epigenetic modifications of histones in cancer Genome Biol 2019 20 245 10.1186/s13059-019-1870-5 31747960
Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:245.31747960
163. Yang Y Zhang M Wang Y The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy J Natl Cancer Cent 2022 2 277 290 10.1016/j.jncc.2022.09.002 39036551
Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent. 2022;2:277–90.39036551
164. Campbell MJ Turner BM Altered histone modifications in cancer Adv Exp Med Biol 2013 754 81 107 10.1007/978-1-4419-9967-2_4 22956497
Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv Exp Med Biol. 2013;754:81–107.22956497
165. Anastasiadou E Jacob LS Slack FJ Non-coding RNA networks in cancer Nat Rev Cancer 2018 18 5 18 10.1038/nrc.2017.99 29170536
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18:5–18.29170536
166. Bartel DP Metazoan MicroRNAs Cell 2018 173 20 51 10.1016/j.cell.2018.03.006 29570994
Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.29570994
167. Rottiers V Näär AM MicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol 2012 13 239 250 10.1038/nrm3313 22436747
Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–50.22436747
168. Singh R Yadav V kumar S Saini N MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 Sci Rep 2015 5 17454 10.1038/srep17454 26632252
Singh R, Yadav V, kumar S, Saini N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep. 2015;5:17454.26632252
169. Schmitt AM Chang HY Long noncoding RNAs in cancer pathways Cancer Cell 2016 29 452 63 10.1016/j.ccell.2016.03.010 27070700
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63.27070700
170. Xiao Y Yu T-J Xu Y Ding R Wang Y-P Jiang Y-Z Shao Z-M Emerging therapies in cancer metabolism Cell Metab 2023 35 1283 1303 10.1016/j.cmet.2023.07.006 37557070
Xiao Y, Yu T-J, Xu Y, Ding R, Wang Y-P, Jiang Y-Z, Shao Z-M. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283–303.37557070
171. Sedlak JC Yilmaz ÖH Roper J Metabolism and colorectal cancer Annu Rev Pathol 2023 18 467 492 10.1146/annurev-pathmechdis-031521-041113 36323004
Sedlak JC, Yilmaz ÖH, Roper J. Metabolism and colorectal cancer. Annu Rev Pathol. 2023;18:467–92.36323004
172. Dong C Yuan T Wu Y Wang Y Fan TWM Miriyala S Lin Y Yao J Shi J Kang T Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer Cancer Cell 2013 23 316 331 10.1016/j.ccr.2013.01.022 23453623
Dong C, Yuan T, Wu Y, Wang Y, Fan TWM, Miriyala S, Lin Y, Yao J, Shi J, Kang T. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316–31.23453623
173. Kaelin WG McKnight SL Influence of metabolism on epigenetics and disease Cell 2013 153 56 69 10.1016/j.cell.2013.03.004 23540690
Kaelin WG, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153:56–69.23540690
174. Xu W Yang H Liu Y Yang Y Wang P Kim S-H Ito S Yang C Wang P Xiao M-T Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao M-T. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.21251613
175. Mentch SJ Mehrmohamadi M Huang L Liu X Gupta D Mattocks D Padilla PG Ables G Bamman MM Thalacker-Mercer AE Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism Cell Metab 2015 22 861 73 10.1016/j.cmet.2015.08.024 26411344
Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, Padilla PG, Ables G, Bamman MM, Thalacker-Mercer AE. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 2015;22:861–73.26411344
176. Chen C Wang Z Qin Y Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy Front Pharmacol 2022 13 13
Chen C, Wang Z, Qin Y. Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Front Pharmacol. 2022;13:13.
177. Thakur C Chen F Connections between metabolism and epigenetics in cancers Semin Cancer Biol 2019 57 52 58 10.1016/j.semcancer.2019.06.006 31185282
Thakur C, Chen F. Connections between metabolism and epigenetics in cancers. Semin Cancer Biol. 2019;57:52–8.31185282
178. Ramalingam SS Parise RA Ramananthan RK Lagattuta TF Musguire LA Stoller RG Potter DM Argiris AE Zwiebel JA Egorin MJ Belani CP Phase I and pharmacokinetic study of Vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for Advanced Solid malignancies Clin Cancer Res 2007 13 3605 3610 10.1158/1078-0432.CCR-07-0162 17510206
Ramalingam SS, Parise RA, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of Vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for Advanced Solid malignancies. Clin Cancer Res. 2007;13:3605–10.17510206
179. Wang Y Janku F Piha-Paul S Hess K Broaddus R Liu L Shi N Overman M Kopetz S Subbiah V Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies Sci Rep 2020 10 3080 10.1038/s41598-020-58366-z 32080210
Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, et al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020;10:3080.32080210
180. Chen JJ Wang AQ Chen QQ DNA methylation assay for colorectal carcinoma Cancer Biol Med 2017 14 42 49 10.20892/j.issn.2095-3941.2016.0082 28443202
Chen JJ, Wang AQ, Chen QQ. DNA methylation assay for colorectal carcinoma. Cancer Biol Med. 2017;14:42–9.28443202
181. Sahin IH Akce M Alese O Shaib W Lesinski GB El-Rayes B Wu C Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms Br J Cancer 2019 121 809 818 10.1038/s41416-019-0599-y 31607751
Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809–18.31607751
182. Heregger R Huemer F Steiner M Gonzalez-Martinez A Greil R Weiss L Unraveling resistance to Immunotherapy in MSI-High Colorectal Cancer Cancers (Basel) 2023 15 15 10.3390/cancers15205090
Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, Greil R, Weiss L. Unraveling resistance to Immunotherapy in MSI-High Colorectal Cancer. Cancers (Basel). 2023;15:15.
183. Quail DF Joyce JA Microenvironmental regulation of tumor progression and metastasis Nat Med 2013 19 1423 1437 10.1038/nm.3394 24202395
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.24202395
184. Bussard KM Mutkus L Stumpf K Gomez-Manzano C Marini FC Tumor-associated stromal cells as key contributors to the tumor microenvironment Breast Cancer Res 2016 18 1 11 10.1186/s13058-016-0740-2 26728744
Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:1–11.26728744
185. Pickup MW Mouw JK Weaver VM The extracellular matrix modulates the hallmarks of cancer EMBO Rep 2014 15 1243 1253 10.15252/embr.201439246 25381661
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–53.25381661
186. Kalluri R The biology and function of fibroblasts in cancer Nat Rev Cancer 2016 16 582 598 10.1038/nrc.2016.73 27550820
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98.27550820
187. Sahai E Astsaturov I Cukierman E DeNardo DG Egeblad M Evans RM Fearon D Greten FR Hingorani SR Hunter T A framework for advancing our understanding of cancer-associated fibroblasts Nat Rev Cancer 2020 20 174 186 10.1038/s41568-019-0238-1 31980749
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174–86.31980749
188. Binnewies M Roberts EW Kersten K Chan V Fearon DF Merad M Coussens LM Gabrilovich DI Ostrand-Rosenberg S Hedrick CC Understanding the tumor immune microenvironment (TIME) for effective therapy Nat Med 2018 24 541 550 10.1038/s41591-018-0014-x 29686425
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.29686425
189. Mantovani A Marchesi F Malesci A Laghi L Allavena P Tumour-associated macrophages as treatment targets in oncology Nat Rev Clin Oncol 2017 14 399 416 10.1038/nrclinonc.2016.217 28117416
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416.28117416
190. Jing X Yang F Shao C Wei K Xie M Shen H Shu Y Role of hypoxia in cancer therapy by regulating the tumor microenvironment Mol Cancer 2019 18 157 10.1186/s12943-019-1089-9 31711497
Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157.31711497
191. Semenza GL Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology Annu Rev Pathol 2014 9 47 71 10.1146/annurev-pathol-012513-104720 23937437
Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47–71.23937437
192. Rankin EB Giaccia AJ Hypoxic control of metastasis Science 2016 352 175 180 10.1126/science.aaf4405 27124451
Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175–80.27124451
193. Lyssiotis CA Kimmelman AC Metabolic interactions in the tumor microenvironment Trends Cell Biol 2017 27 863 875 10.1016/j.tcb.2017.06.003 28734735
Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27:863–75.28734735
194. Klein K He K Younes AI Barsoumian HB Chen D Ozgen T Mosaffa S Patel RR Gu M Novaes J Role of mitochondria in cancer immune evasion and potential therapeutic approaches Front Immunol 2020 11 11 10.3389/fimmu.2020.573326 32082309
Klein K, He K, Younes AI, Barsoumian HB, Chen D, Ozgen T, Mosaffa S, Patel RR, Gu M, Novaes J, et al. Role of mitochondria in cancer immune evasion and potential therapeutic approaches. Front Immunol. 2020;11:11.32082309
195. Elia I Haigis MC Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism Nat Metab 2021 3 21 32 10.1038/s42255-020-00317-z 33398194
Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21–32.33398194
196. Chen X Ma Z Yi Z Wu E Shang Z Tuo B Li T Liu X The effects of metabolism on the immune microenvironment in colorectal cancer Cell Death Disc 2024 10 118 10.1038/s41420-024-01865-z
Chen X, Ma Z, Yi Z, Wu E, Shang Z, Tuo B, Li T, Liu X. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Disc. 2024;10:118.
197. Liberti MV Locasale JW The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016 41 211 218 10.1016/j.tibs.2015.12.001 26778478
Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8.26778478
198. Pajak B Siwiak E Sołtyka M Priebe A Zieliński R Fokt I Ziemniak M Jaśkiewicz A Borowski R Domoradzki T Priebe W 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents Int J Mol Sci 2019 21 234 10.3390/ijms21010234 31905745
Pajak B, Siwiak E, Sołtyka M, Priebe A, Zieliński R, Fokt I, Ziemniak M, Jaśkiewicz A, Borowski R, Domoradzki T, Priebe W. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21:234.31905745
199. Singh R Gupta V Kumar A Singh K 2-Deoxy-D-glucose: a novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in covid-19, and other pharmacological activities Adv Pharmacol Pharm Sci 2023 2023 9993386 36911357
Singh R, Gupta V, Kumar A, Singh K. 2-Deoxy-D-glucose: a novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in covid-19, and other pharmacological activities. Adv Pharmacol Pharm Sci. 2023;2023:9993386.36911357
200. Bhutia YD Babu E Ganapathy V Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine Biochem J 2016 473 1503 1506 10.1042/BCJ20160068 27234586
Bhutia YD, Babu E, Ganapathy V. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Biochem J. 2016;473:1503–6.27234586
201. Liu H Kurtoglu M León-Annicchiarico CL Munoz-Pinedo C Barredo J Leclerc G Merchan J Liu X Lampidis TJ Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress Oncotarget 2016 7 36461 36473 10.18632/oncotarget.9263 27183907
Liu H, Kurtoglu M, León-Annicchiarico CL, Munoz-Pinedo C, Barredo J, Leclerc G, Merchan J, Liu X, Lampidis TJ. Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress. Oncotarget. 2016;7:36461–73.27183907
202. Zielinski R Castillo MM Grybowski D Grela K Cardenas-Zuniga R Fokt I Skora S Ramirez G Priebe W Abstract B179: 2-Deoxy-D-glucose (2-DG) combination with ketogenic diet induces sedation and hypothermia in mice that becomes lethal Mol Cancer Ther 2023 22 B179 179 10.1158/1535-7163.TARG-23-B179
Zielinski R, Castillo MM, Grybowski D, Grela K, Cardenas-Zuniga R, Fokt I, Skora S, Ramirez G, Priebe W. Abstract B179: 2-Deoxy-D-glucose (2-DG) combination with ketogenic diet induces sedation and hypothermia in mice that becomes lethal. Mol Cancer Ther. 2023;22:B179–179.
203. Ning SC Hahn GM Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro Cancer Res 1990 50 7867 7870 2253227
Ning SC, Hahn GM. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res. 1990;50:7867–70.2253227
204. Orlovskiy S Gupta PK Roman J Arias-Mendoza F Nelson DS Koch CJ Narayan V Putt ME Nath K Lonidamine induced selective acidification and De-energization of prostate cancer xenografts: enhanced tumor response to radiation therapy Cancers. 2024 16 1384 10.3390/cancers16071384 38611062
Orlovskiy S, Gupta PK, Roman J, Arias-Mendoza F, Nelson DS, Koch CJ, Narayan V, Putt ME, Nath K. Lonidamine induced selective acidification and De-energization of prostate cancer xenografts: enhanced tumor response to radiation therapy. Cancers. 2024;16:1384.38611062
205. Clem B Telang S Clem A Yalcin A Meier J Simmons A Rasku MA Arumugam S Dean WL Eaton J Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol Cancer Ther 2008 7 110 120 10.1158/1535-7163.MCT-07-0482 18202014
Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7:110–20.18202014
206. Emini Veseli B Perrotta P Van Wielendaele P Lambeir AM Abdali A Bellosta S Monaco G Bultynck G Martinet W De Meyer GRY Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) FEBS Lett 2020 594 3067 75 10.1002/1873-3468.13878 32620030
Emini Veseli B, Perrotta P, Van Wielendaele P, Lambeir AM, Abdali A, Bellosta S, Monaco G, Bultynck G, Martinet W, De Meyer GRY. Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). FEBS Lett. 2020;594:3067–75.32620030
207. Kotowski K Supplitt S Wiczew D Przystupski D Bartosik W Saczko J Rossowska J DrĄG-ZalesiŃSka M Michel O Kulbacka J 3PO as a selective inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma cells Anticancer Res 2020 40 2613 10.21873/anticanres.14232 32366406
Kotowski K, Supplitt S, Wiczew D, Przystupski D, Bartosik W, Saczko J, Rossowska J, DrĄG-ZalesiŃSka M, Michel O, Kulbacka J. 3PO as a selective inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma cells. Anticancer Res. 2020;40:2613.32366406
208. Zahra K Dey T Ashish, Mishra SP Pandey U Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis Front Oncol 2020 10 159 10.3389/fonc.2020.00159 32195169
Zahra K, Dey T, Ashish, Mishra SP, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159.32195169
209. Dong G Mao Q Xia W Xu Y Wang J Xu L Jiang F PKM2 and cancer: the function of PKM2 beyond glycolysis (review) Oncol Lett 2016 11 1980 1986 10.3892/ol.2016.4168 26998110
Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, Jiang F. PKM2 and cancer: the function of PKM2 beyond glycolysis (review). Oncol Lett. 2016;11:1980–6.26998110
210. Apostolidi M Vathiotis IA Muthusamy V Gaule P Gassaway BM Rimm DL Rinehart J Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes Cancer Res 2021 81 4346 4359 10.1158/0008-5472.CAN-20-4190 34185676
Apostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes. Cancer Res. 2021;81:4346–59.34185676
211. Manerba M Vettraino M Fiume L Di Stefano G Sartini A Giacomini E Buonfiglio R Roberti M Recanatini M Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase ChemMedChem 2012 7 311 317 10.1002/cmdc.201100471 22052811
Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E, Buonfiglio R, Roberti M, Recanatini M. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem. 2012;7:311–7.22052811
212. Rellinger EJ Craig BT Alvarez AL Dusek HL Kim KW Qiao J Chung DH FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells Surgery 2017 161 747 752 10.1016/j.surg.2016.09.009 27919448
Rellinger EJ, Craig BT, Alvarez AL, Dusek HL, Kim KW, Qiao J, Chung DH. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery. 2017;161:747–52.27919448
213. Han JH Lee EJ Park W Ha KT Chung HS Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases Front Pharmacol 2023 14 1275000 10.3389/fphar.2023.1275000 37915411
Han JH, Lee EJ, Park W, Ha KT, Chung HS. Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front Pharmacol. 2023;14:1275000.37915411
214. Pelicano H Martin DS Xu RH Huang P Glycolysis inhibition for anticancer treatment Oncogene 2006 25 4633 4646 10.1038/sj.onc.1209597 16892078
Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–46.16892078
215. Zhao Y Liu H Liu Z Ding Y LeDoux SP Wilson GL Voellmy R Lin Y Lin W Nahta R Overcoming Trastuzumab resistance in breast Cancer by Targeting Dysregulated glucose metabolism Cancer Res 2011 71 4585 4597 10.1158/0008-5472.CAN-11-0127 21498634
Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al. Overcoming Trastuzumab resistance in breast Cancer by Targeting Dysregulated glucose metabolism. Cancer Res. 2011;71:4585–97.21498634
216. Stine ZE Schug ZT Salvino JM Dang CV Targeting cancer metabolism in the era of precision oncology Nat Rev Drug Disc 2022 21 141 162 10.1038/s41573-021-00339-6
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Disc. 2022;21:141–62.
217. Cluntun AA Lukey MJ Cerione RA Locasale JW Glutamine metabolism in Cancer: understanding the heterogeneity Trends Cancer 2017 3 169 180 10.1016/j.trecan.2017.01.005 28393116
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in Cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80.28393116
218. Gong T Zheng C Ou X Zheng J Yu J Chen S Duan Y Liu W Glutamine metabolism in cancers: targeting the oxidative homeostasis Front Oncol 2022 12 994672 10.3389/fonc.2022.994672 36324588
Gong T, Zheng C, Ou X, Zheng J, Yu J, Chen S, Duan Y, Liu W. Glutamine metabolism in cancers: targeting the oxidative homeostasis. Front Oncol. 2022;12:994672.36324588
219. Anthony J Varalakshmi S Sekar AK Devarajan N Janakiraman B Peramaiyan R Glutaminase - A potential target for cancer treatment Biomed (Taipei) 2024 14 29 37 10.37796/2211-8039.1445
Anthony J, Varalakshmi S, Sekar AK, Devarajan N, Janakiraman B, Peramaiyan R. Glutaminase - A potential target for cancer treatment. Biomed (Taipei). 2024;14:29–37.
220. Xu L Yin Y Li Y Chen X Chang Y Zhang H Liu J Beasley J McCaw P Zhang H A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer Proc Natl Acad Sci 2021 118 e2012748118 10.1073/pnas.2012748118 33753479
Xu L, Yin Y, Li Y, Chen X, Chang Y, Zhang H, Liu J, Beasley J, McCaw P, Zhang H, et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci. 2021;118:e2012748118.33753479
221. Jin H Wang S Zaal EA Wang C Wu H Bosma A Jochems F Isima N Jin G Lieftink C A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer eLife 2020 9 e56749 10.7554/eLife.56749 33016874
Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. eLife. 2020;9:e56749.33016874
222. Kizilbash SH McBrayer S Port J Reid JM Lanza I Allred JB Chakravarti A Kunos C Adjei AA A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642) J Clin Oncol 2019 37 TPS2075 2075 10.1200/JCO.2019.37.15_suppl.TPS2075
Kizilbash SH, McBrayer S, Port J, Reid JM, Lanza I, Allred JB, Chakravarti A, Kunos C, Adjei AA. A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642). J Clin Oncol. 2019;37:TPS2075–2075.
223. Lee CH Motzer R Emamekhoo H Matrana M Percent I Hsieh JJ Hussain A Vaishampayan U Liu S McCune S Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: a Randomized, Double-Blinded, Placebo-Controlled, phase II ENTRATA Trial Clin Cancer Res 2022 28 3248 3255 10.1158/1078-0432.CCR-22-0061 35576438
Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, et al. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: a Randomized, Double-Blinded, Placebo-Controlled, phase II ENTRATA Trial. Clin Cancer Res. 2022;28:3248–55.35576438
224. Yang WH Qiu Y Stamatatos O Janowitz T Lukey MJ Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy Trends Cancer 2021 7 790 804 10.1016/j.trecan.2021.04.003 34020912
Yang WH, Qiu Y, Stamatatos O, Janowitz T, Lukey MJ. Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy. Trends Cancer. 2021;7:790–804.34020912
225. Akram M Citric acid cycle and role of its intermediates in metabolism Cell Biochem Biophys 2014 68 475 478 10.1007/s12013-013-9750-1 24068518
Akram M. Citric acid cycle and role of its intermediates in metabolism. Cell Biochem Biophys. 2014;68:475–8.24068518
226. Anderson NM Mucka P Kern JG Feng H The emerging role and targetability of the TCA cycle in cancer metabolism Protein Cell 2018 9 216 237 10.1007/s13238-017-0451-1 28748451
Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216–37.28748451
227. Baysal BE Ferrell RE Willett-Brozick JE Lawrence EC Myssiorek D Bosch A Mey Avd, Taschner PEM Rubinstein WS Myers EN Mutations in SDHD, a mitochondrial complex II gene, in Hereditary Paraganglioma Science 2000 287 848 51 10.1126/science.287.5454.848 10657297
Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, Mey Avd, Taschner PEM, Rubinstein WS, Myers EN, et al. Mutations in SDHD, a mitochondrial complex II gene, in Hereditary Paraganglioma. Science. 2000;287:848–51.10657297
228. Vanharanta S Buchta M McWhinney SR Virta SK Peçzkowska M Morrison CD Lehtonen R Januszewicz A Järvinen H Juhola M Early-onset renal cell carcinoma as a novel extraparaganglial component of < em > SDHB- associated heritable paraganglioma Am J Hum Genet 2004 74 153 159 10.1086/381054 14685938
Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peçzkowska M, Morrison CD, Lehtonen R, Januszewicz A, Järvinen H, Juhola M, et al. Early-onset renal cell carcinoma as a Novel Extraparaganglial Component of < em > SDHB- Associated Heritable Paraganglioma. Am J Hum Genet. 2004;74:153–9.14685938
229. Selak MA Armour SM MacKenzie ED Boulahbel H Watson DG Mansfield KD Pan Y Simon MC Thompson CB Gottlieb E Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase Cancer Cell 2005 7 77 85 10.1016/j.ccr.2004.11.022 15652751
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7:77–85.15652751
230. Lussey-Lepoutre C Hollinshead KER Ludwig C Menara M Morin A Castro-Vega L-J Parker SJ Janin M Martinelli C Ottolenghi C Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism Nat Commun 2015 6 8784 10.1038/ncomms9784 26522426
Lussey-Lepoutre C, Hollinshead KER, Ludwig C, Menara M, Morin A, Castro-Vega L-J, Parker SJ, Janin M, Martinelli C, Ottolenghi C, et al. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun. 2015;6:8784.26522426
231. Courtney KD Infante JR Lam ET Figlin RA Rini BI Brugarolas J Zojwalla NJ Lowe AM Wang K Wallace EM Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible Factor-2α antagonist in patients with previously treated Advanced Clear Cell Renal Cell Carcinoma J Clin Oncol 2017 36 867 874 10.1200/JCO.2017.74.2627 29257710
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible Factor-2α antagonist in patients with previously treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2017;36:867–74.29257710
232. Hol JA Jongmans MCJ Littooij AS de Krijger RR Kuiper RP van Harssel JJT Mensenkamp A Simons M Tytgat GAM van den Heuvel-Eibrink MM van Grotel M Renal cell carcinoma in young FH mutation carriers: case series and review of the literature Fam Cancer 2020 19 55 63 10.1007/s10689-019-00155-3 31792767
Hol JA, Jongmans MCJ, Littooij AS, de Krijger RR, Kuiper RP, van Harssel JJT, Mensenkamp A, Simons M, Tytgat GAM, van den Heuvel-Eibrink MM, van Grotel M. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. Fam Cancer. 2020;19:55–63.31792767
233. Tan Y Li J Zhao G Huang K-C Cardenas H Wang Y Matei D Cheng J-X Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells Nat Commun 2022 13 4554 10.1038/s41467-022-32101-w 35931676
Tan Y, Li J, Zhao G, Huang K-C, Cardenas H, Wang Y, Matei D, Cheng J-X. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554.35931676
234. Ma Y Temkin SM Hawkridge AM Guo C Wang W Wang XY Fang X Fatty acid oxidation: an emerging facet of metabolic transformation in cancer Cancer Lett 2018 435 92 100 10.1016/j.canlet.2018.08.006 30102953
Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, Fang X. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92–100.30102953
235. Carracedo A Cantley LC Pandolfi PP Cancer metabolism: fatty acid oxidation in the limelight Nat Rev Cancer 2013 13 227 232 10.1038/nrc3483 23446547
Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013;13:227–32.23446547
236. Han S Wei R Zhang X Jiang N Fan M Huang JH Xie B Zhang L Miao W Butler ACP CPT1A/2-Mediated FAO Enhancement—a metabolic target in radioresistant breast cancer Front Oncol 2019 9 1201 10.3389/fonc.2019.01201 31803610
Han S, Wei R, Zhang X, Jiang N, Fan M, Huang JH, Xie B, Zhang L, Miao W, Butler ACP, et al. CPT1A/2-Mediated FAO Enhancement—a metabolic target in radioresistant breast cancer. Front Oncol. 2019;9:1201.31803610
237. Qu Q Zeng F Liu X Wang QJ Deng F Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer Cell Death Dis 2016 7 e2226 2226 10.1038/cddis.2016.132 27195673
Qu Q, Zeng F, Liu X, Wang QJ, Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis. 2016;7:e2226–2226.27195673
238. Mozolewska P Duzowska K Pakiet A Mika A ŚLedziŃSki T Inhibitors of fatty acid synthesis and oxidation as potential Anticancer agents in Colorectal Cancer Treatment Anticancer Res 2020 40 4843 10.21873/anticanres.14487 32878772
Mozolewska P, Duzowska K, Pakiet A, Mika A, ŚLedziŃSki T. Inhibitors of fatty acid synthesis and oxidation as potential Anticancer agents in Colorectal Cancer Treatment. Anticancer Res. 2020;40:4843.32878772
239. Schlaepfer IR Rider L Rodrigues LU Gijón MA Pac CT Romero L Cimic A Sirintrapun SJ Glodé LM Eckel RH Cramer SD Lipid catabolism via CPT1 as a therapeutic target for prostate cancer Mol Cancer Ther 2014 13 2361 2371 10.1158/1535-7163.MCT-14-0183 25122071
Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014;13:2361–71.25122071
240. Dhakal B Tomita Y Drew P Price T Maddern G Smith E Fenix K Perhexiline: old drug, new tricks? A summary of its anti-cancer effects Molecules 2023 28 3624 10.3390/molecules28083624 37110858
Dhakal B, Tomita Y, Drew P, Price T, Maddern G, Smith E, Fenix K. Perhexiline: old drug, new tricks? A summary of its anti-cancer effects. Molecules. 2023;28:3624.37110858
241. An Q Lin R Wang D Wang C Emerging roles of fatty acid metabolism in cancer and their targeted drug development Eur J Med Chem 2022 240 114613 10.1016/j.ejmech.2022.114613 35853429
An Q, Lin R, Wang D, Wang C. Emerging roles of fatty acid metabolism in cancer and their targeted drug development. Eur J Med Chem. 2022;240:114613.35853429
242. Flaig TW Salzmann-Sullivan M Su LJ Zhang Z Joshi M Gijón MA Kim J Arcaroli JJ Van Bokhoven A Lucia MS Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade Oncotarget 2017 8 56051 56065 10.18632/oncotarget.17359 28915573
Flaig TW, Salzmann-Sullivan M, Su LJ, Zhang Z, Joshi M, Gijón MA, Kim J, Arcaroli JJ, Van Bokhoven A, Lucia MS, et al. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 2017;8:56051–65.28915573
243. Shibata S Sogabe S Miwa M Fujimoto T Takakura N Naotsuka A Kitamura S Kawamoto T Soga T Identification of the first highly selective inhibitor of human lactate dehydrogenase B Sci Rep 2021 11 21353 10.1038/s41598-021-00820-7 34725423
Shibata S, Sogabe S, Miwa M, Fujimoto T, Takakura N, Naotsuka A, Kitamura S, Kawamoto T, Soga T. Identification of the first highly selective inhibitor of human lactate dehydrogenase B. Sci Rep. 2021;11:21353.34725423
244. Yao H Yang F Li Y Natural products targeting human lactate dehydrogenases for cancer therapy: a mini review Front Chem 2022 10 10 10.3389/fchem.2022.1013670
Yao H, Yang F, Li Y. Natural products targeting human lactate dehydrogenases for cancer therapy: a mini review. Front Chem. 2022;10:10.
245. Mishra D Banerjee D Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment Cancers (Basel) 2019 11 11 10.3390/cancers11060750
Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers (Basel). 2019;11:11.
246. Le A Cooper CR Gouw AM Dinavahi R Maitra A Deck LM Royer RE Vander Jagt DL Semenza GL Dang CV Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc Natl Acad Sci 2010 107 5 2037 42 10.1073/pnas.0914433107 20133848
Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci. 2010;107(5):2037–42.20133848
247. Hashim AAI Abrahams D Xu L Centeno B Sunassee E Abddelgader R Dubois L Lambin P Gatenby RA Gillies RJ Abstract 5932: targeting tumor acidity with the LDHA inhibitor (FX11) and CAIX inhibitor (DH348) overcomes resistance to PD-1 blockade and inhibits metastasis in a pancreatic cancer model Cancer Res 2017 77 5932 5932 10.1158/1538-7445.AM2017-5932
Hashim AAI, Abrahams D, Xu L, Centeno B, Sunassee E, Abddelgader R, Dubois L, Lambin P, Gatenby RA, Gillies RJ. Abstract 5932: targeting tumor acidity with the LDHA inhibitor (FX11) and CAIX inhibitor (DH348) overcomes resistance to PD-1 blockade and inhibits metastasis in a pancreatic cancer model. Cancer Res. 2017;77:5932–5932.
248. Liu Y Cao Y Zhang W Bergmeier S Qian Y Akbar H Colvin R Ding J Tong L Wu S A small-molecule inhibitor of glucose transporter 1 Downregulates Glycolysis, induces cell-cycle arrest, and inhibits Cancer Cell Growth in Vitro and in vivo Mol Cancer Ther 2012 11 1672 1682 10.1158/1535-7163.MCT-12-0131 22689530
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al. A small-molecule inhibitor of glucose transporter 1 Downregulates Glycolysis, induces cell-cycle arrest, and inhibits Cancer Cell Growth in Vitro and in vivo. Mol Cancer Ther. 2012;11:1672–82.22689530
249. Zhang X Lu J-J Abudukeyoumu A Hou D-Y Dong J Wu J-N Liu L-B Li M-Q Xie F Glucose transporters: important regulators of endometrial cancer therapy sensitivity. Front Oncol 2022 12 933827
Zhang X, Lu J-J, Abudukeyoumu A, Hou D-Y, Dong J, Wu J-N, Liu L-B, Li M-Q, Xie F. Glucose transporters: important regulators of endometrial cancer therapy sensitivity. Front. Oncol. 2022;12:933827.
250. Pliszka M Szablewski L Glucose transporters as a target for Anticancer Therapy Cancers (Basel) 2021 13 13 10.3390/cancers13164184
Pliszka M, Szablewski L. Glucose transporters as a target for Anticancer Therapy. Cancers (Basel). 2021;13:13.
251. Elmetwalli A Kamosh NH El Safty R Youssef AI Salama MM Abd El-Razek KM El-Sewedy T Novel phloretin-based combinations targeting glucose metabolism in hepatocellular carcinoma through GLUT2/PEPCK axis of action: in silico molecular modelling and in vivo studies Med Oncol 2023 41 12 10.1007/s12032-023-02236-x 38078989
Elmetwalli A, Kamosh NH, El Safty R, Youssef AI, Salama MM, Abd El-Razek KM, El-Sewedy T. Novel phloretin-based combinations targeting glucose metabolism in hepatocellular carcinoma through GLUT2/PEPCK axis of action: in silico molecular modelling and in vivo studies. Med Oncol. 2023;41:12.38078989
252. Tang J Gong Y Synergistic effect of phloretin combined with radiotherapy on lung cancer Int J Radiat Oncol Biol Phys 2021 111 e238 10.1016/j.ijrobp.2021.07.809
Tang J, Gong Y. Synergistic effect of phloretin combined with radiotherapy on lung cancer. Int J Radiat Oncol Biol Phys. 2021;111:e238.
253. Vovdenko S Morozov A Ali S Kogan E Bezrukov E Role of monocarboxylate transporters and glucose transporters in prostate cancer Urol J 2023 90 491 498 10.1177/03915603221111125
Vovdenko S, Morozov A, Ali S, Kogan E, Bezrukov E. Role of monocarboxylate transporters and glucose transporters in prostate cancer. Urol J. 2023;90:491–8.
254. Nwosu ZC Song MG di Magliano MP Lyssiotis CA Kim SE Nutrient transporters: connecting cancer metabolism to therapeutic opportunities Oncogene 2023 42 711 724 10.1038/s41388-023-02593-x 36739364
Nwosu ZC, Song MG, di Magliano MP, Lyssiotis CA, Kim SE. Nutrient transporters: connecting cancer metabolism to therapeutic opportunities. Oncogene. 2023;42:711–24.36739364
255. Liu T Han S Yao Y Zhang G Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment Cancer Manage Res 2023 15 957 75 10.2147/CMAR.S421771
Liu T, Han S, Yao Y, Zhang G. Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment. Cancer Manage Res. 2023;15:957–75.
256. Richiardone E Al Roumi R Lardinois F Giolito MV Ambroise J Boidot R Drotleff B Ghesquière B Bellahcène A Bardelli A MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy Cancer Lett 2024 598 217091 10.1016/j.canlet.2024.217091 38964730
Richiardone E, Al Roumi R, Lardinois F, Giolito MV, Ambroise J, Boidot R, Drotleff B, Ghesquière B, Bellahcène A, Bardelli A. MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy. Cancer Lett. 2024;598:217091.38964730
257. Singh M Afonso J Sharma D Gupta R Kumar V Rani R Baltazar F Kumar V Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics? Elsevier. 2023 90 1 14
Singh M, Afonso J, Sharma D, Gupta R, Kumar V, Rani R, Baltazar F, Kumar V. Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics? Elsevier. 2023;90:1–14.
258. Qian Y Galan-Cobo A Guijarro I Dang M Molkentine D Poteete A Zhang F Wang Q Wang J Parra E MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma Cancer Cell 2023 41 1363 1380 10.1016/j.ccell.2023.05.015 37327788
Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023;41:1363–80.37327788
259. Yamaguchi A Mukai Y Sakuma T Narumi K Furugen A Yamada Y Kobayashi M Monocarboxylate transporter 4 involves in energy metabolism and drug sensitivity in hypoxia Sci Rep 2023 13 1501 10.1038/s41598-023-28558-4 36707650
Yamaguchi A, Mukai Y, Sakuma T, Narumi K, Furugen A, Yamada Y, Kobayashi M. Monocarboxylate transporter 4 involves in energy metabolism and drug sensitivity in hypoxia. Sci Rep. 2023;13:1501.36707650
260. Li Y Song Y Shi Z Hou H Yu Y Pan F Ji J Chen Z Syrosingopine and UK5099 synergistically suppress non-small cell lung cancer by activating the integrated stress response Cell Death Dis 2024 15 431 10.1038/s41419-024-06821-4 38898028
Li Y, Song Y, Shi Z, Hou H, Yu Y, Pan F, Ji J, Chen Z. Syrosingopine and UK5099 synergistically suppress non-small cell lung cancer by activating the integrated stress response. Cell Death Dis. 2024;15:431.38898028
261. Van der Vreken A Oudaert I Ates G Faict S Vlummens P Satilmis H Fan R Maes A Massie A De Veirman K Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis J Pathol 2023 260 112 123 10.1002/path.6066 36807305
Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, Fan R, Maes A, Massie A, De Veirman K, et al. Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. J Pathol. 2023;260:112–23.36807305
262. Chen J Cui L Lu S Xu S Amino acid metabolism in tumor biology and therapy Cell Death Dis 2024 15 42 10.1038/s41419-024-06435-w 38218942
Chen J, Cui L, Lu S, Xu S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 2024;15:42.38218942
263. Bröer S Amino acid transporters as targets for Cancer Therapy: why, where, when, and how Int J Mol Sci 2020 21 6156 10.3390/ijms21176156 32859034
Bröer S. Amino acid transporters as targets for Cancer Therapy: why, where, when, and how. Int J Mol Sci. 2020;21:6156.32859034
264. Butler M van der Meer LT van Leeuwen FN Amino acid depletion therapies: starving Cancer cells to death Trends Endocrinol Metab 2021 32 367 381 10.1016/j.tem.2021.03.003 33795176
Butler M, van der Meer LT, van Leeuwen FN. Amino acid depletion therapies: starving Cancer cells to death. Trends Endocrinol Metab. 2021;32:367–81.33795176
265. Bo T Kobayashi S Inanami O Fujii J Nakajima O Ito T Yasui H LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence Transl Oncol 2021 14 101212 10.1016/j.tranon.2021.101212 34461558
Bo T, Kobayashi S, Inanami O, Fujii J, Nakajima O, Ito T, Yasui H. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence. Transl Oncol. 2021;14:101212.34461558
266. Wang W Pan H Ren F Chen H Ren P Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells Biosci Rep 2022 42 BSR20212171 10.1042/BSR20212171 35237783
Wang W, Pan H, Ren F, Chen H, Ren P. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Biosci Rep. 2022;42:BSR20212171.35237783
267. Liu Y Xu W Li M Yang Y Sun D Chen L Li H Chen L The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer Acta Pharm Sin B 2023 13 1438 1466 10.1016/j.apsb.2022.12.019 37139412
Liu Y, Xu W, Li M, Yang Y, Sun D, Chen L, Li H, Chen L. The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Acta Pharm Sin B. 2023;13:1438–66.37139412
268. Fruchtman H Avigan ZM Waksal JA Brennan N Mascarenhas JO Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia Leukemia 2024 38 927 935 10.1038/s41375-024-02246-2 38600315
Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia. 2024;38:927–35.38600315
269. Woods A Norsworthy KJ Wang X Vallejo J Chiu Yuen Chow E Li R-J Sun J Charlab R Jiang X Pazdur R FDA approval Summary: Ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed Acute myeloid leukemia with an IDH1 mutation Clin Cancer Res 2024 30 1226 31 10.1158/1078-0432.CCR-23-2234 38010220
Woods A, Norsworthy KJ, Wang X, Vallejo J, Chiu Yuen Chow E, Li R-J, Sun J, Charlab R, Jiang X, Pazdur R, et al. FDA approval Summary: Ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed Acute myeloid leukemia with an IDH1 mutation. Clin Cancer Res. 2024;30:1226–31.38010220
270. Yap TA Daver N Mahendra M Zhang J Kamiya-Matsuoka C Meric-Bernstam F Kantarjian HM Ravandi F Collins ME Francesco MED Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials Nat Med 2023 29 115 126 10.1038/s41591-022-02103-8 36658425
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115–26.36658425
271. Chen L-Y Shen Y-A Chu L-H Su P-H Wang H-C Weng Y-C Lin S-F Wen K-C Liew P-L Lai H-C Active DNA demethylase, TET1, increases oxidative phosphorylation and sensitizes ovarian Cancer stem cells to mitochondrial complex I inhibitor Antioxidants 2024 13 735 10.3390/antiox13060735 38929174
Chen L-Y, Shen Y-A, Chu L-H, Su P-H, Wang H-C, Weng Y-C, Lin S-F, Wen K-C, Liew P-L, Lai H-C. Active DNA demethylase, TET1, increases oxidative phosphorylation and sensitizes ovarian Cancer stem cells to mitochondrial complex I inhibitor. Antioxidants. 2024;13:735.38929174
272. Cao J Liao S Zeng F Liao Q Luo G Zhou Y Effects of altered glycolysis levels on CD8 + T cell activation and function Cell Death Dis 2023 14 407 10.1038/s41419-023-05937-3 37422501
Cao J, Liao S, Zeng F, Liao Q, Luo G, Zhou Y. Effects of altered glycolysis levels on CD8 + T cell activation and function. Cell Death Dis. 2023;14:407.37422501
273. Cadassou O Jordheim LP OXPHOS inhibitors, metabolism and targeted therapies in cancer Biochem Pharmacol 2023 211 115531 10.1016/j.bcp.2023.115531 37019188
Cadassou O, Jordheim LP. OXPHOS inhibitors, metabolism and targeted therapies in cancer. Biochem Pharmacol. 2023;211:115531.37019188
274. Machado ND Heather LC Harris AL Higgins GS Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities Br J Cancer 2023 129 897 899 10.1038/s41416-023-02394-9 37563220
Machado ND, Heather LC, Harris AL, Higgins GS. Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities. Br J Cancer. 2023;129:897–9.37563220
275. Zhao Z Mei Y Wang Z He W The effect of oxidative phosphorylation on Cancer Drug Resistance Cancers (Basel) 2022 15 15 10.3390/cancers15010062 36612011
Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on Cancer Drug Resistance. Cancers (Basel). 2022;15:15.36612011
276. Vanauberg D Schulz C Lefebvre T Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies Oncogenesis 2023 12 16 10.1038/s41389-023-00460-8 36934087
Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023;12:16.36934087
277. Wang Z Wang Y Li Z Xue W Hu S Kong X Lipid metabolism as a target for cancer drug resistance: progress and prospects Front Pharmacol 2023 14 1274335 10.3389/fphar.2023.1274335 37841917
Wang Z, Wang Y, Li Z, Xue W, Hu S, Kong X. Lipid metabolism as a target for cancer drug resistance: progress and prospects. Front Pharmacol. 2023;14:1274335.37841917
278. Mallick R Bhowmik P Duttaroy AK Targeting fatty acid uptake and metabolism in cancer cells: a promising strategy for cancer treatment Biomed Pharmacother 2023 167 115591 10.1016/j.biopha.2023.115591 37774669
Mallick R, Bhowmik P, Duttaroy AK. Targeting fatty acid uptake and metabolism in cancer cells: a promising strategy for cancer treatment. Biomed Pharmacother. 2023;167:115591.37774669
279. Shuvalov O Daks A Fedorova O Petukhov A Barlev N Linking metabolic reprogramming, plasticity and tumor progression Cancers (Basel) 2021 13 13 10.3390/cancers13040762
Shuvalov O, Daks A, Fedorova O, Petukhov A, Barlev N. Linking metabolic reprogramming, plasticity and tumor progression. Cancers (Basel). 2021;13:13.
280. Palm W Metabolic plasticity allows cancer cells to thrive under nutrient starvation Proc Natl Acad Sci 2021 118 e2102057118 10.1073/pnas.2102057118 33722932
Palm W. Metabolic plasticity allows cancer cells to thrive under nutrient starvation. Proc Natl Acad Sci. 2021;118:e2102057118.33722932
281. Al-Masri M Paliotti K Tran R Halaoui R Lelarge V Chatterjee S Wang L-T Moraes C McCaffrey L Architectural control of metabolic plasticity in epithelial cancer cells Commun Biology 2021 4 371 10.1038/s42003-021-01899-4
Al-Masri M, Paliotti K, Tran R, Halaoui R, Lelarge V, Chatterjee S, Wang L-T, Moraes C, McCaffrey L. Architectural control of metabolic plasticity in epithelial cancer cells. Commun Biology. 2021;4:371.
282. Mokhtari RB Homayouni TS Baluch N Morgatskaya E Kumar S Das B Yeger H Combination therapy in combating cancer Oncotarget 2017 8 23 10.18632/oncotarget.16723
Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget; Vol. 2017;8:23.
283. Lehár J Krueger AS Avery W Heilbut AM Johansen LM Price ER Rickles RJ Short Iii GF Staunton JE Jin X Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat Biotechnol 2009 27 659 666 10.1038/nbt.1549 19581876
Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short Iii GF, Staunton JE, Jin X, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27:659–66.19581876
284. Palmer AC Sorger PK Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy Cell 2017 171 1678 e16911613 10.1016/j.cell.2017.11.009 29245013
Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171:1678–e16911613.29245013
285. Vasan N Baselga J Hyman DM A view on drug resistance in cancer Nature 2019 575 299 309 10.1038/s41586-019-1730-1 31723286
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309.31723286
286. Zhou Y Tao L Qiu J Xu J Yang X Zhang Y Tian X Guan X Cen X Zhao Y Tumor biomarkers for diagnosis, prognosis and targeted therapy Signal Transd Target Ther 2024 9 132 10.1038/s41392-024-01823-2
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, Tian X, Guan X, Cen X, Zhao Y. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Therapy. 2024;9:132.
287. Li J Eu JQ Kong LR Wang L Lim YC Goh BC Wong ALA Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy Molecules 2020 25 4831 10.3390/molecules25204831 33092283
Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, Wong ALA. Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules. 2020;25:4831.33092283
